

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

#### Trends in obesity defined by the relative fat mass (RFM) index among adults in the United States from 1999 to 2020: population-based study

| Journal:                         | BMJ Open  |
|----------------------------------|---|
| Manuscript ID                    | bmjopen-2022-071295   |
| Article Type:                    | Original research   |
| Date Submitted by the<br>Author: | 22-Dec-2022   |
| Complete List of Authors:        | Woolcott, Orison; Ronin Institute; Institute for Globally Distributed Open<br>Research and Education (IGDORE)<br>Seuring, Till; Luxembourg Institute of Socio-Economic Research (LISER) |
| Keywords:                        | EPIDEMIOLOGY, PUBLIC HEALTH, General endocrinology < DIABETES & ENDOCRINOLOGY, GENERAL MEDICINE (see Internal Medicine)   |
|                                  |   |

SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 1        |          |   |
|----------|----------|---|
| 2        |          |   |
| 3<br>4   | 1        | Trends in obesity defined by the relative fat mass (RFM) index among adults in  |
| 5<br>6   | 2        | the United States from 1999 to 2020: population-based study   |
| 7        |          |   |
| 8<br>9   | 3        |   |
| 10       | 4        | Orison O. Woolcott, research scientist <sup>1,2,*</sup> , Till Seuring, postdoctoral fellow <sup>3</sup>  |
| 11<br>12 | 5        |   |
| 13       |          |   |
| 14<br>15 | 6        | <sup>1</sup> Ronin Institute, Montclair, NJ, USA; <sup>2</sup> Institute for Globally Distributed Open Research and   |
| 16<br>17 | 7        | Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup> Luxembourg Institute of Socio-Economic   |
| 18       | 8        | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 19<br>20 |          |   |
| 21<br>22 | 9        | Correspondence:<br>Orison O. Woolcott, M.D.<br>Ronin Institute<br>Montclair, NJ<br>United States of America<br>Telephone: +1 (323) 253-2562<br>Email: Orison O. |
| 23       | 10       |   |
| 24<br>25 | 11       |   |
| 26       | 12       |   |
| 27       | 13       |   |
| 28       | 14       |   |
| 29       | 15       |   |
| 30       | 16<br>17 | Correspondence:   |
| 31       | 17       | Correspondence.   |
| 32<br>33 | 19       | Orison O. Woolcott, M.D.  |
| 34       | 20       | Ronin Institute   |
| 35       | 21       | Montclair, NJ   |
| 36       | 22       | United States of America  |
| 37       | 23       | Telephone: +1 (323) 253-2562  |
| 38       | 24       |   |
| 39       | 25       |   |
| 40<br>41 | 26       | Abstract word count: 300  |
| 42       | 27       |   |
| 43<br>44 | 28       | Text word count: 2,922  |
| 45       | 29       |   |
| 46<br>47 | 30       | Keywords: General Obesity, NHANES, Prevalence, Relative Fat Mass, RFM, Trends.  |
| 48       |          |   |
| 49       |          |   |
| 50<br>51 |          |   |
| 51<br>52 |          |   |
| 53       |          |   |
| 54       |          |   |
| 55       |          |   |
| 56       |          |   |
| 57<br>58 |          | 1   |
| 58<br>59 |          | 1   |
| 60       |          | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |

#### STRENGTHS AND LIMITATIONS OF THIS STUDY

- This is the first study to compare the prevalence trends of general obesity by sex, ethnicity (Mexican, European and African American), and age group in adults 20-79 years in the United States using the relative fat mass (RFM) index, a validated surrogate for whole-body fat percentage, and the body mass index.
- We used survey data from nationally representative samples of the noninstitutionalized U.S. adults collected by the National Health and Nutrition Examination Survey from 1999 to 2020.
- RFM has a high diagnostic accuracy (91%) for obesity defined by the dual energy X-ray absorptiometry; it requires only measured waist circumference and height; and the diagnosis of general obesity was based on previously validated RFM cutoffs to predict all-cause mortality.
- Estimates of prevalence trends could have been affected by some variability in sampling across survey cycles.
- We did not analyze the prevalence trends for Asian Americans due to the lack of oversampling prior to 2011.

| 2<br>3<br>4  |   |
|--|---|
| 4<br>5<br>6<br>7   |   |
| 8<br>9   |   |
| 10<br>11<br>12   |   |
| 13<br>14   |   |
| 15<br>16   |   |
| 17<br>18<br>19   |   |
| 20<br>21   |   |
| 22<br>23<br>24   |   |
| 20<br>21<br>22<br>23<br>24<br>25<br>26<br>27<br>28<br>29 | 1 |
| 27<br>28   | 1 |
| 29<br>30<br>31   | 1 |
| 32<br>33   | 1 |
| 34<br>35<br>36   | 1 |
| 37<br>38   | 1 |
| 39<br>40   | 1 |
| 41<br>42<br>43   | 1 |
| 44<br>45   | - |
| 46<br>47   | 2 |
| 48<br>49<br>50   | ź |
| 51<br>52   | 2 |
| 53<br>54   |   |
| 55<br>56<br>57   |   |
| 58<br>59   |   |
| 60   |   |

1 2

1

### ABSTRACT

Objectives: The body mass index (BMI) largely underestimates excess body fat, suggesting
that the prevalence of obesity could be underestimated. This study aimed to compare the trends
of general obesity by sex, ethnicity, and age group among adults in the United States using the
relative fat mass (RFM), a validated surrogate for whole-body fat percentage, and the BMI.

6 **Design:** Population-based study

- Setting: U.S. National Health and Nutrition Examination Survey (NHANES), from 1999-2000
  through 2017-March 2020.
- 9 **Participants:** A representative sample of adults 20-79 years in the U.S.

Main outcome measures: Age-adjusted prevalence of general obesity. RFM-defined obesity
 was diagnosed using validated cutoffs to predict all-cause mortality: RFM ≥40% for women and
 ≥30% for men. BMI-defined obesity was diagnosed using a cutoff of 30 kg/m<sup>2</sup>.

13 **Results:** Analysis included 47,667 adults. Among women, RFM-defined obesity prevalence was

14 64.7% (95% confidence interval, 62.1 to 67.3%) in 2017-2020, a linear increase of 13.9

percentage points (9.0 to 18.9%; P<0.001) relative to 1999-2000. In contrast, the prevalence of

16 BMI-defined obesity was 42.2% (39.4 to 45.0%) in 2017-2020. Among men, the corresponding

17 RFM-defined obesity prevalence was 45.8% (42.0 to 49.7%), a linear increase of 12.0

percentage points (6.6 to 17.3%; P<0.001). In contrast, the prevalence of BMI-defined obesity

19 was 42.0 (37.8 to 46.3%). The highest prevalence of RFM-defined obesity across years was

- 20 observed in older adults (60-79 years) and Mexican Americans, in women and men.
- 21 Conversely, the highest prevalence of BMI-defined obesity across years was observed in

middle-age (40-59 years) and older adults, and in African American women.

BMJ Open

| 2        |   |   |
|----------|---|---|
| 3<br>4   | 1 | Conclusions: The use of a surrogate for whole-body fat percentage revealed a much higher        |
| 5<br>6   | 2 | prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, than     |
| 7<br>8   | 3 | that estimated by the BMI, and detected a disproportionate higher prevalence of general obesity |
| 9<br>10  | 4 | in older adults and Mexican Americans.  |
| 11<br>12 | 5 |   |
| 13<br>14 | J |   |
| 15<br>16 |   |   |
| 17<br>18 |   |   |
| 19<br>20 |   |   |
| 21<br>22 |   |   |
| 23<br>24 |   |   |
| 25       |   |   |
| 26<br>27 |   |   |
| 28<br>29 |   |   |
| 30<br>31 |   |   |
| 32<br>33 |   |   |
| 34<br>35 |   |   |
| 36<br>37 |   |   |
| 38<br>39 |   |   |
| 40<br>41 |   |   |
| 42<br>43 |   |   |
| 44<br>45 |   |   |
| 46<br>47 |   |   |
| 48       |   |   |
| 49<br>50 |   |   |
| 51<br>52 |   |   |
| 53<br>54 |   |   |
| 55<br>56 |   |   |
| 57<br>58 |   | 4   |
| 59<br>60 |   | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                       |
|          |   |   |

#### 1 INTRODUCTION

The prevalence of obesity (excess body fat) in the United States has doubled from 15.0% in 1976-1980 to 30.9% in 1999-2000<sup>1</sup>, and it continues to increase <sup>23</sup>. The age-adjusted prevalence of obesity among adults in the U.S. has been estimated at 41.9% in 2017-March 2020<sup>4</sup>. Obesity diagnosis is based on the body mass index (BMI), an indirect measure of body fat <sup>56</sup>. BMI is calculated as the ratio of body weight in kilograms to the square of the height in meters 7. BMI does not distinguish between fat mass and fat-free mass and does not account for differences in adiposity between women and men <sup>8-12</sup>. A meta-analysis of 25 international studies comprising nearly 32,000 adults concluded that BMI underestimates ~50% of all individuals with excess body fat percentage determined by reference techniques <sup>11</sup>, suggesting that the prevalence of obesity could be largely underestimated among countries. 

There is robust evidence linking high whole-body fat percentage with increased risk of death <sup>13-</sup> <sup>20</sup>, supporting the need for a better assessment of body adiposity. Although the limitations of BMI to assess body adiposity are widely acknowledged <sup>6 8-11 21 22</sup>, BMI remains the most widely used anthropometric index in clinical practice, epidemiology, and public health, given its simplicity, very low cost, and its association with several clinical conditions and mortality <sup>6</sup>. The high cost and time required to assess body adiposity using more accurate techniques such as dual-energy x-ray absorptiometry (DXA), dual-labeled water, or magnetic resonance, prevents their use in large populations or clinical practice as part of routine screening. 

The relative fat mass (RFM) is a simple and low-cost anthropometric index developed to
estimate whole-body fat percentage <sup>23</sup>. RFM is a linear equation based on the ratio of height to
waist circumference that has been validated in Mexican, European, and African Americans <sup>23</sup>,
and in other populations <sup>24-26</sup>. Compared with BMI, RFM resulted in lower obesity
misclassification when DXA was used as the reference method for diagnosing obesity in adults
<sup>24-27</sup>. The accuracy of RFM in diagnosing high body fat percentage is superior to that of BMI

| 1<br>ว         |    |  |
|----------------|----|--|
| 2<br>3<br>4    | 1  | among men and similar to BMI among women <sup>23</sup> . In an analysis of a representative sample of          |
| 5<br>6         | 2  | the U.S. adult population (NHANES 1999-2006), RFM had a diagnostic accuracy of 91% (C-                         |
| 7<br>8<br>9    | 3  | statistic = 0.91) for DXA-defined obesity in women and men <sup>27</sup> .                                     |
| 10<br>11       | 4  | Recent studies have examined the U.S. prevalence trends in obesity using the BMI as                            |
| 12<br>13       | 5  | diagnostic tool <sup>3 28 29</sup> . Although data on body fat percentage have also been reported for the U.S. |
| 14<br>15       | 6  | adult population <sup>28</sup> , no body fat cutoffs were used to diagnose general obesity, and the analyses   |
| 16<br>17       | 7  | were limited to adults 20-59 years only, and for the period 2011-2018. In fact, body composition               |
| 18<br>19       | 8  | has been inconsistently assessed across NHANES survey cycles and across age groups. In                         |
| 20<br>21<br>22 | 9  | addition, no study has compared the trends of general obesity in the U.S. using the RFM, a                     |
| 22<br>23<br>24 | 10 | surrogate for body fat percentage, and the BMI. Furthermore, no study has examined current                     |
| 25<br>26       | 11 | obesity trends among U.S. adults over a period of nearly 22 years. The aim of this study was to                |
| 27<br>28       | 12 | compare the trends of general obesity by sex, ethnicity, and age group among adults in the U.S.                |
| 29<br>30       | 13 | from 1999 to 2020 using the RFM and the BMI.   |
| 31<br>32       |    |  |
| 33             |    |  |
| 34<br>35<br>36 |    |  |
| 37             |    |  |
| 38<br>39       |    |  |
| 40<br>41       |    |  |
| 42<br>43       |    |  |
| 44<br>45       |    |  |
| 46<br>47       |    |  |
| 48<br>49       |    |  |
| 50             |    |  |
| 51<br>52       |    |  |
| 53<br>54       |    |  |
| 55<br>56       |    |  |
| 57<br>58       |    | 6  |
| 59<br>60       |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                                      |
|                |    |  |

#### 1 MATERIAL AND METHODS

#### 2 <u>Study design, data source, and participants</u>

In this population-based study, we performed an analysis of cross-sectional individual-level data collected by the National Health and Nutrition Examination Survey (NHANES) through interviews and physical examination in a subset of a representative sample of the U.S. population from 1999-2000 through 2017-March 2020. Initial complete dataset included 107,622 participants of all ages. NHANES suspended data collection in March 2020 as a consequence of the COVID-19 pandemic. Thus, the most current cycle data available are "combined data collected from 2019 to March 2020 with data from the NHANES 2017-2018 cycle to form a nationally representative sample of NHANES 2017-March 2020 pre-pandemic data" <sup>30</sup>. Analysis was restricted to adults 20-79 years of age (n=54.232 potentially eligible) because of three reasons: 1) the diagnosis of obesity in younger adults is based on BMI-for-age percentiles as recommended by the Centers for Disease Control and Prevention (CDC)<sup>7</sup>; 2) in NHANES 2007-2008 and subsequent cycles, the upper age limit was 80 years, whereas in earlier cycles the age limit was 85 years; and 3) to obtain age-adjusted prevalence estimates using 5-year intervals according to the strata for age and sex available from the 2000 US Census Bureau (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75-79) <sup>31</sup>. Another criterion for inclusion was that individuals had been interviewed and evaluated by physical examination. Women who reported to be pregnant or had a positive urine pregnancy test were excluded from analysis. Observations with missing data on body weight, height, or waist circumference were also excluded.

According to the NHANES physical examination protocol, waist circumference was measured just above the uppermost lateral border of the right ilium (hip bone). Weight and height were measured using standard methods <sup>32</sup>. Information on ethnicity was collected through a questionnaire. The mean unweighted response rate for examined sample across survey cycles

#### **BMJ** Open

| 2        |
|----------|
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| 8        |
| 9        |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
|          |
| 16<br>17 |
| 17       |
| 18       |
| 19<br>20 |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32       |
| 33       |
| 34       |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 40<br>41 |
| 42       |
| 42<br>43 |
| 45<br>44 |
| 44<br>45 |
| 45<br>46 |
| 46<br>47 |
|          |
| 48       |
| 49<br>50 |
|          |
| 51       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 59       |

60

between 1999-2000 and 2017-March 2020 for individuals 20-79 years was 67.5% (range 50.8 74.5%) <sup>33</sup>.

Since this study used publicly available de-identified data, approval from an Institutional Review
Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects
(detailed in 45 CFR part 46)<sup>34</sup>.

#### 6 <u>Obesity diagnosis</u>

General obesity was diagnosed based on the RFM, a validated surrogate for whole-body fat
percentage <sup>23</sup>, and validated cutoffs to predict all-cause mortality: RFM ≥40% for women and
≥30% for men <sup>27</sup>. RFM was calculated as follows: RFM = 64 - (20 × height/waist circumference)
+ (12 × sex); sex equals 0 for men and 1 for women <sup>23</sup>. BMI-defined obesity was diagnosed if
BMI was 30 kg/m<sup>2</sup> or higher <sup>7</sup>.

#### 12 <u>Statistical Analysis</u>

Data collected during the survey cycles from 1999-2000 through 2017-2020 were analyzed 13 14 using sampling weights following the recommended analytic guidelines, to account for 15 oversampling, nonresponse rates, and subsampling for physical examination <sup>35</sup>. The proportion 16 of missing data was 5.2% of all eligible participants. Given this low percentage of missing data, we performed a complete case analysis <sup>36</sup>. Since age distribution of study samples may vary 17 18 across survey cycles, all prevalence estimates were adjusted for age to make the estimates 19 more comparable throughout the study period <sup>31</sup>. Estimates across the age categories 20-39, 40-59, and 60-79 years were also adjusted for age using 5-year intervals according to 20 corresponding 2000 US Census Bureau age categories by sex <sup>31</sup>. The changes in obesity 21 22 prevalence from 1999-2000 to 2017-March 2020 were assessed using the Wald test. For 23 multiple comparisons of prevalence across ethnic groups and age groups, we applied the Bonferroni correction. Because Asian Americans were not oversampled before NHANES 2011, 24

| ~              |    |  |
|----------------|----|--|
| 3<br>4         | 1  | our analyses by ethnicity were restricted to Mexican, European, and African Americans.                         |
| 5<br>6         | 2  | Prevalence trends were tested for the assumption of linearity using logistic regression models,                |
| 7<br>8         | 3  | comparing linear and non-linear regression models using the likelihood-ratio test <sup>37</sup> . For the non- |
| 9<br>10        | 4  | linear models, restricted cubic splines with 3 knots were used at years 2001-2002, 2009-2010,                  |
| 11<br>12       | 5  | and 2017-2020, based on the quantiles recommended by Harrel <sup>38</sup> . Survey cycles were                 |
| 13<br>14       | 6  | analyzed as a continuous variable. For visualization purposes, trend lines were smoothed using                 |
| 15<br>16       | 7  | the Lowes method <sup>39</sup> . Statistical significance was set to an alpha level of 0.05. All statistical   |
| 17<br>18       | 8  | analyses were performed using Stata 14 for Windows (StataCorp LP, College Station, TX).                        |
| 19<br>20       | 9  | Prevalence estimates and standard errors were obtained using the survey 'svy' command with                     |
| 21<br>22<br>23 | 10 | Taylor linearization.  |
| 24<br>25<br>26 | 11 | Patient and public involvement   |
| 27<br>28       | 12 | Patients and the public were not involved in this study. This study will be available to the public            |
| 29<br>30       | 13 | once it is published in the scientific literature.   |
| 31<br>32       |    |  |
| 33             |    |  |
| 34             |    |  |
| 35             |    |  |
| 36<br>37       |    |  |
| 38             |    |  |
| 39             |    |  |
| 40             |    |  |
| 41<br>42       |    |  |
| 42<br>43       |    |  |
| 44             |    |  |
| 45             |    |  |
| 46             |    |  |
| 47<br>48       |    |  |
| 40<br>49       |    |  |
| 50             |    |  |
| 51             |    |  |
| 52             |    |  |
| 53<br>54       |    |  |
| 54<br>55       |    |  |
| 56             |    |  |
| 57             |    |  |
| 58             |    | 9  |
| 59<br>60       |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                                      |
| 60             |    | for peer review only inteps/onlyopen.only.com/site/about/guidelines.xittini                                    |

#### 1 RESULTS

#### 2 <u>Clinical characteristics</u>

3 After applying the inclusion and exclusion criteria, the final sample for analysis comprised

4 47,667 adults (Supplementary Figure 1). The median age of the study population was 45 years

5 (interquartile range: 33 to 58); 50.6% were women; 67.2% were European Americans, 11.2%

6 were African Americans, and 8.3% were Mexican Americans (Table 1).

| Characteristic                     | All           | Women          | Men            |
|------------------------------------|---------------|----------------|----------------|
|                                    | 47,667        | 23,931 (50.6%) | 23,736 (49.4%) |
| Median age (IQR), years            | 45 (33-58)    | 46 (33-59)     | 44 (32-57)     |
| Ethnicity, n (%)                   |               |                |                |
| Mexican American                   | 8,416 (8.3)   | 4,204 (7.7)    | 4,212 (9.0)    |
| European American                  | 19,691 (67.2) | 9,710 (67.0)   | 9,981 (67.5)   |
| African American                   | 10,673 (11.2) | 5,417 (12.0)   | 5,256 (10.4)   |
| Other/multi-racial                 | 8,887 (13.3)  | 4,600 (13.4)   | 3,928 (13.1)   |
| Body weight (SD), kg               | 82.6 (21.3)   | 76.3 (20.5)    | 89.0 (20.1)    |
| Mean height (SD), cm               | 168.9 (10.0)  | 162.1 (6.9)    | 175.9 (7.5)    |
| Mean waist circumference (SD), cm  | 98.5 (16.5)   | 95.9 (16.9)    | 101.2 (15.6)   |
| Mean BMI (SD), kg/m <sup>2</sup> † | 28.9 (6.8)    | 29.0 (7.5)     | 28.7 (5.9)     |
| Mean RFM (SD), % ‡                 | 34.9 (8.5)    | 41.2 (6.0)     | 28.4 (5.3)     |

\* Sample size represents unweighted data. Estimates represent weighted data.

9 BMI, body mass index; IQR, interquartile range; RFM, relative fat mass; SD, standard deviation.

**†** BMI was calculated as the body weight in kilograms divided by the square of the height in meters.

11 ‡ RFM was calculated as follows: 64 – (20 × height/waist circumference) + (12 × sex); sex equals 0 for

- 12 men and 1 for women; height and waist circumference measured in the same units.
- 14 The characteristics of the population with missing data are shown in Supplementary Table 1.
- 15 Obesity prevalence and trends

16 Our findings indicate a higher proportion of individuals with obesity when RFM was used instead

17 of BMI. The overall age-adjusted prevalence of RFM-defined obesity increased from 42.4%

18 (95% confidence interval, 38.3% to 46.4%) in 1999-2000 to 55.4% (53.0% to 57.9%) in 2017-

19 March 2020. The corresponding BMI-defined obesity prevalence increased from 30.4% (26.7%

to 34.0%) to 42.1% (39.4% to 44.8%). We found a linear increase in the overall prevalence of

1 obesity during the study period using either RFM (P<0.001; P=0.38 for non-linearity) or BMI

2 (P<0.001; P=0.55 for non-linearity).

#### 3 Obesity prevalence and trends by sex

4 We observed a consistently higher prevalence of RFM-defined obesity in women compared with

5 men across years. In contrast, this difference was not consistent for BMI-defined obesity (Figure

6 1). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in

7 women than in men (P<0.001). In contrast, the prevalence of BMI-defined obesity was similar in

8 women and men (P=0.97). Among women, the prevalence of RFM-defined obesity increased

9 from 50.8% (46.2% to 55.3%) in 1999-2000 to 64.7% (62.1% to 67.3%) in 2017-March 2020, a

10 linear increase of 13.9 percentage points (9.0% to18.9%; P<0.001). For comparison, the

prevalence of BMI-defined obesity in women was 42.2% (39.4% to45.0%) in 2017-March 2020,

12 a linear increase of 8.3 percentage points (3.5-13.2%; P<0.001) (Table 2).

 Table 2. Age-adjusted U.S. adult prevalence trends in RFM-defined obesity by sex: 1999-2000 through 2017-Mach 2020.\*

|                      | RFM-defined obesity | BMI-defined obesity |
|----------------------|---------------------|---------------------|
| All participants     | n=47,667            | n=47,667            |
| Prevalence, 95% CI   | 9                   |                     |
| 1999-2000            | 42.4 (38.3-46.4)    | 30.4 (26.7-34)      |
| 2001-2002            | 42.5 (41.1-43.9)    | 30.0 (27.6-32.4)    |
| 2003-2004            | 46.9 (44.7-49.2)    | 32.1 (29.3-34.9)    |
| 2005-2006            | 47.1 (43.7-50.5)    | 34.3 (31.1-37.4)    |
| 2007-2008            | 47.7 (45.0-50.5)    | 33.7 (31.5-36.0)    |
| 2009-2010            | 48.5 (46.1-50.8)    | 35.7 (33.6-37.8)    |
| 2011-2012            | 49.8 (46.6-53.0)    | 35.4 (32.5-38.3)    |
| 2013-2014            | 51.3 (48.7-53.8)    | 37.8 (35.6-40)      |
| 2015-2016            | 53.7 (49.3-58.0)    | 40.0 (36.4-43.6)    |
| 2017-2020            | 55.4 (53.0-57.9)    | 42.1 (39.4-44.8)    |
| Prevalence change†   | 13.0 (8.5-17.5)     | 11.8 (7.4-16.1)     |
| P for non-linearity‡ | 0.38                | 0.55                |
| P value for trend‡   | <0.001              | <0.001              |
| Women                | n=23,931            | n=23,931            |
| Prevalence, 95% CI   |                     |                     |
| 1999-2000            | 50.8 (46.2-55.3)    | 33.9 (29.6-38.1)    |
| 2001-2002            | 51.6 (49.2-53.9)    | 32.9 (29.7-36.0)    |
| 2003-2004            | 55.3 (51.2-59.3)    | 33.5 (29.7-37.2)    |
| 2005-2006            | 53.9 (50.4-57.4)    | 34.8 (31.5-38.1)    |
| 2007-2008            | 56.4 (53.5-59.3)    | 35.4 (32.7-38.0)    |
| 2009-2010            | 58.1 (55.3-60.8)    | 36.0 (34.0-37.9)    |
| 2011-2012            | 60.8 (56.8-63.6)    | 36.9 (33.4-40.5)    |
| 2013-2014            | 61.3 (57.9-64.7)    | 40.0 (36.8-43.2)    |

| 1  |  |
|--|--|
| 2  |  |
| 2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13   |  |
| ر<br>۸   |  |
| 4<br>7   |  |
| 5  |  |
| 6  |  |
| 7  |  |
| 8  |  |
| 9  |  |
| 10   |  |
| 11   |  |
| 12   |  |
| 13   |  |
| 1/   |  |
| 14   |  |
| 15   |  |
| 16   |  |
| 17   |  |
| 18   |  |
| 19   |  |
| 14         14         15         16         17         18         19         20         21         22         23         24         25         26         27         28         29         30         31         32         33         34         35 |  |
| 21   |  |
| 22   |  |
| 22   |  |
| 25   |  |
| 24   |  |
| 25   |  |
| 26   |  |
| 27   |  |
| 28   |  |
| 29   |  |
| 30   |  |
| 20   |  |
| 31   |  |
| 32   |  |
| 33   |  |
| 34<br>35<br>36   |  |
| 35   |  |
| 36   |  |
| 37   |  |
| 38   |  |
| 39   |  |
|  |  |
| 40   |  |
| 41   |  |
| 42   |  |
| 43   |  |
| 44   |  |
| 45   |  |
| 46   |  |
| 47   |  |
| 48   |  |
|  |  |
| 49   |  |
| 50   |  |
| 51   |  |
| 52   |  |
| 53   |  |
| 54   |  |
| 55   |  |
| 55   |  |
|  |  |
| 57   |  |
| 58   |  |

60

1 2

3

4

5

6

7

8

9 10

| 2015-2016            | 64.4 (60.2-68.6) | 41.7 (38.1-45.3) |
|----------------------|------------------|------------------|
| 2017-2020            | 64.7 (62.1-67.3) | 42.2 (39.4-45.0) |
| Prevalence change†   | 13.9 (9.0-18.9)  | 8.3 (3.5-13.2)   |
| P for non-linearity§ | 0.10             | 0.39             |
| P value for trend§   | <0.001           | <0.001           |
| Men                  | n=23,736         | n=23,736         |
| Prevalence, 95% CI   |                  |                  |
| 1999-2000            | 33.9 (29.9-37.8) | 27.0 (23.5-30.4) |
| 2001-2002            | 33.1 (30.6-35.5) | 27.0 (24.8-29.2) |
| 2003-2004            | 38.4 (35.9-40.8) | 30.7 (27.6-33.9) |
| 2005-2006            | 40.2 (35.9-44.4) | 33.5 (29.3-37.8) |
| 2007-2008            | 38.8 (35.6-42.0) | 32.1 (29.3-34.8) |
| 2009-2010            | 38.7 (35.2-42.2) | 35.3 (31.4-39.2) |
| 2011-2012            | 39.2 (35.9-42.5) | 33.8 (30.7-36.9) |
| 2013-2014            | 41.2 (38.7-43.7) | 35.6 (33.2-38.1) |
| 2015-2016            | 42.7 (37.7-47.7) | 38.2 (33.3-43.2) |
| 2017-2020            | 45.8 (42.0-49.7) | 42.0 (37.8-46.3) |
| Prevalence change†   | 12.0 (6.6-17.3)  | 15.1 (9.8-20.4)  |
| P for non-linearity§ | 0.82             | 0.84             |
| P value for trend§   | <0.001           | <0.001           |
|                      |                  |                  |

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows:
 RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women.
 Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval.

+ Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for age, sex, and ethinicity.

§ Adjusted for age and ethnicity.

Among men, the prevalence of RFM-defined obesity increased from 33.9% (29.9% to 37.8%) in

12 1999-2000 to 45.8% (42.0% to 49.7%) in 2017-March 2020, a linear increase of 12.0

13 percentage points (6.6% to 17.3%; P<0.001). The prevalence of BMI-defined obesity in men

14 was 42.0% (37.8% to 46.3%) in 2017-March 2020, a linear increase of 15.1 percentage points

15 (9.8% to 20.4%).

#### 16 Obesity prevalence and trends by ethnicity

- 17 The highest prevalence of RFM-defined obesity across years was observed among Mexican
- Americans. In contrast, the highest prevalence of BMI-defined obesity was observed among
- 19 African American women but not men (Figure 2). In 2017-March 2020, the prevalence of RFM-
- 20 defined obesity was significantly higher in Mexican Americans compared with African Americans
- 21 (Bonferroni corrected P<0.001) or European Americans (P<0.001). BMI-defined obesity

1 prevalence was similar in Mexican and African Americans (P=1.00) and both groups had a

2 higher prevalence than European Americans (P=0.003 and P=0.001, respectively).

3 The largest increase in the prevalence of RFM-defined obesity from 1999-2000 to 2017-March

4 2020 occurred in Mexican American men, with a linear increase of 18.3 percentage points

5 (12.0% to 24.5%; P<0.001) (Table 3 and Figure 2). The highest increase in the prevalence of

6 BMI-defined obesity also occurred in Mexican American men, with a linear increase of 21.2

7 percentage points (15.3% to 27.1%; P<0.001) (Table 3 and Figure 2).

 Table 3. Age-adjusted U.S. adult prevalence trends in RFM-defined obesity by ethnicity: 1999-2000 through 2017 

 March 2020.\*

|                          | RFM-defined obesity  |                      |                      | BMI-defined obesity  |                      |                     |  |
|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|--|
|                          | Mexican              | European             | African              | Mexican              | European             |                     |  |
|                          | American             | American             | American             | American             | American             | American            |  |
| All participants         | n=8,416              | n=19,691             | n=10,673             | n=8,416              | n=19,691             | n=10,673            |  |
| Prevalence,<br>95% Cl    |                      |                      | 4                    |                      |                      |                     |  |
| 1999-2000                | 53.1 (48.5-<br>57.7) | 39.4 (34.2-<br>44.6) | 48.3 (45.0-<br>51.7) | 34.7 (28.9-<br>40.6) | 28.3 (23.9-<br>32.7) | 39.8 (35.7<br>43.8) |  |
| 2001-2002                | 52.1 (47.1-<br>57.1) | 41.0 (38.9-<br>43.1) | 46.0 (42.9-<br>49.0) | 30.7 (26.7-<br>34.7) | 29.8 (27.0-<br>32.6) | 38.3 (34.4<br>42.3) |  |
| 2003-2004                | 60.1 (55.2-<br>65.0) | 44.8 (41.0-<br>48.6) | 52.7 (49.4-<br>56.0) | 36.9 (32.2-<br>41.6) | 30.6 (27.7-<br>33.4) | 45.1 (39.7          |  |
| 2005-2006                | 55.4 (51.8-<br>58.9) | 44.9 (40.7-<br>49.2) | 51.5 (47.9-<br>55.1) | 33.8 (31.2-<br>36.4) | 33.1 (29.2-<br>36.9) | 45.9 (42.3<br>49.5) |  |
| 2007-2008                | 62.2 (56.2-<br>68.2) | 45.7 (41.5-<br>49.9) | 52.5 (49.1-<br>56.0) | 39.9 (33.8-<br>46.1) | 32.4 (28.7-<br>36.0) | 43.7 (39.2<br>48.1) |  |
| 2009-2010                | 61.5 (59.4-<br>63.6) | 46.4 (43.0-<br>49.8) | 56.8 (51.8-<br>61.8) | 40.5 (36.7-<br>44.4) | 34.2 (31.1-<br>37.2) | 49.4 (44.2<br>54.5) |  |
| 2011-2012                | 63.6 (58.6-<br>68.6) | 46.8 (42.8-<br>50.9) | 57.4 (54.8-<br>60.0) | 46.1 (41.3-50.8)     | 33.0 (29.4-<br>36.5) | 48.4 (44.6<br>52.3) |  |
| 2013-2014                | 65.0 (61.2-<br>68.9) | 49.4 (46.6-<br>52.3) | 55.0 (50.0-<br>59.9) | 46.1 (41.0-51.2)     | 36.6 (33.6-<br>39.5) | 47.9 (43.7<br>52.0) |  |
| 2015-2016                | 70.3 (67.0-<br>73.5) | 51.2 (46.9-<br>55.4) | 56.6 (52.0-<br>61.2) | 48.7 (44.3- 53.1)    | 38.5 (34.5-<br>42.5) | 48.7 (43.8<br>53.5) |  |
| 2017-2020                | 68.8 (64.5-<br>73.1) | 54.1 (50.8-<br>57.4) | 57.1 (54.4-<br>59.8) | 50.2 (46.8-<br>53.5) | 41.7 (37.7-<br>45.6) | 49.9 (47.2<br>52.6) |  |
| Prevalence<br>change†    | 15.7 (9.6-<br>21.7)  | 14.7 (8.8-<br>20.5)  | 8.7 (4.6-<br>12.9)   | 15.4 (9.0-<br>21.9)  | 13.4 (7.7-19)        | 10.2 (5.5-<br>14.8) |  |
| P for non-<br>linearity‡ | 0.58                 | 0.97                 | 0.25                 | 0.52                 | 0.10                 | 0.35                |  |
| P value for<br>trend‡    | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001              |  |
| Women                    | n=4,204              | n=9,710              | n=5,417              | n=4,204              | n=9,710              | n=5,417             |  |
| Prevalence,<br>95% Cl    |                      |                      |                      |                      |                      |                     |  |
| 1999-2000                | 62.8 (55.1-<br>70.5) | 46.2 (40.2-<br>52.1) | 64.2 (59.6-<br>68.8) | 39.8 (31.1-<br>48.5) | 30.3 (25.2-<br>35.3) | 49.2 (42.5<br>56.0) |  |
| 2001-2002                | 66.4 (58.6-<br>74.3) | 47.8 (44.2-<br>51.4) | 64.2 (59.0-<br>69.4) | 37.0 (30.2-<br>43.8) | 31.1 (27.6-34.7)     | 48.7 (42.8 54.7)    |  |

Page 15 of 35

#### **BMJ** Open

| 1 |   |
|---|---|
| 2 |   |
|   |   |
| 3 |   |
| 4 |   |
| 5 |   |
| 5 |   |
| 6 |   |
| 7 |   |
| 0 |   |
| 8 |   |
| 9 |   |
| 1 | 0 |
|   |   |
| 1 | 1 |
| 1 | 2 |
| 1 |   |
|   |   |
| 1 | 4 |
| 1 | 5 |
|   |   |
| 1 |   |
| 1 | 7 |
|   | 8 |
|   |   |
| 1 | 9 |
| 2 | 0 |
|   | 1 |
|   |   |
| 2 | 2 |
| 2 | З |
|   |   |
|   | 4 |
| 2 | 5 |
|   |   |
|   |   |
| 2 | 7 |
|   | 8 |
|   |   |
|   | 9 |
| 3 | 0 |
|   | 1 |
|   |   |
| 3 | 2 |
| 3 | 3 |
| - | - |
| _ | 4 |
| 3 | 5 |
| 3 |   |
|   |   |
| 3 | 7 |
| 3 | 8 |
|   |   |
|   | 9 |
| 4 | 0 |
| 4 | 1 |
|   |   |
| 4 | 2 |
| 4 | 3 |
| л | 4 |
|   |   |
| 4 | 5 |
| 4 | 6 |
| 4 |   |
|   |   |
| 4 | 8 |
| 4 |   |
|   |   |
| 5 | 0 |
| 5 | 1 |
| _ | 1 |

| 2003-2004                | 75.0 (68.3- | 50.6 (43.9- | 70.7 (65.5- | 42.7 (36.0- | 30.3 (25.7- | 53.9 (4  |
|--------------------------|-------------|-------------|-------------|-------------|-------------|----------|
|                          | 81.6)       | 57.2)       | 75.8)       | 49.3)       | 34.8)       | 61.5)    |
| 2005-2006                | 72.0 (66.4- | 49.9 (45.6- | 66.2 (60.9- | 41.3 (34.8- | 32.8 (28.3- | 52.7 (4  |
|                          | 77.5)       | 54.2)       | 71.5)       | 47.7)       | 37.3)       | 56.9)    |
| 2007-2008                | 74.8 (71.2- | 52.3 (47.5- | 67.9 (63.2- | 44.7 (38.8- | 32.8 (28.7- | 49.2 (4  |
|                          | 78.4)       | 57.2)       | 72.6)       | 50.6)       | 36.9)       | 53.3)    |
| 2009-2010                | 77.8 (74.8- | 53.4 (49.5- | 74.6 (68.6- | 45.7 (42.0- | 32.1 (29.0- | 58.5 (5  |
|                          | 80.9)       | 57.2)       | 80.7)       | 49.3)       | 35.3)       | 64.9)    |
| 2011-2012                | 74.6 (66.2- | 56.3 (51.4- | 74.9 (72.1- | 49.0 (40.4- | 33.3 (28.0- | 57.9 (5  |
|                          | 83.0)       | 61.3)       | 77.8)       | 57.5)       | 38.7)       | 62.3)    |
| 2013-2014                | 81.2 (74.7- | 57.3 (53.4- | 72.5 (68.8- | 51.7 (45.2- | 37.6 (33.7- | 56.7 (5  |
|                          | 87.6)       | 61.2)       | 76.2)       | 58.3)       | 41.6)       | 60.3)    |
| 2015-2016                | 84.6 (79.7- | 60.0 (56.2- | 72.3 (68.3- | 52.2 (48.4- | 38.5 (34.0- | 57.1 (5  |
|                          | 89.5)       | 63.8)       | 76.4)       | 56.1)       | 43.0)       | 61.5)    |
| 2017-2020                | 76.9 (70.8- | 62.3 (59.0- | 72.4 (68.6- | 49.6 (43.1- | 40.3 (36.4- | 57.3 (5  |
|                          | 83.1)       | 65.7)       | 76.2)       | 56.0)       | 44.2)       | 60.9)    |
| Prevalence               | 14.1 (4.7-  | 16.2 (9.7-  | 8.3 (2.5-   | 9.8 (-0.6-  | 10.0 (3.9-  | 8.1 (0.8 |
| change†                  | 23.6)       | 22.7)       | 14.0)       | 20.1)       | 16.1)       | 15.4)    |
| P for non-<br>linearity§ | 0.026       | 0.77        | 0.34        | 0.76        | 0.12        | 0.71     |
| P value for<br>trend§    |             | <0.001      | <0.001      | <0.001      | <0.001      | <0.001   |
| Men                      | n=4,212     | n=9,981     | n=5,256     | n=4,212     | n=9,981     | n=5,25   |
| Prevalence,<br>95% Cl    |             |             |             |             |             |          |
| 1999-2000                | 42.9 (39.4- | 33.2 (28.6- | 27.5 (23.1- | 29.1 (24.6- | 26.8 (22.9- | 26.8 (2  |
|                          | 46.5)       | 37.7)       | 31.9)       | 33.6)       | 30.6)       | 30.6)    |
| 2001-2002                | 40.6 (34.7- | 34.1 (30.9- | 25.8 (21.4- | 25.9 (21.9- | 28.3 (25.3- | 26.5 (2  |
|                          | 46.4)       | 37.4)       | 30.1)       | 29.9)       | 31.4)       | 30.1)    |
| 2003-2004                | 47.1 (39.3- | 38.9 (35.5- | 31.2 (27.2- | 31.7 (25.0- | 30.9 (27.0- | 34.2 (2  |
|                          | 54.8)       | 42.4)       | 35.2)       | 38.3)       | 34.7)       | 40.7)    |
| 2005-2006                | 40.8 (34.1- | 40.0 (35.1- | 34.1 (28.3- | 27.4 (22.7- | 33.3 (28.7- | 37.2 (3  |
|                          | 47.4)       | 44.9)       | 39.9)       | 32.1)       | 37.9)       | 43.2)    |
| 2007-2008                | 50.9 (43.3- | 38.8 (34.7- | 33.8 (28.8- | 35.1 (28.0- | 32.0 (27.9- | 36.9 (3  |
|                          | 58.4)       | 42.9)       | 38.9)       | 42.1)       | 36.0)       | 42.7)    |
| 2009-2010                | 47.8 (44.6- | 39.4 (34.6- | 35.4 (31.4- | 36.3 (30.9- | 36.1 (30.8- | 38.6 (3  |
|                          | 51.0)       | 44.3)       | 39.5)       | 41.6)       | 41.3)       | 44.0)    |
| 2011-2012                | 52.5 (45.6- | 37.6 (34.3- | 36.4 (32.3- | 42.7 (36.0- | 32.5 (29.7- | 37.5 (3  |
|                          | 59.4)       | 40.9)       | 40.5)       | 49.5)       | 35.3)       | 42.2)    |
| 2013-2014                | 52.4 (48.6- | 41.7 (38.1- | 35.2 (28.6- | 43.6 (38.2- | 35.6 (31.6- | 37.9 (3  |
|                          | 56.3)       | 45.3)       | 41.8)       | 49.1)       | 39.5)       | 43.4)    |
| 2015-2016                | 55.9 (50.9- | 42.3 (36.5- | 38.1 (31.9- | 45.3 (38.5- | 38.4 (32.5- | 38.9 (3  |
|                          | 60.8)       | 48.1)       | 44.2)       | 52.1)       | 44.3)       | 44.2)    |
| 2017-2020                | 61.2 (55.8- | 45.8 (40.3- | 39.1 (35.4- | 50.3 (46.1- | 43.1 (36.9- | 41.2 (3  |
|                          | 66.6)       | 51.2)       | 42.8)       | 54.5)       | 49.2)       | 45.7)    |
| Prevalence               | 18.3 (12.0- | 12.6 (5.7-  | 11.6 (6.1-  | 21.2 (15.3- | 16.3 (9.3-  | 14.4 (8  |
| change†                  | 24.5)       | 19.5)       | 17.1)       | 27.1)       | 23.3)       | 20.1)    |
| P for non-               | 0.21        | 0.80        | 0.50        | 0.24        | 0.45        | 0.08     |
| linearity§               |             |             |             |             |             |          |
| P value for              | <0.001      | <0.001      | <0.001      | <0.001      | <0.001      | <0.001   |
| trend§                   |             | 1           |             | -           |             |          |

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval. 

† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for age and sex.

§ Adjusted for age. 

#### 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58

59

60

#### Obesity prevalence and trends by age group

2013-2014

2015-2016

2017-2020

Prevalence

change<sup>†</sup>

P for non-

linearity<sup>‡</sup>

trend<sup>±</sup>

P value for

Prevalence, 95% Cl

1999-2000

2001-2002

2003-2004

2005-2006

Women

40.0 (36.2-

43.0 (39.0-

44.6 (40.5-

15.5 (9.7-

43.9)

47.0)

48.6)

21.3)

0.65

<0.001

n=8,295

36.9 (30.9-

39.9 (35.3-

42.0 (35.8-

40.3 (35.3-

42.9)

44.5)

48.2)

45.4)

54.5 (50.3-

57.1 (50.6-

59.4 (56.2-

12.5 (5.6-

58.7)

63.6)

62.7)

19.4)

0.94

< 0.001

n=8,684

56.2 (48.9-

52.9 (48.1-

59.7 (54.9-

58.7 (53.5-

63.5)

57.6)

64.5)

63.8)

In women and men, the highest prevalence of RFM-defined obesity across years was observed

4 in older adults (60-79 years) (Table 4 and Figure 3).

5

1

2

3

1 2

| Table 4. Age-adju<br>2017-March 2020 |                    | prevalence trend | ds in RFM-defined  | d obesity by age g  | group: 1999-200    | 0 through   |  |
|--------------------------------------|--------------------|------------------|--------------------|---------------------|--------------------|-------------|--|
|                                      | RI                 | -M-defined obes  | sity               | BMI-defined obesity |                    |             |  |
|                                      | 20-39 years<br>old | 40-59 years      | 60-79 years<br>old | 20-39 years<br>old  | 40-59 years<br>old | 60-79 years |  |
| All participants                     | n=16,747           | n=16,912         | n=14,008           | n=16,747            | n=16,912           | n=14,008    |  |
| Prevalence,<br>95% Cl                |                    |                  |                    |                     |                    |             |  |
| 1999-2000                            | 29.0 (24.5-        | 46.9 (40.5-      | 61.8 (58.1-        | 25.4 (21.5-         | 33.2 (26.9-        | 35.4 (31.3- |  |
|                                      | 33.6)              | 53.4)            | 65.6)              | 29.3)               | 39.4)              | 39.5)       |  |
| 2001-2002                            | 30.2 (27.2-        | 45.0 (42.2-      | 63.8 (61.3-        | 25.3 (22.4-         | 33.2 (29.9-        | 33.7 (30.7- |  |
|                                      | 33.1)              | 47.8)            | 66.3)              | 28.1)               | 36.4)              | 36.8)       |  |
| 2003-2004                            | 34.2 (31.2-        | 51.2 (47.8-      | 65.8 (62.5-        | 28.1 (24.6-         | 35.9 (32.1-        | 33.0 (29.4- |  |
|                                      | 37.1)              | 54.6)            | 69.0)              | 31.7)               | 39.7)              | 36.5)       |  |
| 2005-2006                            | 32.6 (28.7-        | 53.2 (47.9-      | 66.0 (62.2-        | 28.5 (24.1-         | 40.1 (35.6-        | 34.9 (31.5- |  |
|                                      | 36.5)              | 58.5)            | 69.8)              | 32.9)               | 44.6)              | 38.3)       |  |
| 2007-2008                            | 35.5 (31.1-        | 51.6 (48.5-      | 66.1 (62.4-        | 30.2 (26.2-         | 35.7 (32.4-        | 37.4 (33.8- |  |
|                                      | 39.9)              | 54.7)            | 69.8)              | 34.3)               | 39.1)              | 40.9)       |  |
| 2009-2010                            | 37.2 (32.8-        | 50.5 (47.7-      | 68.5 (65.2-        | 32.5 (28.7-         | 36.0 (33.9-        | 41.8 (38.0- |  |
|                                      | 41.6)              | 53.4)            | 71.8)              | 36.3)               | 38.2)              | 45.7)       |  |
| 2011-2012                            | 37.7 (33.1-        | 53.6 (49.9-      | 68.0 (62.9-        | 30.4 (26.2-         | 39.3 (36.1-        | 38.3 (33.8- |  |
|                                      | 42.3)              | 57.3)            | 73.1)              | 34.5)               | 42.5)              | 42.9)       |  |

68.8 (64.6-

69.8 (64.7-

70.6 (67.2-

73.0)

74.9)

74.0)

13.6)

0.25

<0.001

n=6,952

67.7 (63.3-

72.0 (69.3-

73.0 (68.3-

71.3 (66.4-

72.2)

74.7)

77.7)

76.2)

8.8 (3.9-

34.4 (31.3-

36.0 (32.2-

39.8 (35.6-

14.5 (8.9-

37.5)

39.8)

44.0)

20.0)

0.48

<0.001

n=8,295

28.7 (23.6-

28.9 (24.1-

29.0 (23.8-

29.2 (24.1-

33.7)

33.6)

34.1)

34.3)

40.6 (36.2-

42.8 (37.5-

44.3 (41.2-

11.2 (4.5-

45.1)

48.2)

47.4)

17.8)

0.21

< 0.001

n=8,684

37.4 (30.2-

35.0 (30.2-

38.1 (32.3-

40.7 (35.9-

44.5)

39.8)

43.9)

45.6)

39.3 (35.2-

42.8 (37.5-

42.7 (39.1-46.3)

7.3 (2.0-

12.5)

0.46

< 0.001

n=6,952

37.4 (31.6-

36.6 (32.0-

33.6 (28.5-

34.8 (28.4-

43.2)

41.2)

38.7)

41.2)

43.5)

48.2)

#### **BMJ** Open

| 2007-2008                | 46.1 (40.4- | 60.0 (56.2- | 69.8 (64.5- | 33.0 (27.3- | 37.6 (32.6- | 36.0 (30.  |
|--------------------------|-------------|-------------|-------------|-------------|-------------|------------|
|                          | 51.7)       | 63.8)       | 75.1)       | 38.6)       | 42.5)       | 41.9)      |
| 2009-2010                | 46.4 (40.6- | 59.3 (55.5- | 78.5 (75.8- | 31.8 (28.2- | 35.5 (31.7- | 45.1 (40.  |
|                          | 52.2)       | 63.1)       | 81.3)       | 35.4)       | 39.3)       | 49.5)      |
| 2011-2012                | 47.6 (42.1- | 64.6 (60.1- | 76.7 (69.8- | 31.9 (28.0- | 39.4 (35.1- | 42.1 (34.  |
|                          | 53.1)       | 69.0)       | 83.5)       | 35.9)       | 43.6)       | 49.7)      |
| 2013-2014                | 50.8 (46.6- | 63.3 (58.1- | 78.0 (74.6- | 36.6 (33.9- | 43.6 (38.2- | 40.2 (34.  |
|                          | 55.1)       | 68.5)       | 81.4)       | 39.3)       | 48.9)       | 46.2)      |
| 2015-2016                | 53.3 (48.9- | 69.1 (62.7- | 77.1 (70.6- | 37.1 (33.5- | 44.8 (38.4- | 45.0 (37.  |
|                          | 57.8)       | 75.5)       | 83.6)       | 40.7)       | 51.1)       | 52.8)      |
| 2017-2020                | 53.3 (48.5- | 67.9 (63.6- | 81.0 (76.4- | 39.9 (35.3- | 42.8 (38.9- | 45.4 (40.  |
|                          | 58.0)       | 72.3)       | 85.6)       | 44.4)       | 46.7)       | 49.8)      |
| Prevalence               | 16.4 (9.1-  | 11.7 (3.6-  | 13.3 (7.1-  | 11.2 (4.7-  | 5.5 (-2.3-  | 8.0 (1.0-  |
| change†                  | 23.7)       | 19.9)       | 19.5)       | 17.7)       | 13.2)       | 15.0)      |
| P for non-<br>linearity§ | 0.16        | 0.39        | 0.99        | 0.44        | 0.42        | 0.97       |
| P value for              | <0.001      | <0.001      | <0.001      | <0.001      | <0.001      | <0.001     |
| trend§                   |             |             |             |             |             |            |
| Men                      | n=8,452     | n=8,228     | n=7,056     | n=8,452     | n=8,228     | n=7,056    |
| Prevalence,              |             |             |             |             |             |            |
| 95% CI                   |             |             |             |             |             |            |
| 1999-2000                | 22.4 (18.0- | 36.8 (30.4- | 54.7 (49.9- | 22.7 (18.3- | 28.8 (22.8- | 33.2 (28.  |
|                          | 26.8)       | 43.2)       | 59.5)       | 27.0)       | 34.8)       | 38.1)      |
| 2001-2002                | 20.8 (17.4- | 37.1 (33.5- | 53.5 (49.8- | 21.7 (18.5- | 31.2 (28.0- | 30.4 (26.  |
|                          | 24.1)       | 40.7)       | 57.1)       | 24.9)       | 34.5)       | 34.8)      |
| 2003-2004                | 26.9 (23.3- | 42.3 (36.7- | 57.2 (52.5- | 27.4 (22.5- | 33.6 (28.4- | 32.3 (27.  |
|                          | 30.4)       | 47.9)       | 62.0)       | 32.3)       | 38.9)       | 37.2)      |
| 2005-2006                | 25.4 (20.1- | 47.4 (40.5- | 59.8 (54.8- | 27.6 (22.0- | 39.5 (33.1- | 34.7 (29.  |
|                          | 30.7)       | 54.2)       | 64.7)       | 33.1)       | 45.9)       | 39.5)      |
| 2007-2008                | 25.4 (21.2- | 42.8 (37.8- | 61.8 (57.7- | 27.6 (23.8- | 33.7 (28.8- | 39.2 (34.  |
|                          | 29.5)       | 47.8)       | 65.9)       | 31.4)       | 38.5)       | 43.5)      |
| 2009-2010                | 28.5 (23.6- | 41.6 (37.7- | 56.9 (51.1- | 33.2 (27.2- | 36.6 (33.0- | 37.5 (32.  |
|                          | 33.3)       | 45.5)       | 62.7)       | 39.2)       | 40.2)       | 42.8)      |
| 2011-2012                | 28.4 (23.9- | 42.3 (38.0- | 58.1 (52.1- | 28.9 (23.5- | 39.1 (35.6- | 34.2 (29.  |
|                          | 33.0)       | 46.6)       | 64.2)       | 34.2)       | 42.5)       | 39.2)      |
| 2013-2014                | 30.0 (25.5- | 45.5 (40.3- | 58.6 (51.6- | 32.5 (28.1- | 37.7 (32.2- | 38.6 (30.  |
|                          | 34.5)       | 50.7)       | 65.5)       | 36.8)       | 43.3)       | 46.4)      |
| 2015-2016                | 33.1 (28.3- | 44.5 (36.5- | 61.4 (55.4- | 35.0 (29.0- | 40.8 (34.6- | 40.2 (34.  |
|                          | 38.0)       | 52.6)       | 67.5)       | 41.0)       | 47.1)       | 45.5)      |
| 2017-2020                | 35.9 (30.2- | 50.8 (46.2- | 58.8 (54.3- | 39.5 (33.1- | 45.8 (41.1- | 39.7 (34.  |
|                          | 41.5)       | 55.4)       | 63.3)       | 46.0)       | 50.6)       | 45.4)      |
| Prevalence               | 13.4 (6.5-  | 14.0 (6.4-  | 4.1 (-2.3-  | 16.8 (9.3-  | 17.0 (9.7-  | 6.5 (-0.7- |
| change†                  | 20.4)       | 21.6)       | 10.5)       | 24.4)       | 24.4)       | 13.8)      |
| P for non-               | 0.47        | 0.42        | 0.16        | 0.97        | 0.41        | 0.24       |
| linearity§               |             |             |             |             |             |            |
| P value for              | <0.001      | <0.001      | <0.001      | <0.001      | <0.001      | <0.001     |
|                          |             | 1           | 1           | 1           | 1           | 1          |

 \* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated

and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was

as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men

† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

30% or higher for men. CI denotes confidence interval.

**‡** Adjusted for sex and ethnicity.

§ Adjusted for ethnicity.

In contrast, no differences were observed in the prevalence of obesity between individuals 60-79 years and 40-59 years when using BMI for the diagnosis of obesity (Figure 3). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in individuals 60-79 years compared with those 40-59 years (Bonferroni corrected P<0.001) or 20-39 years (P<0.001). We found no statistically significant differences in the prevalence of BMI-defined obesity across age groups (P>0.17 for all comparisons). 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 19 of 35

BMJ Open

#### 1 DISCUSSION

Our study shows that, compared with BMI, the use of a surrogate for whole-body fat percentage revealed a much higher prevalence of general obesity among adults in the U.S., particularly among women, affecting nearly two-thirds of all women and nearly half of all men in 2017-2020, with an overall prevalence of 55.4%. This is an additional 22.5% of women and 3.8% of men 20-79 years being defined as obese compared with a BMI-based definition with the current criteria.

The use of RFM also revealed that the highest prevalence of general obesity over the study
period from 1999 to 2020 occurred among Mexican Americans and not among African
Americans, as was observed when BMI was used to diagnose obesity. Likewise, the use of
RFM showed that the highest prevalence of general obesity over this study period occurred
among older adults (60-79 years) and not among adults 40-59 years, as was observed when
BMI was used.

Overall, women had a markedly higher prevalence of RFM-defined obesity across years than men, a difference that was less evident when using BMI. Previous studies have shown no differences in the prevalence of BMI-defined obesity between women and men <sup>3 4 40</sup>. In the present study, the difference in the prevalence of RFM-defined obesity for 2017-2020 between women and men was nearly 20 percentage points.

The highest prevalence of RFM-defined obesity was observed in Mexican Americans, and the increase was linear over the study period, albeit this linear increase was largely driven by a steady increase among men. Among Mexican American women, a decrease was observed since 2015. A previous study reported that, between 2003 and 2006, the prevalence of BMIdefined obesity was higher among African Americans compared with Mexican Americans, but between 2015 and 2018, Mexican American men had a higher prevalence than African American men <sup>29</sup>. In contrast, RFM revealed a consistently higher prevalence of general obesity

among Mexican Americans over the observed time, in both women and men. Socio-economic
 characteristics are probably the main determinants of differences in the prevalence of general
 obesity between ethnic groups <sup>41</sup>.

Further research is needed to better understand the clinical implications of our study findings: 1) the much higher prevalence of general obesity among women when RFM is used as opposed to BMI; 2) the higher burden of general obesity on Mexican Americans compared with African and European Americans; and 3) the higher prevalence of general obesity in older individuals. Since RFM is based on waist circumference, and waist circumference is a surrogate for intra-abdominal fat <sup>42 43</sup>, RFM could be a surrogate for both general obesity and abdominal obesity. Although RFM has been shown to predict trunk fat percentage, the prediction error is greater for trunk fat percentage than for whole-body fat percentage <sup>23</sup>. 

The higher prevalence of RFM-defined obesity in older individuals found in our study is consistent with the higher body fat percentage observed in older individuals <sup>12 23 44-48</sup>. Whether the increased whole-body fat percentage in older individuals confers a higher risk on mortality requires further investigation. For instance, age per se is a strong risk factor for mortality, and the relationship between obesity and mortality could be mediated by age <sup>49</sup>. Conversely, the high body fat percentage in older individuals could explain the association of BMI-defined obesity with diabetes and cardiovascular disease in older individuals <sup>50-53</sup>. The increase in body adiposity with aging coincides with the high prevalence of many cardiometabolic alterations occurring more often in older individuals, such as glucose intolerance, insulin resistance, dyslipidemia, and hypertension <sup>49</sup>. BMI did not detect a higher prevalence of general obesity in individuals aged 60 years and older compared with younger adults, unlike when RFM was used. These findings further support that notion that BMI is a poor predictor of morbidity and mortality in older individuals <sup>48 54</sup>. 

Page 21 of 35

#### **BMJ** Open

| 1              |  |
|----------------|--|
| 2              |  |
| 3              |  |
| 4              |  |
| 5              |  |
| 6              |  |
| 7              |  |
| 8              |  |
| 9              |  |
| 9<br>10        |  |
|                |  |
| 11             |  |
| 12             |  |
| 13<br>14<br>15 |  |
| 14             |  |
| 15             |  |
| 16             |  |
| 17             |  |
| 18             |  |
| 19             |  |
| 19<br>20       |  |
| 21             |  |
| 22             |  |
| 23             |  |
| 24             |  |
| 25             |  |
| 26             |  |
| 27             |  |
| 27             |  |
| 20             |  |
| 29             |  |
| 30             |  |
| 31             |  |
| 32             |  |
| 33             |  |
| 34             |  |
| 35             |  |
| 36             |  |
| 37             |  |
| 38             |  |
| 39             |  |
| 40             |  |
| 41             |  |
| 42             |  |
| 43             |  |
| 44             |  |
| 45             |  |
|                |  |
| 46             |  |
| 47             |  |
| 48             |  |
| 49             |  |
| 50             |  |
| 51             |  |
| 52             |  |
| 53             |  |
| 54             |  |
| 55             |  |
| 56             |  |
| 57             |  |
| 58             |  |
| 59             |  |
| 60             |  |
| 00             |  |

1 Our study has strengths. First, we used RFM, a previously validated surrogate for whole-body 2 fat percentage in adults in the U.S.<sup>23</sup>, which has a high diagnostic accuracy (91%) for DXAdefined obesity <sup>27</sup> and has been shown to result in lower total misclassification of DXA-defined 3 high body adiposity compared with BMI among women (RFM: 12.7%; BMI: 56.5%) and men 4 5 (RFM: 9.4% BMI: 13.0%)<sup>23</sup>. Second, to define general obesity, we used previously validated 6 RFM cutoffs to predict all-cause mortality in a large U.S. adult population <sup>27</sup>. Previously 7 proposed cutoffs for fat-defined obesity have been based on arbitrary values <sup>55 56</sup> or on 8 corresponding BMI cutoffs <sup>12</sup>. Third, RFM requires only measured waist circumference and 9 height, which allowed us to estimate the prevalence of general obesity in a large adult 10 population of the U.S. (n=44,754) with a wide age range, over a period of nearly 22 years. 11 Fourth, NHANES have used a consistent methodology across survey cycles to measure anthropometrics, reducing the risk of measurement error to influence our results. 12 13 Our study also has limitations. First, our analysis was performed using data from a 14 representative sample of the non-institutionalized U.S. population only. Second, our estimates of prevalence trends could have been affected by some variability in sampling across NHANES 15 survey cycles <sup>35</sup>. Third, we did not analyze the prevalence trends for Asian Americans during the 16 17 period studied because NHANES began oversampling Asian Americans only from 2011-2012 onwards and the RFM cutoffs used to diagnose general obesity have not been validated among 18 19 Asian populations. 20 From a public health perspective, we argue that due to the underdiagnosis of obesity when 21 using BMI, the most affected populations are not receiving adequate medical care that they 22 require. Aspects that will need further research are the implications of some possible overdiagnosis of obesity <sup>57</sup> and the stigma that would be associated with it <sup>58</sup>. 23 In conclusion, the use of RFM, a surrogate for whole-body fat percentage, revealed a much 24 25 higher prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, 20

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

than that estimated by the BMI. RFM, but not BMI, also revealed a disproportionate higher
prevalence of general obesity in adults aged 60 years and older and Mexican Americans. Using
BMI as the lone measure to define obesity may lead to significant misclassification of large
obese subpopulations as non-obese, particularly among women. Our findings may have
implications for the use of resources in public health to tackle obesity-related health problems in

6 the most affected populations.

to beet terien only

| 1              |    |  |
|----------------|----|--|
| 2              |    |  |
| 3<br>4         | 1  | ETHICS APPROVAL  |
| 5              |    |  |
| 6<br>7         | 2  | Since this study used publicly available de-identified data, approval from an Institutional Review |
| 8<br>9         | 3  | Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects    |
| 10<br>11       | 4  | (detailed in 45 CFR part 46) 35.   |
| 12<br>13<br>14 | 5  |  |
| 15<br>16       | 6  | DATA AVAILABILITY STATEMENT  |
| 17             |    |  |
| 18<br>19       | 7  | All data utilized for analysis in this study are fully available at:                               |
| 20<br>21       | 8  | https://wwwn.cdc.gov/nchs/nhanes/  |
| 22<br>23       |    |  |
| 24             | 9  |  |
| 25             |    |  |
| 26             | 10 | ACKNOWLEDGMENTS  |
| 27             |    |  |
| 28<br>29       | 11 | We thank the Centers for Disease Control and Prevention (CDC) and the National Center for          |
| 30             |    |  |
| 31<br>32       | 12 | Health Statistics (NCHS) for providing access to the NHANES datasets. We also thank all            |
| 33<br>34       | 13 | subjects who participated in the surveys from 1999 through 2020.                                   |
| 35             |    |  |
| 36             | 14 |  |
| 37             |    |  |
| 38             |    |  |
| 39<br>40       |    |  |
| 40<br>41       |    |  |
| 42             |    |  |
| 43             |    |  |
| 44             |    |  |
| 45             |    |  |
| 46             |    |  |
| 47             |    |  |
| 48             |    |  |
| 49<br>50       |    |  |
| 51             |    |  |
| 52             |    |  |
| 53             |    |  |
| 54             |    |  |
| 55             |    |  |
| 56             |    |  |
| 57<br>50       |    | 22   |
| 58<br>59       |    | 22   |
| 60             |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                          |
|                |    |  |

#### 

## AUTHOR CONTRIBUTIONS

OOW was responsible for the conception and design of the study. OOW contributed to the statistical analysis. OOW and TS contributed to the interpretation of data and critical revision of the manuscript. OOW and TS drafted the final version of the manuscript and agreed to the submitted version of the manuscript. OOW is the manuscript's guarantor. OOW accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to submit for publication. 

#### FUNDING

This research received no specific grant from any funding agency in the public, commercial or 

### 

not-for-profit sectors.
COMPETING INTERESTS
The authors declare no conflict of interest. 

## 

- OW (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and
- transparent account of the study being reported; that no important aspects of the study have
- been omitted; and that any discrepancies from the study as originally planned have been
- explained.

#### PATIENT AND PUBLIC INVOLVEMENT

Patients and the public were not involved in this study. This study will be available to the public once it is published in the scientific literature.

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults,

| 1              |  |
|----------------|--|
| 2              |  |
| 3              |  |
| 4              |  |
| 5              |  |
| 6              |  |
| 7              |  |
| /              |  |
| 8              |  |
| 9              |  |
| 10             |  |
| 11             |  |
| 12             |  |
| 13             |  |
|                |  |
| 14             |  |
| 15             |  |
| 16             |  |
| 17             |  |
| 18             |  |
| 19             |  |
| 20             |  |
| 20             |  |
| 21             |  |
| 22<br>23       |  |
| 23             |  |
| 24             |  |
| 25             |  |
| 26             |  |
| 27             |  |
| 27             |  |
| 28             |  |
| 29             |  |
| 30             |  |
| 31             |  |
| 32             |  |
| 33             |  |
| 33<br>34       |  |
| 34             |  |
| 35             |  |
| 36             |  |
| 36<br>37<br>38 |  |
| 38             |  |
| 39             |  |
| 40             |  |
| 41             |  |
|                |  |
| 42             |  |
| 43             |  |
| 44             |  |
| 45             |  |
| 46             |  |
| 40<br>47       |  |
|                |  |
| 48             |  |
| 49             |  |
| 50             |  |
| 51             |  |
| 52             |  |
| 53             |  |
|                |  |

54

55

56 57

59

60

#### 1 REFERENCES

3 1999-2000. JAMA 2002;288(14):1723-7. doi: 10.1001/jama.288.14.1723 4 2. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in Obesity Among Adults in the 5 United States, 2005 to 2014, JAMA 2016;315(21);2284-91, doi: 10.1001/iama.2016.6458 3. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among 6 7 adults: United States, 2017-2018. NCHS Data Brief 2020(360):1-8. 8 4. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files - Development of files and prevalence estimates 9 for selected health outcomes. National Health Statistics Reports 2021(158):1-20. 10 5. Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond) 2008;32 11 Suppl 3:S56-9. doi: 10.1038/ijo.2008.87 12 13 6. WHO. Physical status: the use and interpretation of anthropometry. WHO Technical Report 14 Series. Geneva, 1995. 7. CDC. Defining adult overweight & obesity. Available at: 15 https://www.cdc.gov/obesity/basics/adult-defining.html. Accessed April 18, 2022. 16 17 8. Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. Am J Clin Nutr 1986;44(6):996-7. doi: 10.1093/ajcn/44.6.996 18 9. Gallagher D. Visser M. Sepulveda D. et al. How useful is body mass index for comparison of 19 body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996;143(3):228-39. 20 10. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total 21 22 mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368(9536):666-78. doi: 10.1016/S0140-6736(06)69251-9 23 24 11. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index 25 to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010;34(5):791-9. doi: 10.1038/ijo.2010.5 26 27 12. Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 28 29 2000;72(3):694-701. 13. Heitmann BL, Erikson H, Ellsinger BM, et al. Mortality associated with body fat, fat-free 30 mass and body mass index among 60-year-old swedish men-a 22-year follow-up. The study 31 32 of men born in 1913. Int J Obes Relat Metab Disord 2000;24(1):33-7. 14. Ortega FB, Sui X, Lavie CJ, et al. Body Mass Index, the most widely used but also widely 33 criticized index: Would a criterion standard measure of total body fat be a better predictor of 34 cardiovascular disease mortality? Mayo Clin Proc 2016;91(4):443-55. 35 15. Padwal R, Leslie WD, Lix LM, et al. Relationship Among Body Fat Percentage, Body Mass 36 37 Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med 2016;164(8):532-41. 16. Zong G, Zhang Z, Yang Q, et al. Total and regional adiposity measured by dual-energy X-38 ray absorptiometry and mortality in NHANES 1999-2006. Obesity (Silver Spring) 39 40 2016;24(11):2414-21. doi: 10.1002/oby.21659 17. Dong B, Peng Y, Wang Z, et al. Joint association between body fat and its distribution with 41 all-cause mortality: A data linkage cohort study based on NHANES (1988-2011). PLoS One 42 2018;13(2):e0193368. doi: 10.1371/journal.pone.0193368 43 18. Lahmann PH, Lissner L, Gullberg B, et al. A prospective study of adiposity and all-cause 44 mortality: the Malmo Diet and Cancer Study. Obes Res 2002;10(5):361-9. doi: 45 10.1038/oby.2002.50 46 47 19. Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 48 diabetes, coronary heart disease, and cancer subgroups in the UK Biobank, and their modification by smoking. *Diabetes Care* 2018;41(9):1878-86. doi: 10.2337/dc17-2508 49 58 24 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 3<br>4<br>5 | 1<br>2<br>3 | 20. | Jayedi A, Khan TA, Aune D, et al. Body fat and risk of all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. <i>Int J Obes (Lond)</i> 2022;46(9):1573-81. doi: 10.1038/s41366-022-01165-5 |
|-------------|-------------|-----|---|
| 6           | 3<br>4      | 21. | Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. <i>Nutr Today</i>   |
| 7           | 5           |     | 2015;50(3):117-28. doi: 10.1097/NT.0000000000000092   |
| 8           | 6           | 22. | CDC. Body mass index : considerations for practitioners.  |
| 9           | 7           |     | https://stacks.cdc.gov/view/cdc/25368 [Accessed December 8, 2021].  |
| 10          | 8           | 23  | Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat   |
| 11          | 9           | _0. | percentage – A cross-sectional study in American adult individuals. Sci Rep   |
| 12          | 10          |     | 2018;8(1):10980. doi: doi.org/10.1038/s41598-018-29362-1  |
| 13          | 11          | 24  | Paek JK, Kim J, Kim K, et al. Usefulness of relative fat mass in estimating body adiposity in   |
| 14<br>15    | 12          | ۲۰. | Korean adult population. <i>Endocr J</i> 2019;66(8):723-29. doi: 10.1507/endocrj.EJ19-0064  |
| 15<br>16    | 13          | 25  | Guzman-Leon AE, Velarde AG, Vidal-Salas M, et al. External validation of the relative fat   |
| 16<br>17    |             | 25. |   |
| 17          | 14          |     | mass (RFM) index in adults from north-west Mexico using different reference methods.  |
| 18          | 15          | 00  | PLoS One 2019;14(12):e0226767. doi: 10.1371/journal.pone.0226767  |
| 19<br>20    | 16          | 20. | Correa CR, Formolo NPS, Dezanetti T, et al. Relative fat mass is a better tool to diagnose  |
| 20          | 17          |     | high adiposity when compared to body mass index in young male adults: A cross-section   |
| 21          | 18          |     | study. Clin Nutr ESPEN 2021;41:225-33. doi: 10.1016/j.clnesp.2020.12.009  |
| 22          | 19          | 27. | Woolcott OO, Bergman RN. Defining cutoffs to diagnose obesity using the relative fat mass   |
| 23<br>24    | 20          |     | (RFM): Association with mortality in NHANES 1999-2014. Int J Obes (Lond) 2020;44:1301-  |
| 24<br>25    | 21          |     | 10. doi: 10.1038/s41366-019-0516-8  |
| 25<br>26    | 22          | 28. | Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity   |
| 26<br>27    | 23          |     | among adults in the United States 2011-18: population based study. <i>BMJ</i> 2021;372:n365.  |
| 27<br>28    | 24          |     | doi: 10.1136/bmj.n365   |
| 28<br>29    | 25          | 29. | Gupta RD, Chakraborty PA, Al Kibria GM. Racial/Ethnic disparities in prevalence and trends  |
| 30          | 26          |     | of obesity, grade 3 obesity, and abdominal obesity among US adults, 2003-18. Obesity  |
| 31          | 27          |     | Medicine 2021;28 (no pagination)(100372) doi:   |
| 32          | 28          |     | https://dx.doi.org/10.1016/j.obmed.2021.100372  |
| 33          | 29          | 30. | CDC. NHANES 2017-March 2020 pre-pandemic data release notes.  |
| 34          | 30          |     | https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/releasenotes.aspx?Cycle=2017-2020   |
| 35          | 31          |     | [Accessed October 10, 2022].  |
| 36          | 32          | 31. | Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic   |
| 37          | 33          |     | Origin: 1995 to 2050, U.S. Bureau of the Census, Current Population Reports. Reports,   |
| 38          | 34          |     | P25-1130, U.S. Washington, DC, 1996.  |
| 39          | 35          | 32. | National Health and Nutrition Examination Survey (NHANES). Anthropometry procedures   |
| 40          | 36          |     | manual. http://www.cdc.gov/nchs/data/nhanes/nhanes 07 08/manual an.pdf [Accessed  |
| 41          | 37          |     | May 16, 2016].  |
| 42          | 38          | 33. | CDC. NHANES response rates and population totals. Available at:   |
| 43          | 39          |     | https://wwwn.cdc.gov/nchs/nhanes/responserates.aspx. Accessed July 19, 2022.  |
| 44          | 40          | 34. | HHS. U.S. Department of Health & Human Services. Federal policy for the protection of   |
| 45          | 41          | •   | human subjects. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-   |
| 46          | 42          |     | rule/index.html. Accessed April 2, 2022., 2020.   |
| 47          | 43          | 35  | Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination   |
| 48          | 44          | 00. | survey: analytic guidelines, 1999-2010. <i>Vital Health Stat</i> 2 2013(161):1-24.  |
| 49          | 45          | 36  | CDC. National Health and Nutrition Examination Survey. Module 1: Datasets and   |
| 50          | 45          | 50. | Documentation. https://wwwn.cdc.gov/nchs/nhanes/tutorials/module1.aspx [accessed July   |
| 51          | 40<br>47    |     |   |
| 52          |             | 27  | 18, 2022].<br>Durriaman S. Simon P. Elavible regression models with subis splings. Stat Mod   |
| 53          | 48          | 57. | Durrleman S, Simon R. Flexible regression models with cubic splines. <i>Stat Med</i>  |
| 54          | 49          | 20  | 1989;8(5):551-61. doi: 10.1002/sim.4780080504   |
| 55          | 50          | აბ. | Harrell FE. Regression modeling strategies: With applications to linear models, logistic  |
| 56          | 51          |     | regression, and survival analysis. New York: Springer 2001.   |
| 57          |             |     | 25  |
| 58<br>59    |             |     | 25  |
|             |             |     |   |

| 1        |          |  |
|----------|----------|--|
| 2        |          |  |
| 3        | 1        | 39. Cox NJ. Speaking Stata: Smoothing in various directions. Stata Journal 2005;5(4):574-93.   |
| 4        | 2        | 40. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of  |
| 5        | 3        | body mass index among US adults, 1999-2010. JAMA 2012;307(5):491-7.  |
| 6<br>7   | 4        | 41. Lakerveld J, Mackenbach J. The upstream determinants of adult obesity. Obes Facts  |
| 8        | 5        | 2017;10(3):216-22. doi: 10.1159/000471489  |
| 9        | 6        | 42. Edston E. A correlation between the weight of visceral adipose tissue and selected   |
| 10       | 7        | anthropometric indices: an autopsy study. <i>Clin Obes</i> 2013;3(3-4):84-9. doi:  |
| 11       | 8        | 10.1111/cob.12021  |
| 12       | 9        | 43. Conway JM, Chanetsa FF, Wang P. Intraabdominal adipose tissue and anthropometric surrogates in African American women with upper- and lower-body obesity. <i>Am J Clin Nutr</i>          |
| 13       | 10<br>11 | 1997;66(6):1345-51. doi: 10.1093/ajcn/66.6.1345  |
| 14<br>15 | 12       | 44. Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females   |
| 16       | 13       | between ages 18 and 85 years. <i>J Gerontol</i> 1972;27(4):438-43. doi: 10.1093/geronj/27.4.438  |
| 17       | 14       | 45. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness:   |
| 18       | 15       | age- and sex-specific prediction formulas. Br J Nutr 1991;65(2):105-14.  |
| 19       | 16       | 46. Noppa H, Andersson M, Bengtsson C, et al. Body composition in middle-aged women with   |
| 20       | 17       | special reference to the correlation between body fat mass and anthropometric data. Am J   |
| 21       | 18       | <i>Clin Nutr</i> 1979;32(7):1388-95.   |
| 22<br>23 | 19       | 47. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A, et al. Validity and reliability of body  |
| 23       | 20       | composition analysers in children and adults. <i>Br J Nutr</i> 2008;100(4):859-65. doi:  |
| 25       | 21       | 10.1017/S0007114508925460  |
| 26       | 22<br>23 | <ol> <li>Kuk JL, Saunders TJ, Davidson LE, et al. Age-related changes in total and regional fat<br/>distribution. Ageing Res Rev 2009;8(4):339-48. doi: 10.1016/j.arr.2009.06.001</li> </ol> |
| 27       | 23<br>24 | 49. Schwartz RS. Obesity in the elderly: Prevalence, consequences, and treatment. In: Bray   |
| 28       | 25       | GA, Bouchard C, eds. Handbook of obesity Etiology and pathophysiology. Second edition  |
| 29<br>30 | 26       | ed. New York: Marcel Dekker, Inc. 2004:135-48.   |
| 30       | 27       | 50. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident  |
| 32       | 28       | diabetes in Chinese adults: a population-based cohort study. BMJ Open 2018;8(9):e021768.   |
| 33       | 29       | doi: 10.1136/bmjopen-2018-021768   |
| 34       | 30       | 51. Lind L, Sundstrom J, Arnlov J, et al. Impact of aging on the strength of cardiovascular risk   |
| 35       | 31       | factors: A longitudinal study over 40 years. <i>J Am Heart Assoc</i> 2018;7(1) doi:  |
| 36<br>37 | 32<br>33 | 10.1161/JAHA.117.007061  |
| 38       | 33<br>34 | 52. Masaki KH, Curb JD, Chiu D, et al. Association of body mass index with blood pressure in<br>elderly Japanese American men. The Honolulu Heart Program. <i>Hypertension</i>               |
| 39       | 35       | 1997;29(2):673-7. doi: 10.1161/01.hyp.29.2.673   |
| 40       | 36       | 53. Tromp J, Paniagua SMA, Lau ES, et al. Age dependent associations of risk factors with  |
| 41       | 37       | heart failure: pooled population based cohort study. BMJ 2021;372:n461. doi:   |
| 42       | 38       | 10.1136/bmj.n461   |
| 43       | 39       | 54. Chang SH, Beason TS, Hunleth JM, et al. A systematic review of body fat distribution and   |
| 44<br>45 | 40       | mortality in older people. <i>Maturitas</i> 2012;72(3):175-91. doi: 10.1016/j.maturitas.2012.04.004  |
| 45       | 41       | [published Online First: 2012/05/19]   |
| 47       | 42       | 55. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause   |
| 48       | 43       | and cardiovascular disease mortality in men. <i>Am J Clin Nutr</i> 1999;69(3):373-80. doi:   |
| 49       | 44<br>45 | 10.1093/ajcn/69.3.373<br>56. Lobman TG, Houtkooper L, Going SB. Body Fat Measurement Goes High-Tech: Not All Are   |
| 50       | 45<br>46 | Created Equal. ACSM's Health & Fitness Journal 1997;1(1):30-35.  |
| 51<br>52 | 47       | 57. Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what it is and what it isn't.  |
| 52       | 48       | <i>BMJ Evid Based Med</i> 2018;23(1):1-3. doi: 10.1136/ebmed-2017-110886   |
| 54       | 49       | 58. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public   |
| 55       | 50       | Health 2010;100(6):1019-28. doi: 10.2105/AJPH.2009.159491  |
| 56       |          |  |
| 57       |          |  |
| 58<br>59 |          | 26   |
| 60       |          | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml  |
|          |          |  |


## 1 FIGURE LEGENDS


Figure 1. Age-adjusted U.S. adult prevalence trends in RFM-defined obesity by sex: 19992000 through 2017-March 2020. Trend lines were smoothed using the Lowes method on
weighted prevalence estimates. Body fat-defined obesity was determined using the relative fat
mass (RFM). RFM was calculated as follows: RFM = 64 - (20 × height/waist circumference) +
(12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or
higher for women and RFM was 30% or higher for men.


8 Figure 2. Age-adjusted U.S. adult prevalence trends in RFM-defined obesity by ethnicity:

9 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes method on
10 weighted prevalence estimates. The relative fat mass (RFM) was calculated as follows: RFM =
11 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women.
12 Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for
13 men.

Figure 3. Age-adjusted U.S. adult prevalence trends in RFM-defined obesity by age group: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes method on weighted prevalence estimates. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. 







## **Supplementary Material**

## Trends in obesity defined by the relative fat mass (RFM) index among adults in

the United States from 1999 to 2020: population-based study

Orison O. Woolcott<sup>1,2,\*</sup>, Till Seuring<sup>3</sup>


<sup>1</sup>Ronin Institute, Montclair, NJ, USA; <sup>2</sup>Institute for Globally Distributed Open Research and Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup>Luxembourg Institute of Socio-Economic Research (LISER), Esch-sur-Alzette, Luxembourg

| Characteristic          | All           | With complete | With missing data |  |
|-------------------------|---------------|---------------|-------------------|--|
|                         |               | data          |                   |  |
| Sample size, n (%)      | 50,283 (100)  | 47,667 (95.6) | 2,616 (4.4)       |  |
| Median age (IQR), years | 45 (33-58)    | 45 (33-58)    | 47 (34-63)        |  |
| Male sex, n (%)         | 24,954 (49.2) | 23,736 (49.4) | 1,218 (45.4)      |  |
| Ethnicity, n (%)        |               |               |                   |  |
| Mexican American        | 8,827 (8.3)   | 8,416 (8.3)   | 411 (8.6)         |  |
| European American       | 20,618 (66.9) | 19,691(67.2)  | 927 (58.6)        |  |
| African American        | 11,433 (11.4) | 10,673(11.2)  | 760 (16.7)        |  |
| Other/multi-racial      | 9,405 (13.4)  | 8,887 (13.2)  | 518 (16.1)        |  |

Supplementary Table 1. Characteristics of study participants with missing data.\*

\* Sample size represents unweighted data. Estimates represent weighted data.

NHANES 1999-March 2020



Supplementary Figure 1



STROBE Statement—checklist of items that should be included in reports of observational studies

|  | Item<br>No | Recommendation   | Pag<br>No |
|--|------------|--|-----------|
| Title and abstract   | 1          | (a) Indicate the study's design with a commonly used term in the title or            | 1         |
|  |            | the abstract   |           |
|  |            | (b) Provide in the abstract an informative and balanced summary of what              | 3         |
|  |            | was done and what was found  |           |
| Introduction   |            |  |           |
| Background/rationale   | 2          | Explain the scientific background and rationale for the investigation being reported | 5-6       |
| Objectives   | 3          | State specific objectives, including any prespecified hypotheses                     | 6         |
| Methods  |            |  | •         |
| Study design   | 4          | Present key elements of study design early in the paper                              | 7         |
| Setting  | 5          | Describe the setting, locations, and relevant dates, including periods of            | 7-8       |
|  |            | recruitment, exposure, follow-up, and data collection                                |           |
| Participants   | 6          | (a) Cohort study—Give the eligibility criteria, and the sources and                  | 7         |
|  |            | methods of selection of participants. Describe methods of follow-up                  |           |
|  |            | Case-control study—Give the eligibility criteria, and the sources and                |           |
|  |            | methods of case ascertainment and control selection. Give the rationale              |           |
|  |            | for the choice of cases and controls   |           |
|  |            | Cross-sectional study—Give the eligibility criteria, and the sources and             |           |
|  |            | methods of selection of participants   |           |
|  |            | (b) Cohort study—For matched studies, give matching criteria and                     |           |
|  |            | number of exposed and unexposed  |           |
|  |            | Case-control study—For matched studies, give matching criteria and the               |           |
|  |            | number of controls per case  |           |
| Variables  | 7          | Clearly define all outcomes, exposures, predictors, potential confounders,           | 7-9       |
|  |            | and effect modifiers. Give diagnostic criteria, if applicable                        |           |
| Data sources/ 8* For each variable of interest, give sources of data and details of method |            | 7-9  |           |
| measurement  |            | of assessment (measurement). Describe comparability of assessment                    |           |
|  |            | methods if there is more than one group  |           |
| Bias   | 9          | Describe any efforts to address potential sources of bias                            | 8-9       |
| Study size   | 10         | Explain how the study size was arrived at  | 7         |
| Quantitative variables   | 11         | Explain how quantitative variables were handled in the analyses. If                  | 8-9       |
|  |            | applicable, describe which groupings were chosen and why                             |           |
| Statistical methods  | 12         | (a) Describe all statistical methods, including those used to control for            | 8-9       |
|  |            | confounding  |           |
|  |            | (b) Describe any methods used to examine subgroups and interactions                  | 8-9       |
|  |            | (c) Explain how missing data were addressed  | 8         |
|  |            | (d) Cohort study—If applicable, explain how loss to follow-up was                    | 7,9       |
|  |            | addressed  |           |
|  |            | Case-control study—If applicable, explain how matching of cases and                  |           |
|  |            | controls was addressed   |           |
|  |            | Cross-sectional study—If applicable, describe analytical methods taking              |           |
|  |            | · · · · · · · ·  | 1         |
|  |            | account of sampling strategy   |           |

Continued on next page

| Participants        | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study,                | 10              |
|---------------------|-----|---|-----------------|
|                     |     | completing follow-up, and analysed  |                 |
|                     |     | (b) Give reasons for non-participation at each stage  | 10              |
|                     |     | (c) Consider use of a flow diagram  | Suj<br>Fig      |
| Descriptive<br>data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders                                      | 10              |
|                     |     | (b) Indicate number of participants with missing data for each variable of interest   | Suj<br>Tal<br>1 |
|                     |     | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)  |                 |
| Outcome data        | 15* | Cohort study-Report numbers of outcome events or summary measures over time   |                 |
|                     |     | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure  |                 |
|                     |     | Cross-sectional study—Report numbers of outcome events or summary measures  | 10-             |
| Main results        | 16  | ( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were | 8, 1            |
|                     |     | adjusted for and why they were included   |                 |
|                     |     | (b) Report category boundaries when continuous variables were categorized   | 15-             |
|                     |     | ( <i>c</i> ) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | NA              |
| Other analyses      | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  | 12-             |
| Discussion          |     |   |                 |
| Key results         | 18  | Summarise key results with reference to study objectives  | 18              |
| Limitations         |     |   | 20              |
| Interpretation      | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence    | 20-             |
| Generalisability    | 21  | Discuss the generalisability (external validity) of the study results   | 20              |
| Other informati     | on  |   |                 |
| Funding             | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                 | 23              |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

# **BMJ Open**

## Temporal trends in obesity defined by the relative fat mass (RFM) index among adults in the United States from 1999 to 2020: population-based study

| Journal:                             | BMJ Open  |
|--------------------------------------|---|
| Manuscript ID                        | bmjopen-2022-071295.R1  |
| Article Type:                        | Original research   |
| Date Submitted by the<br>Author:     | 25-May-2023   |
| Complete List of Authors:            | Woolcott, Orison; Ronin Institute; Institute for Globally Distributed Open<br>Research and Education (IGDORE)<br>Seuring, Till; Luxembourg Institute of Socio-Economic Research (LISER) |
| <b>Primary Subject<br/>Heading</b> : | Epidemiology  |
| Secondary Subject Heading:           | Diabetes and endocrinology, General practice / Family practice, Public health   |
| Keywords:                            | EPIDEMIOLOGY, PUBLIC HEALTH, General endocrinology < DIABETES & ENDOCRINOLOGY, GENERAL MEDICINE (see Internal Medicine), Obesity  |
|                                      |   |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 1             |    |   |
|---------------|----|---|
| 2             |    |   |
| 3<br>4        | 1  | Temporal trends in obesity defined by the relative fat mass (RFM) index among   |
| 5<br>6        | 2  | adults in the United States from 1999 to 2020: population-based study   |
| 7<br>8        | 3  |   |
| 9<br>10<br>11 | 4  | Orison O. Woolcott, research scientist <sup>1,2,*</sup> , Till Seuring, postdoctoral fellow <sup>3</sup>  |
| 12<br>13      | 5  |   |
| 14<br>15      | 6  | <sup>1</sup> Ronin Institute, Montclair, NJ, USA; <sup>2</sup> Institute for Globally Distributed Open Research and   |
| 16<br>17      | 7  | Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup> Luxembourg Institute of Socio-Economic   |
| 18<br>19      | 8  | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 20<br>21      | 9  | Correspondence:<br>Orison O. Woolcott, M.D.<br>Ronin Institute<br>Montclair, NJ<br>United States of America<br>Telephone: +1 (323) 253-2562<br>Email: Orison Woolcott@gmail.com |
| 22<br>23      | 10 |   |
| 24            | 11 |   |
| 25            | 12 |   |
| 26            | 13 |   |
| 27            | 14 |   |
| 28<br>29      | 15 |   |
| 30            | 16 |   |
| 31            | 17 | Correspondence:   |
| 32            | 18 |   |
| 33            | 19 | Orison O. Woolcott, M.D.  |
| 34            | 20 | Ronin Institute   |
| 35            | 21 | Montclair, NJ   |
| 36            | 22 | United States of America  |
| 37            | 23 | Telephone: +1 (323) 253-2562  |
| 38            | 24 | Email: Orison.Woolcott@gmail.com  |
| 39            | 25 |   |
| 40            | 26 |   |
| 41<br>42      | 27 | Abstract word count: 300  |
| 43<br>44      | 28 | Text word count: 3,918  |
| 45<br>46      | 29 |   |
| 47<br>48      | 30 | Keywords: General Obesity, NHANES, Prevalence, Relative Fat Mass, RFM, Trends.  |
| 49            |    |   |
| 50            |    |   |
| 51            |    |   |
| 52            |    |   |
| 53            |    |   |
| 54            |    |   |
| 55            |    |   |
| 56            |    |   |
| 57            |    |   |
| 58<br>59      |    | 1   |
|               |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |
| 60            |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |

BMJ Open

| 2<br>3<br>4          | 1  | ABSTRACT  |
|----------------------|----|---|
| 5<br>6<br>7          | 2  | Objectives: The body mass index (BMI) largely underestimates excess body fat, suggesting        |
| 7<br>8<br>9          | 3  | that the prevalence of obesity could be underestimated. Biologically, women are known to have   |
| 10<br>11             | 4  | higher body fat than men. This study aimed to compare the temporal trends in general obesity    |
| 12<br>13             | 5  | by sex, ethnicity, and age among adults in the United States using the relative fat mass (RFM), |
| 14<br>15<br>16       | 6  | a validated surrogate for whole-body fat percentage, and BMI.                                   |
| 17<br>18             | 7  | Design: Population-based study  |
| 19<br>20<br>21       | 8  | Setting: U.S. National Health and Nutrition Examination Survey (NHANES), from 1999-2000         |
| 21<br>22<br>23       | 9  | through 2017-March 2020.  |
| 24<br>25<br>26       | 10 | Participants: A representative sample of adults 20-79 years in the U.S.                         |
| 27<br>28             | 11 | Main outcome measures: Age-adjusted prevalence of general obesity. RFM-defined obesity          |
| 29<br>30             | 12 | was diagnosed using validated cutoffs to predict all-cause mortality: RFM ≥40% for women and    |
| 31<br>32<br>33       | 13 | ≥30% for men. BMI-defined obesity was diagnosed using a cutoff of 30 kg/m <sup>2</sup> .        |
| 34<br>35             | 14 | Results: Analysis included data from 47,667 adults. Among women, RFM-defined obesity            |
| 36<br>37             | 15 | prevalence was 64.7% (95% confidence interval, 62.1-67.3%) in 2017-2020, a linear increase of   |
| 38<br>39<br>40       | 16 | 13.9 percentage points (9.0-18.9%; P<0.001) relative to 1999-2000. In contrast, the prevalence  |
| 40<br>41<br>42       | 17 | of BMI-defined obesity was 42.2% (39.4-45.0%) in 2017-2020. Among men, the corresponding        |
| 43<br>44             | 18 | RFM-defined obesity prevalence was 45.8% (42.0-49.7%), a linear increase of 12.0 percentage     |
| 45<br>46             | 19 | points (6.6-17.3%; P<0.001). In contrast, the prevalence of BMI-defined obesity was 42.0 (37.8- |
| 47<br>48             | 20 | 46.3%). The highest prevalence of RFM-defined obesity across years was observed in older        |
| 49<br>50             | 21 | adults (60-79 years) and Mexican Americans, in women and men. Conversely, the highest           |
| 51<br>52             | 22 | prevalence of BMI-defined obesity across years was observed in middle-age (40-59 years) and     |
| 53<br>54<br>55<br>56 | 23 | older adults, and in African American women.  |
| 50<br>57<br>58       |    | 2   |
| 59<br>60             |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                       |

**Conclusions:** The use of a surrogate for whole-body fat percentage revealed a much higher prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, than that estimated using BMI, and detected a disproportionate higher prevalence of general obesity in older adults and Mexican Americans.

<text><text><text>

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- RFM is a validated surrogate for whole-body fat percentage that has a high diagnostic accuracy (91%) for DXA-defined obesity.
- The diagnosis of obesity was based on measured anthropometrics and validated RFM cutoffs associated with increased risk for all-cause mortality.
- RFM requires only waist circumference and height for its calculation.
- The proportion of obesity misclassification is not trivial when using RFM.
- Estimates of temporal trends in obesity was not possible for Asian Americans.

# 1 INTRODUCTION

The prevalence of obesity (excess body fat) in the United States has doubled from 15.0% in 1976-1980 to 30.9% in 1999-2000<sup>1</sup>, and it continues to increase <sup>23</sup>. The age-adjusted prevalence of obesity among adults in the U.S. has been estimated at 41.9% in 2017-March 2020<sup>4</sup>. Obesity diagnosis is based on the body mass index (BMI), an indirect measure of body fat <sup>56</sup>. BMI is calculated as the ratio of body weight in kilograms to the square of the height in meters 7. BMI does not distinguish between fat mass and fat-free mass and does not account for differences in adiposity between women and men. Biologically, women are known to have higher body fat than men<sup>8-12</sup>. A meta-analysis of 25 international studies comprising nearly 32,000 adults concluded that BMI underestimates ~50% of all individuals with excess body fat percentage determined by reference techniques <sup>11</sup>, suggesting that the prevalence of obesity could be largely underestimated among countries. 

There is robust evidence linking high whole-body fat percentage with increased risk of death <sup>13-</sup> <sup>20</sup>, supporting the need for a better assessment of body adiposity. Although the limitations of BMI to assess body adiposity are widely acknowledged <sup>6 8-11 21 22</sup>. BMI remains the most widely used anthropometric index in clinical practice, epidemiology, and public health, given its simplicity, very low cost, and its association with several clinical conditions and mortality <sup>6</sup>. The high cost and time required to assess body adiposity using more accurate techniques such as dual-energy x-ray absorptiometry (DXA), dual-labeled water, or magnetic resonance, prevents their use in large populations or clinical practice as part of routine screening. 

The relative fat mass (RFM) is a simple and low-cost anthropometric index developed to estimate whole-body fat percentage <sup>23</sup>. RFM is a linear equation based on the ratio of height to waist circumference that has been validated in Mexican, European, and African Americans <sup>23</sup>, and in other populations <sup>24-26</sup>. Compared with BMI, RFM resulted in lower obesity misclassification when DXA was used as the reference method for diagnosing obesity in adults 

Page 7 of 41

1

#### BMJ Open

| 2              |    |      |
|----------------|----|------|
| 3<br>4         | 1  | 24 2 |
| 5              | 2  | am   |
| 6<br>7         | 3  | the  |
| 8<br>9         |    |      |
| 10<br>11       | 4  | sta  |
| 12<br>13       | 5  | Re   |
| 14<br>15       | 6  | toc  |
| 16<br>17       | 7  | ро   |
| 18<br>19       | 8  | lim  |
| 20<br>21       | 9  | be   |
| 22<br>23       | 10 | ad   |
| 24<br>25       | 11 | sui  |
| 26<br>27<br>28 | 12 | ob   |
| 28<br>29<br>30 | 13 | COI  |
| 31<br>32       | 14 | in t |
| 33             |    |      |
| 34<br>35       |    |      |
| 36<br>37       |    |      |
| 38             |    |      |
| 39<br>40       |    |      |
| 40<br>41       |    |      |
| 42             |    |      |
| 43<br>44       |    |      |
| 44<br>45       |    |      |
| 46             |    |      |
| 47<br>48       |    |      |
| 40<br>49       |    |      |
| 50             |    |      |
| 51<br>52       |    |      |
| 52<br>53       |    |      |
| 54             |    |      |
| 55             |    |      |
| 56<br>57       |    |      |
| 57<br>58       |    |      |
| 59             |    |      |

60

<sup>24 27</sup>. The accuracy of RFM in diagnosing high body fat percentage is superior to that of BMI
 among men and similar to BMI among women <sup>23</sup>. In an analysis of a representative sample of
 the U.S. adult population (NHANES 1999-2006), RFM had a diagnostic accuracy of 91% (C statistic = 0.91) for DXA-defined obesity in women and men <sup>27</sup>.
 Recent studies have examined the U.S. prevalence trends in obesity using BMI as diagnostic
 tool <sup>3 28 29</sup>. Although data on body fat percentage have also been reported for the U.S. adult
 population <sup>28</sup>, no body fat cutoffs were used to diagnose general obesity, and the analyses were

8 limited to adults 20-59 years only, and for the period 2011-2018. In fact, body composition has

9 been inconsistently assessed across NHANES survey cycles and across age groups. In

10 addition, no study has compared the trends of general obesity in the U.S. using RFM, a

11 surrogate for body fat percentage, and BMI. Furthermore, no study has examined current

12 obesity trends among U.S. adults over a period of nearly 22 years. The aim of this study was to

13 compare the temporal trends in general obesity by sex, ethnicity, and age group among adults

14 in the U.S. from 1999 to 2020 using RFM and BMI.

## 1 MATERIAL AND METHODS

## 2 <u>Study design, data source, and participants</u>

In this population-based study, we performed an analysis of cross-sectional individual-level data collected by the National Health and Nutrition Examination Survey (NHANES) through interviews and physical examination in a subset of a representative sample of the U.S. population from 1999-2000 through 2017-March 2020. Initial complete dataset included 107,622 participants of all ages. NHANES suspended data collection in March 2020 as a consequence of the COVID-19 pandemic. Thus, the most current cycle data available are "combined data collected from 2019 to March 2020 with data from the NHANES 2017-2018 cycle to form a nationally representative sample of NHANES 2017-March 2020 pre-pandemic data" <sup>30</sup>. Analysis was restricted to adults 20-79 years of age (n=54.232 potentially eligible) because of three reasons: 1) the diagnosis of obesity in younger adults is based on BMI-for-age percentiles as recommended by the Centers for Disease Control and Prevention (CDC)<sup>7</sup>; 2) in NHANES 2007-2008 and subsequent cycles, the upper age limit was 80 years, whereas in earlier cycles the age limit was 85 years; and 3) to obtain age-adjusted prevalence estimates using 5-year intervals according to the strata for age and sex available from the 2000 US Census Bureau (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75-79) <sup>31</sup>. Another criterion for inclusion was that individuals had been interviewed and evaluated by physical examination. Women who reported to be pregnant or had a positive urine pregnancy test were excluded from analysis. Observations with missing data on body weight, height, or waist circumference were also excluded.

According to the NHANES physical examination protocol, waist circumference was measured just above the uppermost lateral border of the right ilium (hip bone). Weight and height were measured using standard methods <sup>32</sup>. Information on ethnicity was collected through a questionnaire. The mean unweighted response rate for examined sample across survey cycles 

**BMJ** Open

| 2        |
|----------|
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| ,<br>8   |
| 9        |
|          |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
| 16       |
| 17       |
| 18       |
| 19       |
| 20       |
| 20<br>21 |
| 21<br>22 |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32       |
| 33       |
| 33<br>34 |
|          |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46       |
| 40<br>47 |
|          |
| 48       |
| 49       |
| 50       |
| 51       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 58<br>59 |
| 22       |

60

between 1999-2000 and 2017-March 2020 for individuals 20-79 years was 67.5% (range 50.8 74.5%) <sup>33</sup>.

Since this study used publicly available de-identified data, approval from an Institutional Review
Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects
(detailed in 45 CFR part 46) <sup>34</sup>.

6 <u>Obesity diagnosis</u>

General obesity was diagnosed using RFM, a validated surrogate for whole-body fat percentage
<sup>23</sup>, and validated cutoffs to predict all-cause mortality: RFM ≥40% for women and ≥30% for men
<sup>27</sup>. RFM was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex);
sex equals 0 for men and 1 for women <sup>23</sup>. BMI-defined obesity was diagnosed if BMI was 30
kg/m<sup>2</sup> or higher <sup>7</sup>.

12 <u>Statistical Analysis</u>

Data collected during the survey cycles from 1999-2000 through 2017-2020 were analyzed 13 14 using sampling weights following the recommended analytic guidelines, to account for 15 oversampling, nonresponse rates, and subsampling for physical examination <sup>35</sup>. The proportion 16 of missing data was 5.2% of all eligible participants. Given this low percentage of missing data, we performed a complete case analysis <sup>36</sup>. Since age distribution of study samples may vary 17 18 across survey cycles, all prevalence estimates were adjusted for age to make the estimates 19 more comparable throughout the study period <sup>31</sup>. Estimates across the age categories 20-39, 40-59, and 60-79 years were also adjusted for age using 5-year intervals according to 20 corresponding 2000 US Census Bureau age categories by sex <sup>31</sup>. The changes in obesity 21 22 prevalence from 1999-2000 to 2017-March 2020 were assessed using the Wald test. For 23 multiple comparisons of prevalence across ethnic groups and age groups, we applied the

Page 10 of 41

#### **BMJ** Open

> Bonferroni correction. Because Asian Americans were not oversampled before NHANES 2011, our analyses by ethnicity were restricted to Mexican, European, and African Americans. To determine the possible role of menopause in the high prevalence of RFM-defined obesity in women, we performed a post hoc analysis. Data related to menopause were self-reported. We defined postmenopausal women as those with natural menopause and no missing information on age at menopause. For this analysis, women were excluded if menopause occurred before age 40 or after age 62<sup>37</sup>, or if they reported oophorectomy (surgical removal of one or two ovaries), treatment with estrogen/progesterone for hysterectomy/oophorectomy, breastfeeding, pregnancy in past year of the interview, or irregular period due to medical conditions or treatment. Temporal trends in prevalence of obesity were tested for the assumption of linearity using logistic regression models, comparing linear and non-linear regression models using the likelihood-ratio test <sup>38</sup>. For the non-linear models, restricted cubic splines with 3 knots were used at years 2001-2002, 2009-2010, and 2017-2020, based on the quantiles recommended by Harrel <sup>39</sup>. Survey cycles were analyzed as a continuous variable. For visualization purposes, trend lines were smoothed using the Lowes method <sup>40</sup>. Statistical significance was set to an alpha level of 0.05. All statistical analyses were performed using Stata 14 for Windows (StataCorp LP, College Station, TX). Prevalence estimates and standard errors were obtained using the survey 'svy' command with Taylor linearization. Patient and public involvement Patients and the public were not involved in this study. This study will be available to the public

22 once it is published in the scientific literature.

## **RESULTS**

## 2 <u>Clinical characteristics</u>

3 After applying the inclusion and exclusion criteria, the final sample for analysis comprised

4 47,667 adults (Supplementary Figure 1). The median age of the study population was 45 years

5 (interquartile range: 33 to 58); 50.6% were women; 67.2% were European Americans, 11.2%

6 were African Americans, and 8.3% were Mexican Americans (Table 1). The overall prevalence

7 of obesity by ethnicity in the study participants is shown in Supplementary Table 1.

| Characteristic  | All              | Women            | Men                       |  |  |  |  |
|---|------------------|------------------|---------------------------|--|--|--|--|
|   | 47,667           | 23,931 (50.6%)   | 23,736 (49.4%)            |  |  |  |  |
| Median age (IQR), years   | 45 (33-58)       | 46 (33-59)       | 44 (32-57)                |  |  |  |  |
| Ethnicity, n (%)  |                  |                  |                           |  |  |  |  |
| Mexican American  | 8,416 (8.3)      | 4,204 (7.7)      | 4,212 (9.0)               |  |  |  |  |
| European American   | 19,691 (67.2)    | 9,710 (67.0)     | 9,981 (67.5)              |  |  |  |  |
| African American  | 10,673 (11.2)    | 5,417 (12.0)     | 5,256 (10.4)              |  |  |  |  |
| Other/multi-racial  | 8,887 (13.3)     | 4,600 (13.4)     | 3,928 (13.1)              |  |  |  |  |
| Body weight (SD), kg  | 82.6 (21.3)      | 76.3 (20.5)      | 89.0 (20.1)               |  |  |  |  |
| Mean height (SD), cm  | 168.9 (10.0)     | 162.1 (6.9)      | 175.9 (7.5)               |  |  |  |  |
| Mean waist circumference (SD), cm   | 98.5 (16.5)      | 95.9 (16.9)      | 101.2 (15.6)              |  |  |  |  |
| Mean BMI (SD), kg/m <sup>2</sup>  | 28.9 (6.8)       | 29.0 (7.5)       | 28.7 (5.9)                |  |  |  |  |
| Mean RFM (SD), %  | 34.9 (8.5)       | 41.2 (6.0)       | 28.4 (5.3)                |  |  |  |  |
| RFM-defined obesity, % (95% CI) †   | 50.1 (48.9-50.8) | 59.4 (58.4-60.5) | 40.6 (39.4-41.8           |  |  |  |  |
| BMI-defined obesity, % (95% CI) ‡   | 36.2 (35.4-37.1) | 37.8 (36.8-38.7) | 34.6 (33.5-35.8           |  |  |  |  |
| Abdominal obesity, % (95% CI) §   | 54.0 (53.0-55.0) | 63.8 (62.8-64.9) | 43.9 (42.7-45.1           |  |  |  |  |
| <ul> <li>* Sample size represents unweighted data. Estimates represent weighted data.</li> <li>BMI, body mass index; CI, confidence interval; IQR, interquartile range; RFM, relative fat mass; SD, standard deviation.</li> <li>† Defined as an RFM ≥40% for women and ≥30% for men. RFM was calculated as follows: 64 – (20 height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women; height and waist circumference measured in the same units. Estimates are not adjusted for age.</li> <li>‡ Defined as a BMI ≥30 kg/m2. BMI was calculated as the body weight in kilograms divided by the square of the height in meters. Estimates are not adjusted for age.</li> <li>§ Defined as a waist circumference &gt;88 cm for women and &gt;102 cm for men, according to the recommendations of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Estimates</li> </ul> |                  |                  |                           |  |  |  |  |
| § Defined as a waist circumference >8<br>recommendations of the National Cho<br>Evaluation, and Treatment of High Blo   |                  |                  | are not adjusted for age. |  |  |  |  |

## 11 The characteristics of the population with missing data are shown in Supplementary Table 2.

| 3              |
|----------------|
| 4              |
| 5              |
| 6              |
| 5<br>6<br>7    |
| 8              |
| 9              |
| 9<br>10        |
|                |
| 11<br>12       |
|                |
|                |
| 14             |
| 15             |
| 16<br>17<br>18 |
| 1/             |
| 18             |
| 19             |
| 20             |
| 21<br>22       |
| 22             |
| 22             |
| 24             |
| 25             |
| 26<br>27       |
| 27             |
| 28             |
| 29             |
| 30             |
| 31             |
| 32             |
| 33             |
| 34             |
| 35             |
| 36<br>37       |
| 37             |
| 38             |
| 39             |
| 40             |
| 41             |
| 42             |
| 43             |
| 44             |
| 45             |
| 46             |
| 47             |
| 48             |
| 40<br>49       |
| 49<br>50       |
| 50<br>51       |
| 51<br>52       |
| 52<br>53       |
|                |
| 54             |
| 55             |
| 56             |
| 57             |
| 58             |
| 59             |
| 60             |

1 2

1

## Obesity prevalence and temporal trends

Our findings indicate a higher proportion of individuals with obesity when RFM was used instead 2 of BMI. The overall age-adjusted prevalence of RFM-defined obesity increased from 42.4% 3 4 (95% confidence interval, 38.3% to 46.4%) in 1999-2000 to 55.4% (53.0% to 57.9%) in 2017-5 March 2020. The corresponding BMI-defined obesity prevalence increased from 30.4% (26.7% 6 to 34.0%) to 42.1% (39.4% to 44.8%). We found a linear increase in the overall prevalence of obesity during the study period using either RFM (P<0.001; P=0.38 for non-linearity) or BMI 7 8 (P<0.001; P=0.55 for non-linearity). Obesity prevalence and temporal trends by sex 9 10 We observed a consistently higher prevalence of RFM-defined obesity in women compared with 11 men across years. In contrast, this difference was not consistent for BMI-defined obesity (Figure 1). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in 12 women than in men (P<0.001). In contrast, the prevalence of BMI-defined obesity was similar in 13 14 women and men (P=0.97). Among women, the prevalence of RFM-defined obesity increased from 50.8% (46.2% to 55.3%) in 1999-2000 to 64.7% (62.1% to 67.3%) in 2017-March 2020, a 15 linear increase of 13.9 percentage points (9.0% to18.9%; P<0.001). For comparison, the 16

prevalence of BMI-defined obesity in women was 42.2% (39.4% to 45.0%) in 2017-March 2020,

a linear increase of 8.3 percentage points (3.5-13.2%; P<0.001) (Table 2).

19

20

**Table 2.** Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by sex: 1999-2000 through 2017-Mach 2020.\*

|                             | RFM-defined obesity | BMI-defined obesity |
|-----------------------------|---------------------|---------------------|
| All participants (n=47,667) |                     |                     |
| Prevalence, % (95% CI)      |                     |                     |
| 1999-2000                   | 42.4 (38.3-46.4)    | 30.4 (26.7-34)      |

| 2001-2002              | 42.5 (41.1-43.9) | 30.0 (27.6-32.4) |
|------------------------|------------------|------------------|
| 2003-2004              |                  | 32.1 (29.3-34.9) |
| 2005-2006              |                  | 34.3 (31.1-37.4) |
| 2007-2008              | 47.7 (45.0-50.5) | 33.7 (31.5-36.0) |
| 2009-2010              |                  | 35.7 (33.6-37.8) |
| 2011-2012              | 49.8 (46.6-53.0) | 35.4 (32.5-38.3) |
| 2013-2014              | 51.3 (48.7-53.8) | 37.8 (35.6-40)   |
| 2015-2016              | 53.7 (49.3-58.0) | 40.0 (36.4-43.6) |
| 2017-2020              | 55.4 (53.0-57.9) | 42.1 (39.4-44.8) |
| Prevalence changet     | 13.0 (8.5-17.5)  | 11.8 (7.4-16.1)  |
| P for non-linearity    | 0.38             | 0.55             |
| P value for trend‡     | <0.001           | <0.001           |
| Women (n=23,931)       | 10.001           | 10.001           |
| Prevalence, % (95% CI) |                  |                  |
| 1999-2000              | 50.8 (46.2-55.3) | 33.9 (29.6-38.1) |
| 2001-2002              | 51.6 (49.2-53.9) | 32.9 (29.7-36.0) |
| 2001-2002              | 55.3 (51.2-59.3) | 33.5 (29.7-37.2) |
| 2003-2004              | 53.9 (50.4-57.4) | 34.8 (31.5-38.1) |
| 2003-2000              |                  | 35.4 (32.7-38.0) |
| 2007-2008              | 58.1 (55.3-60.8) | 36.0 (34.0-37.9) |
| 2009-2010              | 60.8 (56.8-63.6) | 36.9 (33.4-40.5) |
|                        |                  |                  |
| 2013-2014              | 61.3 (57.9-64.7) | 40.0 (36.8-43.2) |
| 2015-2016              |                  | 41.7 (38.1-45.3) |
| 2017-2020              | 64.7 (62.1-67.3) | 42.2 (39.4-45.0) |
| Prevalence change†     | 13.9 (9.0-18.9)  | 8.3 (3.5-13.2)   |
| P for non-linearity§   | 0.10             | 0.39             |
| P value for trend§     | <0.001           | <0.001           |
| Men (n=23,736)         |                  |                  |
| Prevalence, % (95% CI) |                  |                  |
| 1999-2000              | 33.9 (29.9-37.8) | 27.0 (23.5-30.4) |
| 2001-2002              | 33.1 (30.6-35.5) | 27.0 (24.8-29.2) |
| 2003-2004              | 38.4 (35.9-40.8) | 30.7 (27.6-33.9) |
| 2005-2006              | 40.2 (35.9-44.4) | 33.5 (29.3-37.8) |
| 2007-2008              | 38.8 (35.6-42.0) | 32.1 (29.3-34.8) |
| 2009-2010              | 38.7 (35.2-42.2) | 35.3 (31.4-39.2) |
| 2011-2012              | 39.2 (35.9-42.5) | 33.8 (30.7-36.9) |
| 2013-2014              | 41.2 (38.7-43.7) | 35.6 (33.2-38.1) |
| 2015-2016              | 42.7 (37.7-47.7) | 38.2 (33.3-43.2) |
| 2017-2020              | 45.8 (42.0-49.7) | 42.0 (37.8-46.3) |
| Prevalence change†     | 12.0 (6.6-17.3)  | 15.1 (9.8-20.4)  |
| P for non-linearity§   | 0.82             | 0.84             |
| P value for trend§     | <0.001           | <0.001           |

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval.

† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for age, sex, and ethinicity.

§ Adjusted for age and ethnicity.



Among men, the prevalence of RFM-defined obesity increased from 33.9% (29.9% to 37.8%) in 1999-2000 to 45.8% (42.0% to 49.7%) in 2017-March 2020, a linear increase of 12.0 percentage points (6.6% to 17.3%; P<0.001). The prevalence of BMI-defined obesity in men was 42.0% (37.8% to 46.3%) in 2017-March 2020, a linear increase of 15.1 percentage points (9.8% to 20.4%). Obesity prevalence and temporal trends by ethnicity The highest prevalence of RFM-defined obesity across years was observed among Mexican Americans. In contrast, the highest prevalence of BMI-defined obesity was observed among African American women but not men (Figure 2). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in Mexican Americans compared with African Americans (Bonferroni corrected P<0.001) or European Americans (P<0.001). BMI-defined obesity prevalence was similar in Mexican and African Americans (P=0.99) and both groups had a higher prevalence than European Americans (P=0.003 and P=0.001, respectively). The largest increase in the prevalence of RFM-defined obesity from 1999-2000 to 2017-March 2020 occurred in Mexican American men, with a linear increase of 18.3 percentage points (12.0% to 24.5%; P<0.001) (Supplementary Table 3 and Figure 2). The highest increase in the prevalence of BMI-defined obesity also occurred in Mexican American men, with a linear increase of 21.2 percentage points (15.3% to 27.1%; P<0.001) (Supplementary Table 3 and Figure 2). Obesity prevalence and temporal trends by age group In women and men, the highest prevalence of RFM-defined obesity across years was observed in older adults (60-79 years) (Figure 3 and Supplementary Table 4). For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

#### BMJ Open

| 2  |  |
|--|--|
| 3  |  |
| 4  |  |
| -  |  |
| 5  |  |
| 6<br>7<br>8  |  |
| /  |  |
| 8  |  |
| 9  |  |
| 10   |  |
| 11   |  |
| 12   |  |
| 13   |  |
| 14   |  |
| 15   |  |
| 16   |  |
| 10   |  |
| 17   |  |
| 18   |  |
| 19   |  |
| 20   |  |
| 11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25<br>26<br>27<br>28<br>29<br>30 |  |
| 22   |  |
| 23   |  |
| 24   |  |
| 25   |  |
| 26   |  |
| 20   |  |
| 27   |  |
| 28   |  |
| 29   |  |
| 30   |  |
| 31   |  |
| 32<br>33<br>34<br>35   |  |
| 33   |  |
| 34   |  |
| 35   |  |
| 36   |  |
| 36<br>37<br>38   |  |
| 38   |  |
| 39   |  |
|  |  |
| 40   |  |
| 41   |  |
| 42   |  |
| 43   |  |
| 44   |  |
| 45   |  |
| 46   |  |
| 47   |  |
| 48   |  |
| 49   |  |
| 50   |  |
| 50<br>51   |  |
| 51<br>52   |  |
|  |  |
| 53   |  |
| 54   |  |
| 55   |  |
| 56   |  |
| 57   |  |
| 58   |  |
| 59   |  |

60

In contrast, no differences were observed in the prevalence of obesity between individuals 60-79 years and 40-59 years when using BMI for the diagnosis of obesity (Figure 3). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in individuals 60-79 years compared with those 40-59 years (Bonferroni corrected P<0.001) or 20-39 years (P<0.001). We found no statistically significant differences in the prevalence of BMI-defined obesity across age groups (P>0.17 for all comparisons).

7 Although our analysis by age showed an increased prevalence of obesity in older women and 8 men (Figure 3), we performed a sensitivity analysis to specifically explore the possible role of 9 menopause. Our findings from this post hoc analysis revealed that the crude prevalence of RFM-defined obesity in 2017-2020 was 56.4% (95% CI, 53.5-59.3%) among premenopausal 10 women (n=1,935) and 76.4% (71.0-81.8%) among postmenopausal women (n=1,406). The 11 12 mean age at last menstrual period was 49 years in this population. For comparison, among 13 men, the corresponding prevalence of obesity was 39.7% (34.9-44.6%) in those younger than 50 years (n=1,790) and 56.2% (52.9-59.5%) in men 50 years of age and older (n=1,886). 14

## 1 DISCUSSION

 Our study shows that, compared with BMI, the use of a surrogate for whole-body fat percentage revealed a much higher prevalence of general obesity among adults in the U.S., particularly among women, affecting nearly two-thirds of all women and nearly half of all men in 2017-2020, with an overall prevalence of 55.4%. This is an additional 22.5% of women and 3.8% of men 20-79 years being defined as obese compared with a BMI-based definition with the current criteria.

The use of RFM also revealed that the highest prevalence of general obesity over the study period from 1999 to 2020 occurred among Mexican Americans and not among African Americans, as was observed when BMI was used to diagnose obesity. Likewise, the use of RFM showed that the highest prevalence of general obesity over this study period occurred among older adults (60-79 years) and not among adults 40-59 years, as was observed when BMI was used. The higher prevalence of obesity in older individuals does not appear to be fully explained by a loss of skeletal muscle with age, since absolute fat mass also increases with age, although mainly visceral fat <sup>41 42</sup>. However, it is difficult to draw a firm conclusion from cross-sectional data. Our findings are consistent with those from other studies also showing a higher body fat percentage in older individuals <sup>12 23 41 43-46</sup>. 

Overall, women had a markedly higher prevalence of RFM-defined obesity across years than
 men, a difference that was less evident when using BMI. Previous studies have shown no
 differences in the prevalence of BMI-defined obesity between women and men <sup>3447</sup>. In the
 present study, the difference in the prevalence of RFM-defined obesity for 2017-2020 between
 women and men was nearly 20 percentage points.

The highest prevalence of RFM-defined obesity was observed in Mexican Americans, and the increase was linear over the study period, albeit this linear increase was largely driven by a steady increase among men. Among Mexican American women, a decrease was observed

Page 17 of 41

#### **BMJ** Open

| 1        |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 20       |  |
| 22       |  |
| 22       |  |
| 23<br>24 |  |
| 24<br>25 |  |
|          |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |

60

since 2015. A previous study reported that, between 2003 and 2006, the prevalence of BMIdefined obesity was higher among African Americans compared with Mexican Americans, but
between 2015 and 2018, Mexican American men had a higher prevalence than African
American men <sup>29</sup>. In contrast, RFM revealed a consistently higher prevalence of general obesity
among Mexican Americans over the observed time, in both women and men. Socio-economic
characteristics are probably the main determinants of differences in the prevalence of general
obesity between ethnic groups <sup>48</sup>.

8 It has been argued that the fat mass index (FMI, body fat mass adjusted for the square of the 9 height, expressed in kg/m<sup>2</sup>) should be used as a reference of fat mass instead of body fat percentage (body fat mass adjusted for body weight) to avoid including fat mass both in the 10 11 numerator and the denominator, as this is not mathematically advisable <sup>49</sup>. However, the concept of obesity (excess body fat) and all different forms to express it, for example BMI 6 50 51, 12 13 FMI <sup>52 53</sup>, fat mass/fat-free-mass <sup>54 55</sup>, body fat percentage <sup>12 56</sup>, to cite a few, should not be seen only as mathematical constructs but also as biological variables with important implications as 14 risk factors for disease and mortality. In the present study, we chose body fat percentage as the 15 reference because numerous studies have shown that body fat percentage is associated with 16 17 mortality <sup>13-20 57</sup>. What is also important to note is that FMI does not appear to be superior to body fat percentage or BMI as a predictor of cardiovascular mortality <sup>14</sup>, all-cause mortality <sup>58 59</sup> 18 or cardiovascular risk factors <sup>60</sup>. Because of its association with mortality, body fat percentage is 19 of great clinical relevance. Recent studies support the utility of RFM to predict type 2 diabetes <sup>61</sup> 20 21 and heart failure <sup>62</sup>.

Further research is needed to better understand the clinical implications of our study findings: 1)
the much higher prevalence of general obesity among women when RFM is used as opposed to
BMI; 2) the higher burden of general obesity on Mexican Americans compared with African and
European Americans; and 3) the higher prevalence of general obesity in older individuals.

| 2<br>3                           |  |
|----------------------------------|--|
| 3<br>4<br>5<br>6<br>7<br>8       |  |
| 6<br>7                           |  |
| 8<br>9<br>10                     |  |
| 11                               |  |
| 13<br>14                         |  |
| 12<br>13<br>14<br>15<br>16<br>17 |  |
| 17<br>18                         |  |
| 18<br>19<br>20                   |  |
| 20<br>21<br>22                   |  |
| 23                               |  |
| 24<br>25<br>26<br>27             |  |
| 28<br>20                         |  |
| 30<br>31                         |  |
| 30<br>31<br>32<br>33<br>34       |  |
| 34<br>35<br>36<br>37             |  |
| 36<br>37                         |  |
| 38<br>39                         |  |
| 40<br>41<br>42                   |  |
| 43<br>44                         |  |
| 45<br>46                         |  |
| 47<br>48                         |  |
| 49<br>50                         |  |
| 51<br>52<br>53                   |  |
| 55<br>55                         |  |
| 56<br>57                         |  |
| 58<br>59                         |  |
| 60                               |  |

1

1 It is difficult to establish whether the higher prevalence of general obesity estimated using RFM 2 would translate into a higher risk of cardiovascular disease (CVD). The association between 3 obesity and CVD is very complex and several factors may mediate this association <sup>63</sup>. Although subcutaneous fat appears to have a relative protective effect against CVD <sup>64</sup>, others have 4 5 shown that subcutaneous fat is also associated with cardiovascular risk factors, although less strongly than visceral fat <sup>65</sup>. A major limitation of these studies, however, is that the analyses 6 7 involved a small region of the abdominal trunk. 8 In women, who biologically have a higher body adiposity than men, the possible protective 9 effect of estrogens on metabolism could be attenuated by the high prevalence of RFM-defined 10 obesity. This could help explain for example the very similar relative increase in the U.S. prevalence of diabetes in women and men from 1999 to 2019 (by ~74%) (www.healthdata.org) 11 or the similar prevalence of diabetes in women (14.1% [11.8-16.7%]) and men (15.4% [13.5-12 13 17.5%]) in 2017-2020 <sup>66</sup>. Our findings, although cross-sectional, do not appear to support a protective role of estrogens against obesity per se. 14 The temporal trends in RFM- and BMI-defined obesity in both women and men follow a parallel 15 pattern. However, stratified analysis by ethnicity showed some differences. RFM revealed that 16 17 Mexican Americans have a higher prevalence of obesity than European or African Americans. 18 Although we cannot establish causality, this finding coincides with the higher absolute increase in the prevalence of diabetes and liver disease observed in Mexican Americans from 1999 to 19 2018 compared with European and African Americans 67. 20 21 Whether the increased whole-body fat percentage in older individuals confers a higher risk on 22 mortality also requires further investigation as age per se is a strong risk factor for mortality <sup>68</sup>, and the relationship between obesity and mortality could be mediated by age 69. In addition, this 23 can be confounded by concomitant severe disease. For instance, several studies have shown 24 25 an inverse association between body fat percentage (but also BMI and FMI) and mortality in

Page 19 of 41

#### BMJ Open

older patients <sup>59 70 71</sup>. Conversely, the high body fat percentage in older individuals could explain the association of BMI-defined obesity with diabetes and cardiovascular disease in older individuals <sup>72-75</sup>. The increase in body adiposity with aging coincides with the high prevalence of many cardiometabolic alterations occurring more often in older individuals, such as glucose intolerance, insulin resistance, dyslipidemia, and hypertension <sup>69</sup>. BMI did not detect a higher prevalence of general obesity in individuals aged 60 years and older compared with younger adults, unlike when RFM was used. These findings further support that notion that BMI is a poor predictor of morbidity and mortality in older individuals <sup>46 76</sup>. Abdominal obesity and general obesity are overall underestimated when using BMI (Table 1 and Supplementary Table 1). It is also important to mention that the prevalence of abdominal obesity is overall higher compared with the prevalence of RFM-defined obesity, except among Mexican Americans (Supplementary Table 1). However, the closer proportions of abdominal obesity and RFM-defined general obesity is expected. Since RFM is based on waist circumference, and waist circumference is a surrogate for intra-abdominal fat <sup>77 78</sup>, RFM could be a surrogate for both general obesity and abdominal obesity. Although RFM has been shown to predict trunk fat percentage, the prediction error is greater for trunk fat percentage than for whole-body fat percentage <sup>23</sup>. Our study has strengths. First, we used a previously validated surrogate for whole-body fat percentage in adults in the U.S.<sup>23</sup>, which has a high diagnostic accuracy (91%) for DXA-defined 

20 obesity <sup>27</sup> and has been shown to result in lower total misclassification of DXA-defined high

body adiposity compared with BMI among women (RFM: 12.7%; BMI: 56.5%) and men (RFM:

9.4% BMI: 13.0%) <sup>23</sup>. Second, to define general obesity, we used previously validated RFM

23 cutoffs to predict all-cause mortality in a large U.S. adult population <sup>27</sup>. Previously proposed

24 cutoffs for fat-defined obesity have been based on arbitrary values <sup>79 80</sup> or on corresponding BMI

25 cutoffs <sup>12</sup>. Third, we used measured anthropometrics. RFM requires only waist circumference

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 20 of 41

and height for its calculation, which allowed us to estimate the prevalence of general obesity in a large adult population of the U.S. (n=44,754) with a wide age range, over a period of nearly 22 years. Fourth, NHANES have used a consistent methodology across survey cycles to measure anthropometrics, reducing the risk of measurement error that could affect our results. Our study also has limitations. First, RFM was developed and validated using DXA as the reference method. However, DXA is an indirect method to assess body fatness and is susceptible to bias introduced mainly by age, degree of fatness, and disease <sup>81 82</sup>. Thus, there are limitations to the level of accuracy and precision that RFM can perform. Nevertheless, RFM is an attempt to provide a relatively easy and affordable alternative method to BMI to better assess body fatness. Second, although the overall obesity misclassification has been reported to be lower with RFM than with BMI in American (21) and Korean individuals (20), another limitation is that the proportion of obesity misclassification is not trivial when using RFM. Third, our analysis was performed using data from a representative sample of the non-institutionalized U.S. population only. Fourth, our estimates of prevalence trends could have been affected by some variability in sampling across NHANES survey cycles <sup>35</sup>. Finally, we did not analyze the prevalence trends for Asian Americans during the period studied because NHANES began oversampling Asian Americans only from 2011-2012 onwards and RFM cutoffs used to diagnose general obesity have not been validated among Asian populations. From a public health perspective, we argue that due to the underdiagnosis of obesity when using BMI, the most affected populations are not receiving adequate medical care that they require. Aspects that will need further research are the implications of some possible overdiagnosis of obesity <sup>83</sup> and the stigma that would be associated with it <sup>84</sup>. In conclusion, the use of RFM, a surrogate for whole-body fat percentage, revealed a much higher prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, than that estimated by BMI. RFM, but not BMI, also revealed a disproportionate higher 

**BMJ** Open

prevalence of general obesity in adults aged 60 years and older and Mexican Americans. Using
BMI as the lone measure to define obesity may lead to significant misclassification of large
obese subpopulations as non-obese, particularly among women. Our findings may have
implications for the use of resources in public health to tackle obesity-related health problems in

5 the most affected populations.

to beer to wiew only

| 2                                      |  |
|--|--|
| 4                                      |  |
| 5                                      |  |
| 6                                      |  |
| /<br>8                                 |  |
| o<br>9                                 |  |
| 10                                     |  |
| 11                                     |  |
| 12                                     |  |
| 13                                     |  |
| 14                                     |  |
| 16                                     |  |
| 12<br>13<br>14<br>15<br>16<br>17<br>18 |  |
| 18                                     |  |
| 19                                     |  |
| 20<br>21                               |  |
| 21<br>22                               |  |
| 23                                     |  |
| 24                                     |  |
| 25                                     |  |
| 26                                     |  |
| 27<br>28                               |  |
| 29                                     |  |
| 30                                     |  |
| 31                                     |  |
| 32                                     |  |
| 33<br>34                               |  |
| 35                                     |  |
| 36                                     |  |
| 37                                     |  |
| 38<br>39                               |  |
| 40                                     |  |
| 41                                     |  |
| 42                                     |  |
| 43                                     |  |
| 44<br>45                               |  |
| 43<br>46                               |  |
| 47                                     |  |
| 48                                     |  |
| 49                                     |  |
| 50<br>51                               |  |
| 51<br>52                               |  |
| 53                                     |  |
| 54                                     |  |
| 55                                     |  |
| 56                                     |  |
| 57<br>58                               |  |
| 58<br>59                               |  |
| 60                                     |  |
|  |  |

# ETHICS APPROVAL

2 Since this study used publicly available de-identified data, approval from an Institutional Review

3 Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects

4 (detailed in 45 CFR part 46) 35.

#### 6 DATA AVAILABILITY STATEMENT

7 All data utilized are publicly and freely available from the NHANES website at

8 https://wwwn.cdc.gov/nchs/nhanes/

9

1 h

1

5

#### 10 ACKNOWLEDGMENTS

We thank the Centers for Disease Control and Prevention (CDC) and the National Center for 11

12 Health Statistics (NCHS) for providing access to the NHANES datasets. We also thank all

subjects who participated in the surveys from 1999 through 2020. 13

| 1<br>2               |    |   |
|----------------------|----|---|
| 3<br>4               | 1  | AUTHOR CONTRIBUTIONS  |
| 5<br>6<br>7          | 2  | OOW was responsible for the conception and design of the study. OOW contributed to the              |
| ,<br>8<br>9          | 3  | statistical analysis. OOW and TS contributed to the interpretation of data and critical revision of |
| 10<br>11             | 4  | the manuscript. OOW and TS drafted the final version of the manuscript and agreed to the            |
| 12<br>13             | 5  | submitted version of the manuscript. OOW is the manuscript's guarantor. OOW accepts full            |
| 14<br>15             | 6  | responsibility for the work and the conduct of the study, had access to the data, and controlled    |
| 16<br>17             | 7  | the decision to submit for publication.   |
| 18<br>19<br>20       | 8  | FUNDING   |
| 21<br>22<br>23       | 9  | This research received no specific grant from any funding agency in the public, commercial or       |
| 24<br>25             | 10 | not-for-profit sectors.   |
| 26<br>27<br>28       | 11 | COMPETING INTERESTS   |
| 29<br>30             | 12 | OOW is the lead author of the original article describing the development and validation of RFM.    |
| 31<br>32<br>33       | 13 | OOW currently works as an editor for The Lancet group. TS declares no conflict of interest.         |
| 34<br>35             | 14 | TRANSPARENCY STATEMENT  |
| 36<br>37             | 15 | OW (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and             |
| 38<br>39<br>40       | 16 | transparent account of the study being reported; that no important aspects of the study have        |
| 40<br>41<br>42       | 17 | been omitted; and that any discrepancies from the study as originally planned have been             |
| 43<br>44             | 18 | explained.  |
| 45<br>46<br>47       | 19 | PATIENT AND PUBLIC INVOLVEMENT  |
| 48<br>49             | 20 | Patients and the public were not involved in this study. This study will be available to the public |
| 50<br>51<br>52<br>53 | 21 | once it is published in the scientific literature.  |
| 54<br>55<br>56       |    |   |
| 57<br>58             |    | 22  |
| 59<br>60             |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                           |

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000.

# 1 **REFERENCES**

1 2 3

4

2

- *JAMA* 2002;288(14):1723-7. doi: 10.1001/jama.288.14.1723
  2. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in Obesity Among Adults in the United States,
- 5 2005 to 2014. JAMA 2016;315(21):2284-91. doi: 10.1001/jama.2016.6458
- 3. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United
   States, 2017-2018. NCHS Data Brief 2020(360):1-8.
- 13 8 4. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March
- 14 9 2020 prepandemic data files Development of files and prevalence estimates for selected health
- 15 10 outcomes. *National Health Statistics Reports* 2021(158):1-20.
- 16 11 5. Rothman KJ. BMI-related errors in the measurement of obesity. *Int J Obes (Lond)* 2008;32 Suppl 3:S56 17 12 9. doi: 10.1038/ijo.2008.87
- 18
   13
   13
   14
   14
   14
   14
   15
   16
   17
   18
   18
   18
   19
   19
   14
   10
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   14
   1
- 20 14 Geneva, 1993.
   21 15 7. CDC. Defining adult overweight & obesity. Available at: <u>https://www.cdc.gov/obesity/basics/adult-</u>
   22 16 <u>defining.html</u>. Accessed April 18, 2022.
- 17 8. Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. *Am J Clin Nutr*18 1986;44(6):996-7. doi: 10.1093/ajcn/44.6.996
- 9. Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body
   fatness across age, sex, and ethnic groups? *Am J Epidemiol* 1996;143(3):228-39.
- 27
   21
   21
   22
   23
   24
   25
   26
   27
   28
   29
   29
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   26
   27
   28
   29
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   20
   2
- 23 2006;368(9536):666-78. doi: 10.1016/S0140-6736(06)69251-9
- 24 11. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to
- identify obesity as defined by body adiposity: a systematic review and meta-analysis. *Int J Obes (Lond)*26 2010;34(5):791-9. doi: 10.1038/ijo.2010.5
- 12. Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for
   developing guidelines based on body mass index. *Am J Clin Nutr* 2000;72(3):694-701.
- <sup>36</sup> 29 13. Heitmann BL, Erikson H, Ellsinger BM, et al. Mortality associated with body fat, fat-free mass and
- body mass index among 60-year-old swedish men-a 22-year follow-up. The study of men born in 1913.
   *Int L Obes Bolat Match Disord* 2000;24(1):22.7
- 31 Int J Obes Relat Metab Disord 2000;24(1):33-7.
- 32 14. Ortega FB, Sui X, Lavie CJ, et al. Body Mass Index, the most widely used but also widely criticized
- 33 index: Would a criterion standard measure of total body fat be a better predictor of cardiovascular
   34 disease mertality? Mayo Clip Pres 2010;01(4):412-55
- 42 34 disease mortality? *Mayo Clin Proc* 2016;91(4):443-55.
- 45 37 16. Zong G, Zhang Z, Yang Q, et al. Total and regional adiposity measured by dual-energy X-ray
- absorptiometry and mortality in NHANES 1999-2006. *Obesity (Silver Spring)* 2016;24(11):2414-21. doi:
   10.1002/oby.21659
   17. Dang D. Dang V. Mang Z. at al. heiter the state of the state of
- 40 17. Dong B, Peng Y, Wang Z, et al. Joint association between body fat and its distribution with all-cause
- 41 mortality: A data linkage cohort study based on NHANES (1988-2011). *PLoS One* 2018;13(2):e0193368.
- 51
   42
   doi: 10.1371/journal.pone.0193368
- 43 18. Lahmann PH, Lissner L, Gullberg B, et al. A prospective study of adiposity and all-cause mortality: the
- 53 44 Malmo Diet and Cancer Study. *Obes Res* 2002;10(5):361-9. doi: 10.1038/oby.2002.50 54

| 1        |          |   |
|----------|----------|---|
| 2        |          |   |
| 3<br>4   | 1        | 19. Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 diabetes,       |
| 5        | 2        | coronary heart disease, and cancer subgroups in the UK Biobank, and their modification by smoking.        |
| 6        | 3        | Diabetes Care 2018;41(9):1878-86. doi: 10.2337/dc17-2508  |
| 7        | 4        | 20. Jayedi A, Khan TA, Aune D, et al. Body fat and risk of all-cause mortality: a systematic review and   |
| 8        | 5        | dose-response meta-analysis of prospective cohort studies. Int J Obes (Lond) 2022;46(9):1573-81. doi:     |
| 9        | 6        | 10.1038/s41366-022-01165-5  |
| 10       | 7        | 21. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today                  |
| 11       | 8        | 2015;50(3):117-28. doi: 10.1097/NT.0000000000000092   |
| 12       | 9        | 22. CDC. Body mass index : considerations for practitioners. <u>https://stacks.cdc.gov/view/cdc/25368</u> |
| 13       | 10       | [Accessed December 8, 2021].  |
| 14<br>15 | 11       | 23. Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat                 |
| 15<br>16 | 12       | percentage – A cross-sectional study in American adult individuals. Sci Rep 2018;8(1):10980. doi:         |
| 17       | 13       | doi.org/10.1038/s41598-018-29362-1  |
| 18       | 14       | 24. Paek JK, Kim J, Kim K, et al. Usefulness of relative fat mass in estimating body adiposity in Korean  |
| 19       | 15       | adult population. Endocr J 2019;66(8):723-29. doi: 10.1507/endocrj.EJ19-0064                              |
| 20       | 16       | 25. Guzman-Leon AE, Velarde AG, Vidal-Salas M, et al. External validation of the relative fat mass (RFM)  |
| 21       | 17       | index in adults from north-west Mexico using different reference methods. PLoS One                        |
| 22       | 18       | 2019;14(12):e0226767. doi: 10.1371/journal.pone.0226767   |
| 23       | 19       | 26. Correa CR, Formolo NPS, Dezanetti T, et al. Relative fat mass is a better tool to diagnose high       |
| 24       | 20       | adiposity when compared to body mass index in young male adults: A cross-section study. Clin Nutr         |
| 25       | 21       | <i>ESPEN</i> 2021;41:225-33. doi: 10.1016/j.clnesp.2020.12.009  |
| 26<br>27 | 22       | 27. Woolcott OO, Bergman RN. Defining cutoffs to diagnose obesity using the relative fat mass (RFM):      |
| 27<br>28 | 23       | Association with mortality in NHANES 1999-2014. <i>Int J Obes (Lond)</i> 2020;44:1301-10. doi:            |
| 29       | 24       | 10.1038/s41366-019-0516-8   |
| 30       | 25       | 28. Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults  |
| 31       | 26       | in the United States 2011-18: population based study. <i>BMJ</i> 2021;372:n365. doi: 10.1136/bmj.n365     |
| 32       | 27       | 29. Gupta RD, Chakraborty PA, Al Kibria GM. Racial/Ethnic disparities in prevalence and trends of         |
| 33       | 28       | obesity, grade 3 obesity, and abdominal obesity among US adults, 2003-18. <i>Obesity Medicine</i> 2021;28 |
| 34       | 20       | (no pagination)(100372) doi: https://dx.doi.org/10.1016/j.obmed.2021.100372                               |
| 35       | 30       | 30. CDC. NHANES 2017-March 2020 pre-pandemic data release notes.  |
| 36       | 31       | https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/release notes.aspx?Cycle=2017-2020 [Accessed]           |
| 37       | 32       | October 10, 2022].  |
| 38<br>39 | 32<br>33 | 31. Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to   |
| 40       | 33<br>34 | 2050, U.S. Bureau of the Census, Current Population Reports. Reports, P25-1130, U.S. Washington, DC,      |
| 41       | 34<br>35 | 1996.   |
| 42       | 36       | 32. National Health and Nutrition Examination Survey (NHANES). Anthropometry procedures manual.           |
| 43       |          | http://www.cdc.gov/nchs/data/nhanes/nhanes 07 08/manual an.pdf [Accessed May 16, 2016].                   |
| 44       | 37<br>38 | 33. CDC. NHANES response rates and population totals. Available at:                                       |
| 45       |          | https://wwwn.cdc.gov/nchs/nhanes/responserates.aspx. Accessed July 19, 2022.                              |
| 46       | 39       |   |
| 47<br>48 | 40       | 34. HHS. U.S. Department of Health & Human Services. Federal policy for the protection of human           |
| 40<br>49 | 41       | subjects. <u>https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html</u> .     |
| 50       | 42       | Accessed April 2, 2022., 2020.  |
| 51       | 43       | 35. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey:         |
| 52       | 44       | analytic guidelines, 1999-2010. Vital Health Stat 2 2013(161):1-24.                                       |
| 53       | 45       | 36. CDC. National Health and Nutrition Examination Survey. Module 1: Datasets and Documentation.          |
| 54       | 46       | https://wwwn.cdc.gov/nchs/nhanes/tutorials/module1.aspx [accessed July 18, 2022].                         |
| 55       | 47       | 37. Appiah D, Nwabuo CC, Ebong IA, et al. Trends in age at natural menopause and reproductive life        |
| 56       | 48       | span among US women, 1959-2018. JAMA 2021;325(13):1328-30. doi: 10.1001/jama.2021.0278                    |
| 57       |          | 24  |
| 58<br>59 |          | 24  |
| 60       |          | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                                 |
|          |          |   |

| 3        | 1  | 38. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8(5):551-61. doi:        |
|----------|----|---|
| 4        | 2  | 10.1002/sim.4780080504  |
| 5        | 3  | 39. Harrell FE. Regression modeling strategies: With applications to linear models, logistic regression,        |
| 6<br>7   | 4  | and survival analysis. New York: Springer 2001.   |
| 8        | 5  | 40. Cox NJ. Speaking Stata: Smoothing in various directions. Stata Journal 2005;5(4):574-93.                    |
| 9        | 6  | 41. Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females between            |
| 10       | 7  | ages 18 and 85 years. J Gerontol 1972;27(4):438-43. doi: 10.1093/geronj/27.4.438                                |
| 11       | 8  | 42. Song M-Y, Ruts E, Kim J, et al. Sarcopenia and increased adipose tissue infiltration of muscle in           |
| 12       | 9  | elderly African American women. Am J Clin Nutr 2004;79(5):874-80.   |
| 13       | 10 | 43. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and             |
| 14       | 11 | sex-specific prediction formulas. Br J Nutr 1991;65(2):105-14.  |
| 15<br>16 | 12 | 44. Noppa H, Andersson M, Bengtsson C, et al. Body composition in middle-aged women with special                |
| 16<br>17 | 13 | reference to the correlation between body fat mass and anthropometric data. Am J Clin Nutr                      |
| 18       | 14 | 1979;32(7):1388-95.   |
| 19       | 15 | 45. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A, et al. Validity and reliability of body composition     |
| 20       | 16 | analysers in children and adults. Br J Nutr 2008;100(4):859-65. doi: 10.1017/S0007114508925460                  |
| 21       | 17 | 46. Kuk JL, Saunders TJ, Davidson LE, et al. Age-related changes in total and regional fat distribution.        |
| 22       | 18 | Ageing Res Rev 2009;8(4):339-48. doi: 10.1016/j.arr.2009.06.001   |
| 23       | 19 | 47. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass     |
| 24       | 20 | index among US adults, 1999-2010. JAMA 2012;307(5):491-7.   |
| 25       | 21 | 48. Lakerveld J, Mackenbach J. The upstream determinants of adult obesity. <i>Obes Facts</i> 2017;10(3):216-    |
| 26<br>27 | 22 | 22. doi: 10.1159/000471489  |
| 27       | 23 | 49. Wells JC. Toward body composition reference data for infants, children, and adolescents. Adv Nutr           |
| 29       | 24 | 2014;5(3):320S-9S. doi: 10.3945/an.113.005371   |
| 30       | 25 | 50. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: A scientific statement     |
| 31       | 26 | from the American Heart Association. <i>Circulation</i> 2021;143(21):e984-e1010. doi:                           |
| 32       | 27 | 10.1161/CIR.00000000000973  |
| 33       | 28 | 51. Quetelet L. A Treatise on Man and the Development of his Faculties. Cambridge: Cambridge                    |
| 34       | 29 | University Press 2013.  |
| 35<br>36 | 30 | 52. VanItallie TB, Yang MU, Heymsfield SB, et al. Height-normalized indices of the body's fat-free mass         |
| 30<br>37 | 31 | and fat mass: potentially useful indicators of nutritional status. <i>Am J Clin Nutr</i> 1990;52(6):953-9. doi: |
| 38       | 32 | 10.1093/ajcn/52.6.953   |
| 39       | 33 | 53. Kyle UG, Schutz Y, Dupertuis YM, et al. Body composition interpretation. Contributions of the fat-          |
| 40       | 34 | free mass index and the body fat mass index. <i>Nutrition</i> 2003;19(7-8):597-604. doi: 10.1016/s0899-         |
| 41       | 35 | 9007(03)00061-3   |
| 42       | 36 | 54. Goran MI, Allison DB, Poehlman ET. Issues relating to normalization of body fat content in men and          |
| 43       | 37 | women. Int J Obes Relat Metab Disord 1995;19(9):638-43.   |
| 44<br>45 | 38 | 55. Prado CM, Wells JC, Smith SR, et al. Sarcopenic obesity: A Critical appraisal of the current evidence.      |
| 45<br>46 | 39 | <i>Clin Nutr</i> 2012;31(5):583-601. doi: 10.1016/j.clnu.2012.06.010  |
| 40<br>47 | 40 | 56. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis                 |
| 48       | 41 | among different ethnic groups. Int J Obes Relat Metab Disord 1998;22(12):1164-71.                               |
| 49       | 42 | 57. Parra-Soto S, Cowley ES, Rezende LFM, et al. Associations of six adiposity-related markers with             |
| 50       | 43 | incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study. BMC              |
| 51       | 44 | Med 2021;19(1):7. doi: 10.1186/s12916-020-01848-8   |
| 52       | 45 | 58. Auyeung TW, Lee JS, Leung J, et al. Survival in older men may benefit from being slightly overweight        |
| 53       | 46 | and centrally obesea 5-year follow-up study in 4,000 older adults using DXA. J Gerontol A Biol Sci Med          |
| 54<br>57 | 47 | <i>Sci</i> 2010;65(1):99-104. doi: 10.1093/gerona/glp099  |
| 55<br>56 | ., |   |
| 50<br>57 |    |   |
| 58       |    | 25  |
| 59       |    |   |
| 60       |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                                       |

# BMJ Open

| 2        |          |   |
|----------|----------|---|
| 3        | 1        | 59. Rolland Y, Gallini A, Cristini C, et al. Body-composition predictors of mortality in women aged >/= 75  |
| 4        | 2        | y: data from a large population-based cohort study with a 17-y follow-up. Am J Clin Nutr                    |
| 5        | 3        | 2014;100(5):1352-60. doi: 10.3945/ajcn.114.086728   |
| 6<br>7   | 4        | 60. Jeong SM, Lee DH, Rezende LFM, et al. Different correlation of body mass index with body fatness        |
| 8        | 5        | and obesity-related biomarker according to age, sex and race-ethnicity. Sci Rep 2023;13(1):3472. doi:       |
| 9        | 6        | 10.1038/s41598-023-30527-w  |
| 10       | 7        | 61. Suthahar N, Wang K, Zwartkruis VW, et al. Associations of relative fat mass, a new index of adiposity,  |
| 11       | 8        | with type-2 diabetes in the general population. <i>Eur J Intern Med</i> 2023;109:73-78. doi:                |
| 12       | 9        | 10.1016/j.ejim.2022.12.024  |
| 13       | 10       | 62. Suthahar N, Meems LMG, Withaar C, et al. Relative fat mass, a new index of adiposity, is strongly       |
| 14       | 11       | associated with incident heart failure: data from PREVEND. Scientific Reports 2022;12(1):147. doi:          |
| 15       |          |   |
| 16       | 12       | 10.1038/s41598-021-02409-6  |
| 17       | 13       | 63. Tutor AW, Lavie CJ, Kachur S, et al. Updates on obesity and the obesity paradox in cardiovascular       |
| 18       | 14       | diseases. Prog Cardiovasc Dis 2022 doi: 10.1016/j.pcad.2022.11.013  |
| 19       | 15       | 64. Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat       |
| 20       | 16       | depot? <i>Diabetes Care</i> 2009;32(6):1068-75. doi: 10.2337/dc08-2280                                      |
| 21<br>22 | 17       | 65. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue               |
| 22       | 18       | compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation            |
| 24       | 19       | 2007;116(1):39-48. doi: 10.1161/CIRCULATIONAHA.106.675355   |
| 25       | 20       | 66. CDC. National Diabetes Statistics Report. Estimates of diabetes and its burden in the United States.    |
| 26       | 21       | https://www.cdc.gov/diabetes/data/statistics-report/index.html [Accessed April 2, 2023].                    |
| 27       | 22       | 67. Caraballo C, Herrin J, Mahajan S, et al. Temporal trends in racial and ethnic disparities in            |
| 28       | 23       | multimorbidity prevalence in the United States, 1999-2018. Am J Med 2022;135(9):1083-92 e14. doi:           |
| 29       | 24       | 10.1016/j.amjmed.2022.04.010  |
| 30       | 25       | 68. Tian YE, Cropley V, Maier AB, et al. Heterogeneous aging across multiple organ systems and              |
| 31       | 26       | prediction of chronic disease and mortality. Nat Med 2023 doi: 10.1038/s41591-023-02296-6                   |
| 32       | 27       | 69. Schwartz RS. Obesity in the elderly: Prevalence, consequences, and treatment. In: Bray GA, Bouchard     |
| 33       | 28       | C, eds. Handbook of obesity Etiology and pathophysiology. Second edition ed. New York: Marcel Dekker,       |
| 34<br>35 | 29       | Inc. 2004:135-48.   |
| 35<br>36 | 30       | 70. de Santana FM, Domiciano DS, Goncalves MA, et al. Association of appendicular lean mass, and            |
| 37       | 31       | subcutaneous and visceral adipose tissue with mortality in older Brazilians: The Sao Paulo Ageing &         |
| 38       | 32       | Health Study. J Bone Miner Res 2019;34(7):1264-74. doi: 10.1002/jbmr.3710                                   |
| 39       | 33       | 71. Lee JS, Auyeung TW, Kwok T, et al. Survival benefit of abdominal adiposity: a 6-year follow-up study    |
| 40       | 34       | with Dual X-ray absorptiometry in 3,978 older adults. <i>Age (Dordr)</i> 2012;34(3):597-608. doi:           |
| 41       | 35       | 10.1007/s11357-011-9272-y   |
| 42       | 36       | 72. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident diabetes in       |
| 43       | 37       | Chinese adults: a population-based cohort study. <i>BMJ Open</i> 2018;8(9):e021768. doi: 10.1136/bmjopen-   |
| 44       | 38       | 2018-021768   |
| 45       | 39       | 73. Lind L, Sundstrom J, Arnlov J, et al. Impact of aging on the strength of cardiovascular risk factors: A |
| 46<br>47 | 40       | longitudinal study over 40 years. J Am Heart Assoc 2018;7(1) doi: 10.1161/JAHA.117.007061                   |
| 47<br>48 | 40<br>41 | 74. Masaki KH, Curb JD, Chiu D, et al. Association of body mass index with blood pressure in elderly        |
| 49       | 41       | Japanese American men. The Honolulu Heart Program. <i>Hypertension</i> 1997;29(2):673-7. doi:               |
| 50       |          |   |
| 51       | 43       | 10.1161/01.hyp.29.2.673   |
| 52       | 44<br>45 | 75. Tromp J, Paniagua SMA, Lau ES, et al. Age dependent associations of risk factors with heart failure:    |
| 53       | 45       | pooled population based cohort study. <i>BMJ</i> 2021;372:n461. doi: 10.1136/bmj.n461                       |
| 54       | 46       | 76. Chang SH, Beason TS, Hunleth JM, et al. A systematic review of body fat distribution and mortality in   |
| 55       | 47       | older people. <i>Maturitas</i> 2012;72(3):175-91. doi: 10.1016/j.maturitas.2012.04.004 [published Online    |
| 56       | 48       | First: 2012/05/19]  |
| 57       |          |   |
| 58<br>59 |          | 26  |
| 60       |          | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                                   |
|          |          |   |

77. Edston E. A correlation between the weight of visceral adipose tissue and selected anthropometric indices: an autopsy study. Clin Obes 2013;3(3-4):84-9. doi: 10.1111/cob.12021 78. Conway JM, Chanetsa FF, Wang P. Intraabdominal adipose tissue and anthropometric surrogates in African American women with upper- and lower-body obesity. Am J Clin Nutr 1997;66(6):1345-51. doi: 10.1093/ajcn/66.6.1345 79. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999;69(3):373-80. doi: 10.1093/ajcn/69.3.373 80. Lobman TG, Houtkooper L, Going SB. Body Fat Measurement Goes High-Tech: Not All Are Created Equal. ACSM's Health & Fitness Journal 1997;1(1):30-35. 81. Wells JC, Fewtrell MS. Measuring body composition. Arch Dis Child 2006;91(7):612-7. doi: 10.1136/adc.2005.085522 82. Clasey JL, Kanaley JA, Wideman L, et al. Validity of methods of body composition assessment in young and older men and women. J Appl Physiol (1985) 1999;86(5):1728-38. 83. Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what it is and what it isn't. BMJ Evid Based Med 2018;23(1):1-3. doi: 10.1136/ebmed-2017-110886 84. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health 2010;100(6):1019-28. doi: 10.2105/AJPH.2009.159491 

1

BMJ Open

| ן<br>ר   |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
|          |  |
| 17       |  |
| 18       |  |
| 19<br>20 |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
|          |  |
| 37<br>38 |  |
|          |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 57<br>58 |  |
|          |  |
| 59       |  |

60


## FIGURE LEGENDS


Figure 1. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by
sex: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes
method on weighted prevalence estimates. Body fat-defined obesity was determined using the
relative fat mass (RFM). RFM was calculated as follows: RFM = 64 - (20 × height/waist
circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if
RFM was 40% or higher for women and RFM was 30% or higher for men.


8 Figure 2. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by

9 ethnicity: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes
10 method on weighted prevalence estimates. The relative fat mass (RFM) was calculated as
11 follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1
12 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or
13 higher for men.

Figure 3. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by age group: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes method on weighted prevalence estimates. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men.







| 1        |   |
|----------|---|
| 2<br>3   |   |
| 4        | Supplementary Material  |
| 5        |   |
| 6<br>7   | Temporal trends in obesity defined by the relative fat mass (RFM) index among                                       |
| 8        | adulta in the United States from 4000 to 2020, nonvision based study  |
| 9<br>10  | adults in the United States from 1999 to 2020: population-based study   |
| 10       |   |
| 12       |   |
| 13       | Orison O. Woolcott <sup>1,2,*</sup> , Till Seuring <sup>3</sup>   |
| 14       |   |
| 15       |   |
| 16<br>17 |   |
| 18       | <sup>1</sup> Ronin Institute, Montclair, NJ, USA; <sup>2</sup> Institute for Globally Distributed Open Research and |
| 19       | Education (IODODE) Les Annales, OA, LIOA 31 manuel anna les titutes of Ossie, Essenancia                            |
| 20       | Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup> Luxembourg Institute of Socio-Economic                       |
| 21       | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 22<br>23 |   |
| 23       |   |
| 25       |   |
| 26       |   |
| 27       |   |
| 28<br>29 |   |
| 30       |   |
| 31       |   |
| 32       |   |
| 33       |   |
| 34<br>35 |   |
| 36       |   |
| 37       |   |
| 38       |   |
| 39       |   |
| 40<br>41 |   |
| 41       |   |
| 43       |   |
| 44       |   |
| 45       |   |
| 46<br>47 |   |
| 47<br>48 |   |
| 49       |   |
| 50       |   |
| 51       |   |
| 52<br>53 |   |
| 53<br>54 |   |
| 55       |   |
| 56       |   |
| 57       |   |
| 58<br>59 | 1   |
| 59<br>60 | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |
|          |   |

| 3        |  |
|----------|--|
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
|          |  |
|          |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| ~ -      |  |
|          |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 50<br>59 |  |
| 59       |  |

1 2

**Supplementary Table 1.** Prevalence of general and abdominal obesity among study participants by sex and ethnicity.\*

|                                   | Mexican American | European American | African American |
|-----------------------------------|------------------|-------------------|------------------|
| Women                             | n=4,204          | n=9,710           | n=5,417          |
| RFM-defined obesity, % (95% CI) † | 72.7 (70.3-75.1) | 56.6 (55.2-58.0)  | 69.9 (68.3-71.4) |
| BMI-defined obesity, % (95% CI) ‡ | 45.5 (43.2-47.9) | 35.4 (34.0-36.7)  | 54.5 (52.9-56.1) |
| Abdominal obesity, % (95% CI) §   | 71.5 (69.2-73.8) | 62.8 (61.4-64.1)  | 75.0 (73.6-76.3) |
|                                   |                  |                   |                  |
| Men                               | n=4,212          | n=9,981           | n=5,256          |
| RFM-defined obesity, % (95% CI) † | 47.0 (44.9-49.1) | 41.7 (40.3-43.2)  | 33.7 (32.1-35.3) |
| BMI-defined obesity, % (95% CI) ‡ | 38.4 (36.3-40.4) | 35.0 (33.6-36.5)  | 35.9 (34.2-37.6) |
| Abdominal obesity, % (95% CI) §   | 41.2 (39.1-43.2) | 47.6 (46.2-49.1)  | 37.5 (35.9-39.0) |

\* Sample size represents unweighted data. Estimates represent weighted data.

BMI, body mass index; CI, confidence interval IQR, interquartile range; RFM, relative fat mass; SD, standard deviation.

† Defined as an RFM ≥40% for women and ≥30% for men. Estimates are not adjusted for age.

‡ Defined as a BMI ≥30 kg/m<sup>2</sup>. Estimates are not adjusted for age.

§ Defined as a waist circumference >88 cm for women and >102 cm for men, according to the recommendations of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Estimates are not adjusted for age.

| 1                          |  |
|----------------------------|--|
| 2                          |  |
| 3                          |  |
|                            |  |
| 4                          |  |
| 5                          |  |
| 6                          |  |
| /                          |  |
| 8                          |  |
| 9                          |  |
| 10                         |  |
| 11                         |  |
| 12                         |  |
| 13                         |  |
| 12<br>13<br>14<br>15<br>16 |  |
| 15                         |  |
| 16                         |  |
| 17                         |  |
| 18                         |  |
| 19                         |  |
| 20                         |  |
| 21                         |  |
| 22                         |  |
| 23                         |  |
| 23<br>24                   |  |
| 24                         |  |
| 25                         |  |
| 26                         |  |
| 27                         |  |
| 28                         |  |
| 29                         |  |
| 30                         |  |
| 31                         |  |
| 32                         |  |
| 33                         |  |
| 34                         |  |
| 35                         |  |
| 36                         |  |
| 37                         |  |
| 38                         |  |
| 39                         |  |
| 40                         |  |
| 41                         |  |
| 42                         |  |
| 42<br>43                   |  |
|                            |  |
| 44                         |  |
| 45                         |  |
| 46                         |  |
| 47                         |  |
| 48                         |  |
| 49                         |  |
| 50                         |  |
| 51                         |  |
| 52                         |  |
| 53                         |  |
| 5/                         |  |

| Supplementary Table 2. Charact         | teristics of study pa | rticipants with missing o | data.*            |
|--|-----------------------|---------------------------|-------------------|
| Characteristic                         | All†                  | With complete data        | With missing data |
| Sample size, n (%)                     | 50,283 (100)          | 47,667 (95.6)             | 2,616 (4.4)       |
| Median age (IQR), years                | 45 (33-58)            | 45 (33-58)                | 47 (34-63)        |
| Male sex, n (%)                        | 24,954 (49.2)         | 23,736 (49.4)             | 1,218 (45.4)      |
| Ethnicity, n (%)                       |                       |                           |                   |
| Mexican American                       | 8,827 (8.3)           | 8,416 (8.3)               | 411 (8.6)         |
| European American                      | 20,618 (66.9)         | 19,691(67.2)              | 927 (58.6)        |
| African American                       | 11,433 (11.4)         | 10,673(11.2)              | 760 (16.7)        |
| Other/multi-racial                     | 9,405 (13.4)          | 8,887 (13.2)              | 518 (16.1)        |
| height (n=596), or waist circumference | - (11-2,340).         |                           |                   |
|  |                       |                           |                   |
|  |                       |                           |                   |
|  |                       |                           |                   |
|  |                       |                           |                   |

|                       | RF                   | M-defined obes       | itv                  | BMI-defined obesity  |                      |                     |
|-----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|
|                       | Mexican              | European             | African              | Mexican              | European             | African             |
|                       | American             | American             | American             | American             | American             | American            |
| All participants      | n=8,416              | n=19,691             | n=10,673             | n=8,416              | n=19,691             | n=10,673            |
| Prevalence, %         |                      |                      |                      |                      |                      |                     |
| (95% CI)              |                      |                      |                      |                      |                      |                     |
| 1999-2000             | 53.1 (48.5-          | 39.4 (34.2-          | 48.3 (45.0-          | 34.7 (28.9-          | 28.3 (23.9-          | 39.8 (35.7          |
|                       | 57.7)                | 44.6)                | 51.7)                | 40.6)                | 32.7)                | 43.8)               |
| 2001-2002             | 52.1 (47.1-          | 41.0 (38.9-          | 46.0 (42.9-          | 30.7 (26.7-          | 29.8 (27.0-          | 38.3 (34.4          |
| 2002 2004             | 57.1)<br>60.1 (55.2- | 43.1)                | 49.0)                | 34.7)<br>36.9 (32.2- | 32.6)                | 42.3)               |
| 2003-2004             | 65.0)                | 44.8 (41.0-<br>48.6) | 52.7 (49.4-<br>56.0) | 30.9 (32.2-<br>41.6) | 30.6 (27.7-<br>33.4) | 45.1 (39.7<br>50.5) |
| 2005-2006             | 55.4 (51.8-          | 44.9 (40.7-          | 51.5 (47.9-          | 33.8 (31.2-          | 33.1 (29.2-          | 45.9 (42.3          |
| 2000 2000             | 58.9)                | 49.2)                | 55.1)                | 36.4)                | 36.9)                | 49.5)               |
| 2007-2008             | 62.2 (56.2-          | 45.7 (41.5-          | 52.5 (49.1-          | 39.9 (33.8-          | 32.4 (28.7-          | 43.7 (39.2          |
| 2001 2000             | 68.2)                | 49.9)                | 56.0)                | 46.1)                | 36.0)                | 48.1)               |
| 2009-2010             | 61.5 (59.4-          | 46.4 (43.0-          | 56.8 (51.8-          | 40.5 (36.7-          | 34.2 (31.1-          | 49.4 (44.2          |
|                       | 63.6)                | 49.8)                | 61.8)                | 44.4)                | 37.2)                | 54.5)               |
| 2011-2012             | 63.6 (58.6-          | 46.8 (42.8-          | 57.4 (54.8-          | 46.1 (41.3-          | 33.0 (29.4-          | 48.4 (44.6          |
|                       | 68.6)                | 50.9)                | 60.0)                | 50.8)                | 36.5)                | 52.3)               |
| 2013-2014             | 65.0 (61.2-          | 49.4 (46.6-          | 55.0 (50.0-          | 46.1 (41.0-          | 36.6 (33.6-          | 47.9 (43.7          |
|                       | 68.9)                | 52.3)                | 59.9)                | 51.2)                | 39.5)                | 52.0)               |
| 2015-2016             | 70.3 (67.0-          | 51.2 (46.9-          | 56.6 (52.0-          | 48.7 (44.3-          | 38.5 (34.5-          | 48.7 (43.8          |
|                       | 73.5)                | 55.4)                | 61.2)                | 53.1)                | 42.5)                | 53.5)               |
| 2017-2020             | 68.8 (64.5-          | 54.1 (50.8-          | 57.1 (54.4-          | 50.2 (46.8-          | 41.7 (37.7-          | 49.9 (47.2          |
| Dravalaraa            | 73.1)                | 57.4)                | 59.8)                | 53.5)                | 45.6)                | 52.6)               |
| Prevalence<br>change† | 15.7 (9.6-<br>21.7)  | 14.7 (8.8-<br>20.5)  | 8.7 (4.6-<br>12.9)   | 15.4 (9.0-<br>21.9)  | 13.4 (7.7-19)        | 10.2 (5.5-<br>14.8) |
| P for non-            | 0.58                 | 0.97                 | 0.25                 | 0.52                 | 0.10                 | 0.35                |
| linearity‡            | 0.00                 | 0.57                 | 0.23                 | 0.52                 | 0.10                 | 0.00                |
| P value for           | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001              |
| trend‡                |                      |                      |                      |                      |                      |                     |
| Women                 | n=4,204              | n=9,710              | n=5,417              | n=4,204              | n=9,710              | n=5,417             |
| Prevalence, %         |                      |                      |                      |                      |                      |                     |
| (95% CI)              |                      |                      |                      |                      |                      |                     |
| 1999-2000             | 62.8 (55.1-          | 46.2 (40.2-          | 64.2 (59.6-          | 39.8 (31.1-          | 30.3 (25.2-          | 49.2 (42.5          |
|                       | 70.5)                | 52.1)                | 68.8)                | 48.5)                | 35.3)                | 56.0)               |
| 2001-2002             | 66.4 (58.6-          | 47.8 (44.2-          | 64.2 (59.0-          | 37.0 (30.2-          | 31.1 (27.6-          | 48.7 (42.8          |
|                       | 74.3)                | 51.4)                | 69.4)                | 43.8)                | 34.7)                | 54.7)               |
| 2003-2004             | 75.0 (68.3-          | 50.6 (43.9-          | 70.7 (65.5-          | 42.7 (36.0-          | 30.3 (25.7-          | 53.9 (46.3          |
| 2005 2002             | 81.6)                | 57.2)                | 75.8)                | 49.3)                | 34.8)                | 61.5)               |
| 2005-2006             | 72.0 (66.4-          | 49.9 (45.6-          | 66.2 (60.9-<br>71 5) | 41.3 (34.8-          | 32.8 (28.3-          | 52.7 (48.5<br>56.9) |
| 2007-2008             | 77.5)<br>74.8 (71.2- | 54.2)<br>52.3 (47.5- | 71.5)<br>67.9 (63.2- | 47.7)<br>44.7 (38.8- | 37.3)<br>32.8 (28.7- | 49.2 (45.2          |
| 2007-2000             | 78.4)                | 57.2)                | 72.6)                | 50.6)                | 36.9)                | 49.2 (45.2<br>53.3) |
| 2009-2010             | 77.8 (74.8-          | 53.4 (49.5-          | 74.6 (68.6-          | 45.7 (42.0-          | 32.1 (29.0-          | 58.5 (52.0          |
| 2000 2010             | 80.9)                | 57.2)                | 80.7)                | 49.3)                | 35.3)                | 64.9)               |
| 2011-2012             | 74.6 (66.2-          | 56.3 (51.4-          | 74.9 (72.1-          | 49.0 (40.4-          | 33.3 (28.0-          | 57.9 (53.5          |
|                       | 83.0)                | 61.3)                | 77.8)                | 57.5)                | 38.7)                | 62.3)               |
| 2013-2014             | 81.2 (74.7-          | 57.3 (53.4-          | 72.5 (68.8-          | 51.7 (45.2-          | 37.6 (33.7-          | 56.7 (53.1          |
|                       | 87.6)                | 61.2)                | 76.2)                | 58.3)                | 41.6)                | 60.3)               |
| 2015-2016             | 84.6 (79.7-          | 60.0 (56.2-          | 72.3 (68.3-          | 52.2 (48.4-          | 38.5 (34.0-          | 57.1 (52.6          |
|                       | 89.5)                | 63.8)                | 76.4)                | 56.1)                | 43.0)                | 61.5)               |
| 2017-2020             | 76.9 (70.8-          | 62.3 (59.0-          | 72.4 (68.6-          | 49.6 (43.1-          | 40.3 (36.4-          | 57.3 (53.7          |
|                       | 83.1)                | 65.7)                | 76.2)                | 56.0)                | 44.2)                | 60.9)               |
| Prevalence            | 14.1 (4.7-           | 16.2 (9.7-           | 8.3 (2.5-            | 9.8 (-0.6-           | 10.0 (3.9-           | 8.1 (0.8-           |
| change†               | 23.6)                | 22.7)                | 14.0)                | 20.1)                | 16.1)                | 15.4)               |

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| P for non-<br>linearity§  | 0.026                | 0.77                 | 0.34                 | 0.76                 | 0.12                 | 0.71                 |
|---------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| P value for<br>trend§     |                      | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               |
| Men                       | n=4,212              | n=9,981              | n=5,256              | n=4,212              | n=9,981              | n=5,256              |
| Prevalence, %<br>(95% CI) |                      |                      |                      |                      |                      |                      |
| 1999-2000                 | 42.9 (39.4-<br>46.5) | 33.2 (28.6-<br>37.7) | 27.5 (23.1-<br>31.9) | 29.1 (24.6-<br>33.6) | 26.8 (22.9-<br>30.6) | 26.8 (23.0-<br>30.6) |
| 2001-2002                 | 40.6 (34.7-<br>46.4) | 34.1 (30.9-<br>37.4) | 25.8 (21.4-<br>30.1) | 25.9 (21.9-<br>29.9) | 28.3 (25.3-<br>31.4) | 26.5 (22.8-<br>30.1) |
| 2003-2004                 | 47.1 (39.3-<br>54.8) | 38.9 (35.5-<br>42.4) | 31.2 (27.2-<br>35.2) | 31.7 (25.0-<br>38.3) | 30.9 (27.0-<br>34.7) | 34.2 (27.7-<br>40.7) |
| 2005-2006                 | 40.8 (34.1-<br>47.4) | 40.0 (35.1-<br>44.9) | 34.1 (28.3-<br>39.9) | 27.4 (22.7-<br>32.1) | 33.3 (28.7-<br>37.9) | 37.2 (31.2-43.2)     |
| 2007-2008                 | 50.9 (43.3-<br>58.4) | 38.8 (34.7-<br>42.9) | 33.8 (28.8-<br>38.9) | 35.1 (28.0-<br>42.1) | 32.0 (27.9-<br>36.0) | 36.9 (31.0-<br>42.7) |
| 2009-2010                 | 47.8 (44.6-<br>51.0) | 39.4 (34.6-<br>44.3) | 35.4 (31.4-<br>39.5) | 36.3 (30.9-<br>41.6) | 36.1 (30.8-<br>41.3) | 38.6 (33.1-<br>44.0) |
| 2011-2012                 | 52.5 (45.6-<br>59.4) | 37.6 (34.3-<br>40.9) | 36.4 (32.3-<br>40.5) | 42.7 (36.0-<br>49.5) | 32.5 (29.7-<br>35.3) | 37.5 (32.8-          |
| 2013-2014                 | 52.4 (48.6-<br>56.3) | 41.7 (38.1-<br>45.3) | 35.2 (28.6-<br>41.8) | 43.6 (38.2-<br>49.1) | 35.6 (31.6-<br>39.5) | 37.9 (32.5-<br>43.4) |
| 2015-2016                 | 55.9 (50.9-<br>60.8) | 42.3 (36.5-<br>48.1) | 38.1 (31.9-<br>44.2) | 45.3 (38.5-<br>52.1) | 38.4 (32.5-<br>44.3) | 38.9 (33.5-<br>44.2) |
| 2017-2020                 | 61.2 (55.8-<br>66.6) | 45.8 (40.3-<br>51.2) | 39.1 (35.4-<br>42.8) | 50.3 (46.1-<br>54.5) | 43.1 (36.9-<br>49.2) | 41.2 (36.7-45.7)     |
| Prevalence<br>change†     | 18.3 (12.0-<br>24.5) | 12.6 (5.7-<br>19.5)  | 11.6 (6.1-<br>17.1)  | 21.2 (15.3-<br>27.1) | 16.3 (9.3-<br>23.3)  | 14.4 (8.7-<br>20.1)  |
| P for non-<br>linearity§  | 0.21                 | 0.80                 | 0.50                 | 0.24                 | 0.45                 | 0.08                 |
| P value for<br>trend§     | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               |

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 – (20 x height/waist circumference) + (12 x sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval.
 † Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for age and sex.

§ Adjusted for age.

|                          | RFM-defined obesity  |                      |                      | BMI-defined obesity  |                      |                      |  |
|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|--|
|                          | 20-39 years<br>old   | 40-59 years<br>old   | 60-79 years<br>old   | 20-39 years<br>old   | 40-59 years old      | 60-79 years          |  |
| All participants         | n=16,747             | n=16,912             | n=14,008             | n=16,747             | n=16,912             | n=14,008             |  |
| Prevalence, 95%<br>Cl    |                      |                      |                      |                      |                      |                      |  |
| 1999-2000                | 29.0 (24.5-<br>33.6) | 46.9 (40.5-<br>53.4) | 61.8 (58.1-<br>65.6) | 25.4 (21.5-<br>29.3) | 33.2 (26.9-<br>39.4) | 35.4 (31.3-<br>39.5) |  |
| 2001-2002                | 30.2 (27.2-<br>33.1) | 45.0 (42.2-<br>47.8) | 63.8 (61.3-<br>66.3) | 25.3 (22.4-<br>28.1) | 33.2 (29.9-<br>36.4) | 33.7 (30.7-<br>36.8) |  |
| 2003-2004                | 34.2 (31.2-<br>37.1) | 51.2 (47.8-<br>54.6) | 65.8 (62.5-<br>69.0) | 28.1 (24.6-<br>31.7) | 35.9 (32.1-<br>39.7) | 33.0 (29.4-<br>36.5) |  |
| 2005-2006                | 32.6 (28.7-<br>36.5) | 53.2 (47.9-<br>58.5) | 66.0 (62.2-<br>69.8) | 28.5 (24.1-<br>32.9) | 40.1 (35.6-<br>44.6) | 34.9 (31.5-<br>38.3) |  |
| 2007-2008                | 35.5 (31.1-<br>39.9) | 51.6 (48.5-<br>54.7) | 66.1 (62.4-<br>69.8) | 30.2 (26.2-<br>34.3) | 35.7 (32.4-<br>39.1) | 37.4 (33.8-<br>40.9) |  |
| 2009-2010                | 37.2 (32.8-<br>41.6) | 50.5 (47.7-<br>53.4) | 68.5 (65.2-<br>71.8) | 32.5 (28.7-<br>36.3) | 36.0 (33.9-<br>38.2) | 41.8 (38.0-<br>45.7) |  |
| 2011-2012                | 37.7 (33.1-<br>42.3) | 53.6 (49.9-<br>57.3) | 68.0 (62.9-<br>73.1) | 30.4 (26.2-<br>34.5) | 39.3 (36.1-<br>42.5) | 38.3 (33.8-<br>42.9) |  |
| 2013-2014                | 40.0 (36.2-<br>43.9) | 54.5 (50.3-<br>58.7) | 68.8 (64.6-<br>73.0) | 34.4 (31.3-<br>37.5) | 40.6 (36.2-<br>45.1) | 39.3 (35.2-<br>43.5) |  |
| 2015-2016                | 43.0 (39.0-<br>47.0) | 57.1 (50.6-<br>63.6) | 69.8 (64.7-<br>74.9) | 36.0 (32.2-<br>39.8) | 42.8 (37.5-<br>48.2) | 42.8 (37.5-<br>48.2) |  |
| 2017-2020                | 44.6 (40.5-<br>48.6) | 59.4 (56.2-<br>62.7) | 70.6 (67.2-<br>74.0) | 39.8 (35.6-<br>44.0) | 44.3 (41.2-<br>47.4) | 42.7 (39.1-<br>46.3) |  |
| Prevalence<br>change†    | 15.5 (9.7-<br>21.3)  | 12.5 (5.6-<br>19.4)  | 8.8 (3.9-<br>13.6)   | 14.5 (8.9-<br>20.0)  | 11.2 (4.5-<br>17.8)  | 7.3 (2.0-<br>12.5)   |  |
| P for non-<br>linearity‡ | 0.65                 | 0.94                 | 0.25                 | 0.48                 | 0.21                 | 0.46                 |  |
| P value for<br>trend‡    | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               |  |
| Women                    | n=8,295              | n=8,684              | n=6,952              | n=8,295              | n=8,684              | n=6,952              |  |
| Prevalence, 95%<br>Cl    |                      |                      |                      | 0                    |                      |                      |  |
| 1999-2000                | 36.9 (30.9-<br>42.9) | 56.2 (48.9-<br>63.5) | 67.7 (63.3-<br>72.2) | 28.7 (23.6-<br>33.7) | 37.4 (30.2-<br>44.5) | 37.4 (31.6-<br>43.2) |  |
| 2001-2002                | 39.9 (35.3-<br>44.5) | 52.9 (48.1-<br>57.6) | 72.0 (69.3-<br>74.7) | 28.9 (24.1-<br>33.6) | 35.0 (30.2-<br>39.8) | 36.6 (32.0-<br>41.2) |  |
| 2003-2004                | 42.0 (35.8-<br>48.2) | 59.7 (54.9-<br>64.5) | 73.0 (68.3-<br>77.7) | 29.0 (23.8-<br>34.1) | 38.1 (32.3-<br>43.9) | 33.6 (28.5-<br>38.7) |  |
| 2005-2006                | 40.3 (35.3-<br>45.4) | 58.7 (53.5-<br>63.8) | 71.3 (66.4-<br>76.2) | 29.2 (24.1-<br>34.3) | 40.7 (35.9-<br>45.6) | 34.8 (28.4-<br>41.2) |  |
| 2007-2008                | 46.1 (40.4-<br>51.7) | 60.0 (56.2-<br>63.8) | 69.8 (64.5-<br>75.1) | 33.0 (27.3-<br>38.6) | 37.6 (32.6-<br>42.5) | 36.0 (30.0-<br>41.9) |  |
| 2009-2010                | 46.4 (40.6-<br>52.2) | 59.3 (55.5-<br>63.1) | 78.5 (75.8-<br>81.3) | 31.8 (28.2-<br>35.4) | 35.5 (31.7-<br>39.3) | 45.1 (40.7-<br>49.5) |  |
| 2011-2012                | 47.6 (42.1-<br>53.1) | 64.6 (60.1-<br>69.0) | 76.7 (69.8-<br>83.5) | 31.9 (28.0-<br>35.9) | 39.4 (35.1-<br>43.6) | 42.1 (34.4-<br>49.7) |  |
| 2013-2014                | 50.8 (46.6-<br>55.1) | 63.3 (58.1-<br>68.5) | 78.0 (74.6-<br>81.4) | 36.6 (33.9-<br>39.3) | 43.6 (38.2-<br>48.9) | 40.2 (34.1-<br>46.2) |  |
| 2015-2016                | 53.3 (48.9-<br>57.8) | 69.1 (62.7-<br>75.5) | 77.1 (70.6-<br>83.6) | 37.1 (33.5-<br>40.7) | 44.8 (38.4-<br>51.1) | 45.0 (37.3-<br>52.8) |  |
| 2017-2020                | 53.3 (48.5-<br>58.0) | 67.9 (63.6-<br>72.3) | 81.0 (76.4-<br>85.6) | 39.9 (35.3-<br>44.4) | 42.8 (38.9-<br>46.7) | 45.4 (40.9-<br>49.8) |  |

| Ρ      | ag                                   |
|--------|--------------------------------------|
|        |                                      |
|        |                                      |
| 1      |                                      |
| 2      |                                      |
| 4      |                                      |
| 5      |                                      |
| 6      |                                      |
| 7      |                                      |
| 8      |                                      |
| 9      | ~                                    |
| 1      | 0                                    |
| 1<br>1 | •                                    |
| 1      |                                      |
| 1      |                                      |
| 1      | 5                                    |
| 1      | 5<br>6<br>7<br>8<br>9<br>0           |
| 1      | 7                                    |
| 1      | 8                                    |
| 1      | 9                                    |
| 2      | 1                                    |
| 2      | י<br>כ                               |
| 2      | 3                                    |
| 2      | 3<br>4                               |
| 2      | 5                                    |
| 2      | 6                                    |
| 2      | 7                                    |
| 2      | 0<br>7<br>8<br>9<br>0<br>1<br>2<br>3 |
| 2      | 9                                    |
| 3      | 1                                    |
| כ<br>ר | י<br>ר                               |
| 3      | 3                                    |
| 3      | 4                                    |
| 3      | 5                                    |
|        | 6                                    |
| 3      |                                      |
| 3      |                                      |
|        | 9<br>0                               |
| 4      | 1                                    |
| 4      |                                      |
| 4      |                                      |
| 4      | 4                                    |
| 4      |                                      |
| 4      |                                      |
| 4      |                                      |
| 4      |                                      |
|        | 9<br>0                               |
|        | 0<br>1                               |
| 5      |                                      |
| 5      |                                      |
|        | 4                                    |
| F      | F                                    |


59

60

| Prevalence            | 16.4 (9.1-           | 11.7 (3.6-           | 13.3 (7.1-           | 11.2 (4.7-           | 5.5 (-2.3-           | 8.0 (1.0-           |
|-----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|---------------------|
| change†               | 23.7)                | 19.9)                | 19.5)                | 17.7)                | 13.2)                | 15.0)               |
| P for non-            | 0.16                 | 0.39                 | 0.99                 | 0.44                 | 0.42                 | 0.97                |
| linearity§            |                      |                      |                      |                      |                      |                     |
| P value for           | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001              |
| trend§                |                      |                      |                      |                      |                      |                     |
| Men                   | n=8,452              | n=8,228              | n=7,056              | n=8,452              | n=8,228              | n=7,056             |
| Prevalence, 95%<br>Cl |                      |                      |                      |                      |                      |                     |
| 1999-2000             | 22.4 (18.0-<br>26.8) | 36.8 (30.4-<br>43.2) | 54.7 (49.9-<br>59.5) | 22.7 (18.3-<br>27.0) | 28.8 (22.8-<br>34.8) | 33.2 (28.2<br>38.1) |
| 2001-2002             | 20.8 (17.4-          | 37.1 (33.5-          | 53.5 (49.8-          | 21.7 (18.5-          | 31.2 (28.0-          | 30.4 (26.0          |
|                       | 24.1)                | 40.7)                | 57.1)                | 24.9)                | 34.5)                | 34.8)               |
| 2003-2004             | 26.9 (23.3-          | 42.3 (36.7-          | 57.2 (52.5-          | 27.4 (22.5-          | 33.6 (28.4-          | 32.3 (27.4          |
|                       | 30.4)                | 47.9)                | 62.0)                | 32.3)                | 38.9)                | 37.2)               |
| 2005-2006             | 25.4 (20.1-          | 47.4 (40.5-          | 59.8 (54.8-          | 27.6 (22.0-          | 39.5 (33.1-          | 34.7 (29.9          |
|                       | 30.7)                | 54.2)                | 64.7)                | 33.1)                | 45.9)                | 39.5)               |
| 2007-2008             | 25.4 (21.2-          | 42.8 (37.8-          | 61.8 (57.7-          | 27.6 (23.8-          | 33.7 (28.8-          | 39.2 (34.8          |
|                       | 29.5)                | 47.8)                | 65.9)                | 31.4)                | 38.5)                | 43.5)               |
| 2009-2010             | 28.5 (23.6- 🧹        | 41.6 (37.7-          | 56.9 (51.1-          | 33.2 (27.2-          | 36.6 (33.0-          | 37.5 (32.3          |
|                       | 33.3)                | 45.5)                | 62.7)                | 39.2)                | 40.2)                | 42.8)               |
| 2011-2012             | 28.4 (23.9-          | 42.3 (38.0-          | 58.1 (52.1-          | 28.9 (23.5-          | 39.1 (35.6-          | 34.2 (29.2          |
|                       | 33.0)                | 46.6)                | 64.2)                | 34.2)                | 42.5)                | 39.2)               |
| 2013-2014             | 30.0 (25.5-          | 45.5 (40.3-          | 58.6 (51.6-          | 32.5 (28.1-          | 37.7 (32.2-          | 38.6 (30.7          |
|                       | 34.5)                | 50.7)                | 65.5)                | 36.8)                | 43.3)                | 46.4)               |
| 2015-2016             | 33.1 (28.3-          | 44.5 (36.5-          | 61.4 (55.4-          | 35.0 (29.0-          | 40.8 (34.6-          | 40.2 (34.9          |
|                       | 38.0)                | 52.6)                | 67.5)                | 41.0)                | 47.1)                | 45.5)               |
| 2017-2020             | 35.9 (30.2-          | 50.8 (46.2-          | 58.8 (54.3-          | 39.5 (33.1-          | 45.8 (41.1-          | 39.7 (34.0          |
|                       | 41.5)                | 55.4)                | 63.3)                | 46.0)                | 50.6)                | 45.4)               |
| Prevalence            | 13.4 (6.5-           | 14.0 (6.4-           | 4.1 (-2.3-           | 16.8 (9.3-           | 17.0 (9.7-           | 6.5 (-0.7-          |
| change†               | 20.4)                | 21.6)                | 10.5)                | 24.4)                | 24.4)                | 13.8)               |
| P for non-            | 0.47                 | 0.42                 | 0.16                 | 0.97                 | 0.41                 | 0.24                |
| linearity§            |                      |                      |                      |                      |                      |                     |
| P value for           | <0.001               | <0.001               | <0.001               | <0.001               | <0.001               | <0.001              |
| trend§                |                      |                      |                      |                      |                      |                     |

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 -(20 x height/waist circumference) + (12 x sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval. A Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).
Adjusted for sex and ethnicity.
Adjusted for ethnicity.

NHANES 1999-March 2020



Supplementary Figure 1. Selection of study participants.

STROBE Statement—checklist of items that should be included in reports of observational studies

|                        | Item<br>No | Recommendation   | Pag<br>No |
|------------------------|------------|--|-----------|
| Title and abstract     | 1          | ( <i>a</i> ) Indicate the study's design with a commonly used term in the title or                           | 1         |
|                        |            | the abstract   | 2.4       |
|                        |            | ( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found | 3-4       |
| <b>.</b>               |            | was done and what was found  |           |
| Introduction           | 2          | Explain the scientific background and rationals for the investigation being                                  | 6-7       |
| Background/rationale   | Z          | Explain the scientific background and rationale for the investigation being reported                         | 0-/       |
| Objectives             | 3          | State specific objectives, including any prespecified hypotheses   | 7         |
| Methods                |            |  |           |
| Study design           | 4          | Present key elements of study design early in the paper  | 8         |
| Setting                | 5          | Describe the setting, locations, and relevant dates, including periods of                                    | 8         |
| -                      |            | recruitment, exposure, follow-up, and data collection  |           |
| Participants           | 6          | (a) Cohort study—Give the eligibility criteria, and the sources and  | 8, 1      |
| -                      |            | methods of selection of participants. Describe methods of follow-up  |           |
|                        |            | Case-control study—Give the eligibility criteria, and the sources and  |           |
|                        |            | methods of case ascertainment and control selection. Give the rationale                                      |           |
|                        |            | for the choice of cases and controls   |           |
|                        |            | Cross-sectional study—Give the eligibility criteria, and the sources and                                     |           |
|                        |            | methods of selection of participants   |           |
|                        |            | (b) Cohort study—For matched studies, give matching criteria and   | NA        |
|                        |            | number of exposed and unexposed  |           |
|                        |            | Case-control study—For matched studies, give matching criteria and the                                       |           |
|                        |            | number of controls per case  |           |
| Variables              | 7          | Clearly define all outcomes, exposures, predictors, potential confounders,                                   | 9-1       |
|                        |            | and effect modifiers. Give diagnostic criteria, if applicable  |           |
| Data sources/          | 8*         | For each variable of interest, give sources of data and details of methods                                   | 8-1       |
| measurement            |            | of assessment (measurement). Describe comparability of assessment  |           |
|                        |            | methods if there is more than one group  |           |
| Bias                   | 9          | Describe any efforts to address potential sources of bias  | 9-1       |
| Study size             | 10         | Explain how the study size was arrived at  | 8         |
| Quantitative variables | 11         | Explain how quantitative variables were handled in the analyses. If  | 9-1       |
|                        |            | applicable, describe which groupings were chosen and why   |           |
| Statistical methods    | 12         | (a) Describe all statistical methods, including those used to control for                                    | 9-1       |
|                        |            | confounding  |           |
|                        |            | (b) Describe any methods used to examine subgroups and interactions  | 9-1       |
|                        |            | (c) Explain how missing data were addressed  | 8         |
|                        |            | (d) Cohort study—If applicable, explain how loss to follow-up was  | 9-1       |
|                        |            | addressed  |           |
|                        |            | Case-control study-If applicable, explain how matching of cases and  |           |
|                        |            | controls was addressed   |           |
|                        |            | Cross-sectional study-If applicable, describe analytical methods taking                                      |           |
|                        |            | account of sampling strategy   |           |
|                        |            | ( <u>e</u> ) Describe any sensitivity analyses   | 10        |

Continued on next page

| Participants      | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially  | 11             |
|-------------------|-----|--|----------------|
|                   |     | eligible, examined for eligibility, confirmed eligible, included in the study,   |                |
|                   |     | completing follow-up, and analysed   |                |
|                   |     | (b) Give reasons for non-participation at each stage   | 11             |
|                   |     | (c) Consider use of a flow diagram   | Supp<br>Fig 1  |
| Descriptive       | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and notantial confounders | 11             |
| data              |     | information on exposures and potential confounders   | 0              |
|                   |     | (b) Indicate number of participants with missing data for each variable of interest  | Suppl<br>Table |
|                   |     | (c) Cohort study—Summarise follow-up time (eg, average and total amount)   | NA             |
| Outcome data      | 15* | Cohort study—Report numbers of outcome events or summary measures over time  | NA             |
|                   |     | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure                                     | NA             |
|                   |     | Cross-sectional study—Report numbers of outcome events or summary measures   | 11-18          |
| Main results      | 16  | ( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and   | NA             |
| Wall results      | 10  | their precision (eg, 95% confidence interval). Make clear which confounders were   |                |
|                   |     | adjusted for and why they were included  |                |
|                   |     | (b) Report category boundaries when continuous variables were categorized  | 12-18          |
|                   |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period                         | NA             |
| Other analyses    | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 11-18          |
| Discussion        |     |  | 1              |
| Key results       | 18  | Summarise key results with reference to study objectives   | 19             |
| Limitations       | 19  | Discuss limitations of the study, taking into account sources of potential bias or   | 23-24          |
|                   |     | imprecision. Discuss both direction and magnitude of any potential bias  |                |
| Interpretation    | 20  | Give a cautious overall interpretation of results considering objectives, limitations,   | 24             |
|                   |     | multiplicity of analyses, results from similar studies, and other relevant evidence  |                |
| Generalisability  | 21  | Discuss the generalisability (external validity) of the study results  | 24             |
| Other information | on  |  |                |
| Other miormatio   |     |  |                |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

# **BMJ Open**

## Temporal trends in obesity defined by the relative fat mass (RFM) index among adults in the United States from 1999 to 2020: population-based study

| Journal:                             | BMJ Open  |
|--------------------------------------|---|
| Manuscript ID                        | bmjopen-2022-071295.R2  |
| Article Type:                        | Original research   |
| Date Submitted by the Author:        | 06-Jul-2023   |
| Complete List of Authors:            | Woolcott, Orison; Ronin Institute; Institute for Globally Distributed Open<br>Research and Education (IGDORE)<br>Seuring, Till; Luxembourg Institute of Socio-Economic Research (LISER) |
| <b>Primary Subject<br/>Heading</b> : | Epidemiology  |
| Secondary Subject Heading:           | Diabetes and endocrinology, General practice / Family practice, Public health   |
| Keywords:                            | EPIDEMIOLOGY, PUBLIC HEALTH, General endocrinology < DIABETES & ENDOCRINOLOGY, GENERAL MEDICINE (see Internal Medicine), Obesity  |
|                                      |   |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 1             |    |   |
|---------------|----|---|
| 2             |    |   |
| 3<br>4        | 1  | Temporal trends in obesity defined by the relative fat mass (RFM) index among   |
| 5<br>6        | 2  | adults in the United States from 1999 to 2020: population-based study   |
| 7<br>8        | 3  |   |
| 9<br>10<br>11 | 4  | Orison O. Woolcott, research scientist <sup>1,2,*</sup> , Till Seuring, postdoctoral fellow <sup>3</sup>  |
| 12<br>13      | 5  |   |
| 14<br>15      | 6  | <sup>1</sup> Ronin Institute, Montclair, NJ, USA; <sup>2</sup> Institute for Globally Distributed Open Research and   |
| 16<br>17      | 7  | Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup> Luxembourg Institute of Socio-Economic   |
| 18<br>19      | 8  | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 20<br>21      | 9  | Correspondence:<br>Orison O. Woolcott, M.D.<br>Ronin Institute<br>Montclair, NJ<br>United States of America<br>Telephone: +1 (323) 253-2562<br>Email: Orison Woolcott@gmail.com |
| 22<br>23      | 10 |   |
| 24            | 11 |   |
| 25            | 12 |   |
| 26            | 13 |   |
| 27            | 14 |   |
| 28<br>29      | 15 |   |
| 30            | 16 |   |
| 31            | 17 | Correspondence:   |
| 32            | 18 |   |
| 33            | 19 | Orison O. Woolcott, M.D.  |
| 34            | 20 | Ronin Institute   |
| 35            | 21 | Montclair, NJ   |
| 36            | 22 | United States of America  |
| 37            | 23 | Telephone: +1 (323) 253-2562  |
| 38            | 24 | Email: Orison.Woolcott@gmail.com  |
| 39            | 25 |   |
| 40            | 26 |   |
| 41<br>42      | 27 | Abstract word count: 300  |
| 43<br>44      | 28 | Text word count: 4,225  |
| 45<br>46      | 29 |   |
| 47<br>48      | 30 | Keywords: General Obesity, NHANES, Prevalence, Relative Fat Mass, RFM, Trends.  |
| 49            |    |   |
| 50            |    |   |
| 51            |    |   |
| 52            |    |   |
| 53            |    |   |
| 54            |    |   |
| 55            |    |   |
| 56            |    |   |
| 57            |    |   |
| 58<br>59      |    | 1   |
|               |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |
| 60            |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |

BMJ Open

| 2<br>3<br>4          | 1  | ABSTRACT  |
|----------------------|----|---|
| 5<br>6<br>7          | 2  | Objectives: The body mass index (BMI) largely underestimates excess body fat, suggesting        |
| 7<br>8<br>9          | 3  | that the prevalence of obesity could be underestimated. Biologically, women are known to have   |
| 10<br>11             | 4  | higher body fat than men. This study aimed to compare the temporal trends in general obesity    |
| 12<br>13             | 5  | by sex, ethnicity, and age among adults in the United States using the relative fat mass (RFM), |
| 14<br>15<br>16       | 6  | a validated surrogate for whole-body fat percentage, and BMI.                                   |
| 17<br>18             | 7  | Design: Population-based study  |
| 19<br>20<br>21       | 8  | Setting: U.S. National Health and Nutrition Examination Survey (NHANES), from 1999-2000         |
| 21<br>22<br>23       | 9  | through 2017-March 2020.  |
| 24<br>25<br>26       | 10 | Participants: A representative sample of adults 20-79 years in the U.S.                         |
| 27<br>28             | 11 | Main outcome measures: Age-adjusted prevalence of general obesity. RFM-defined obesity          |
| 29<br>30             | 12 | was diagnosed using validated cutoffs to predict all-cause mortality: RFM ≥40% for women and    |
| 31<br>32<br>33       | 13 | ≥30% for men. BMI-defined obesity was diagnosed using a cutoff of 30 kg/m <sup>2</sup> .        |
| 34<br>35             | 14 | Results: Analysis included data from 47,667 adults. Among women, RFM-defined obesity            |
| 36<br>37             | 15 | prevalence was 64.7% (95% confidence interval, 62.1-67.3%) in 2017-2020, a linear increase of   |
| 38<br>39<br>40       | 16 | 13.9 percentage points (9.0-18.9%; P<0.001) relative to 1999-2000. In contrast, the prevalence  |
| 40<br>41<br>42       | 17 | of BMI-defined obesity was 42.2% (39.4-45.0%) in 2017-2020. Among men, the corresponding        |
| 43<br>44             | 18 | RFM-defined obesity prevalence was 45.8% (42.0-49.7%), a linear increase of 12.0 percentage     |
| 45<br>46             | 19 | points (6.6-17.3%; P<0.001). In contrast, the prevalence of BMI-defined obesity was 42.0 (37.8- |
| 47<br>48             | 20 | 46.3%). The highest prevalence of RFM-defined obesity across years was observed in older        |
| 49<br>50             | 21 | adults (60-79 years) and Mexican Americans, in women and men. Conversely, the highest           |
| 50<br>51<br>52       | 22 | prevalence of BMI-defined obesity across years was observed in middle-age (40-59 years) and     |
| 53<br>54<br>55<br>56 | 23 | older adults, and in African American women.  |
| 50<br>57<br>58       |    | 2   |
| 59<br>60             |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                       |

**Conclusions:** The use of a surrogate for whole-body fat percentage revealed a much higher prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, than that estimated using BMI, and detected a disproportionate higher prevalence of general obesity in older adults and Mexican Americans.

<text><text><text>

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- RFM is a validated surrogate for whole-body fat percentage that has a high diagnostic accuracy (91%) for DXA-defined obesity.
- The diagnosis of obesity was based on measured anthropometrics and validated RFM cutoffs associated with increased risk for all-cause mortality.
- RFM requires only waist circumference and height for its calculation.
- The proportion of obesity misclassification is not trivial when using RFM.
- Estimates of temporal trends in obesity was not possible for Asian Americans.

## 1 INTRODUCTION

The prevalence of obesity (excess body fat) in the United States has doubled from 15.0% in 1976-1980 to 30.9% in 1999-2000<sup>1</sup>, and it continues to increase <sup>23</sup>. The age-adjusted prevalence of obesity among adults in the U.S. has been estimated at 41.9% in 2017-March 2020<sup>4</sup>. Obesity diagnosis is based on the body mass index (BMI), an indirect measure of body fat <sup>56</sup>. BMI is calculated as the ratio of body weight in kilograms to the square of the height in meters 7. BMI does not distinguish between fat mass and fat-free mass and does not account for differences in adiposity between women and men. Biologically, women are known to have higher body fat than men<sup>8-12</sup>. A meta-analysis of 25 international studies comprising nearly 32,000 adults concluded that BMI underestimates ~50% of all individuals with excess body fat percentage determined by reference techniques <sup>11</sup>, suggesting that the prevalence of obesity could be largely underestimated among countries. 

There is robust evidence linking high whole-body fat percentage with increased risk of death <sup>13-</sup> <sup>20</sup>, supporting the need for a better assessment of body adiposity. Although the limitations of BMI to assess body adiposity are widely acknowledged <sup>6 8-11 21 22</sup>. BMI remains the most widely used anthropometric index in clinical practice, epidemiology, and public health, given its simplicity, very low cost, and its association with several clinical conditions and mortality <sup>6</sup>. The high cost and time required to assess body adiposity using more accurate techniques such as dual-energy x-ray absorptiometry (DXA), dual-labeled water, or magnetic resonance, prevents their use in large populations or clinical practice as part of routine screening. 

The relative fat mass (RFM) is a simple and low-cost anthropometric index developed to estimate whole-body fat percentage <sup>23</sup>. RFM is a linear equation based on the ratio of height to waist circumference that has been validated in Mexican, European, and African Americans <sup>23</sup>, and in other populations <sup>24-26</sup>. Compared with BMI, RFM resulted in lower obesity misclassification when DXA was used as the reference method for diagnosing obesity in adults 

Page 7 of 41

1

#### BMJ Open

| 2              |    |      |
|----------------|----|------|
| 3<br>4         | 1  | 24 2 |
| 5              | 2  | am   |
| 6<br>7         | 3  | the  |
| 8<br>9         |    |      |
| 10<br>11       | 4  | sta  |
| 12<br>13       | 5  | Re   |
| 14<br>15       | 6  | toc  |
| 16<br>17       | 7  | ро   |
| 18<br>19       | 8  | lim  |
| 20<br>21       | 9  | be   |
| 22<br>23       | 10 | ad   |
| 24<br>25<br>26 | 11 | sui  |
| 26<br>27<br>28 | 12 | ob   |
| 28<br>29<br>30 | 13 | COI  |
| 31<br>32       | 14 | in t |
| 33             |    |      |
| 34<br>35       |    |      |
| 36<br>37       |    |      |
| 38             |    |      |
| 39<br>40       |    |      |
| 40<br>41       |    |      |
| 42             |    |      |
| 43<br>44       |    |      |
| 44<br>45       |    |      |
| 46             |    |      |
| 47<br>48       |    |      |
| 40<br>49       |    |      |
| 50             |    |      |
| 51<br>52       |    |      |
| 52<br>53       |    |      |
| 54             |    |      |
| 55             |    |      |
| 56<br>57       |    |      |
| 57<br>58       |    |      |
| 59             |    |      |

60

<sup>24 27</sup>. The accuracy of RFM in diagnosing high body fat percentage is superior to that of BMI
 among men and similar to BMI among women <sup>23</sup>. In an analysis of a representative sample of
 the U.S. adult population (NHANES 1999-2006), RFM had a diagnostic accuracy of 91% (C statistic = 0.91) for DXA-defined obesity in women and men <sup>27</sup>.
 Recent studies have examined the U.S. prevalence trends in obesity using BMI as diagnostic
 tool <sup>3 28 29</sup>. Although data on body fat percentage have also been reported for the U.S. adult
 population <sup>28</sup>, no body fat cutoffs were used to diagnose general obesity, and the analyses were

8 limited to adults 20-59 years only, and for the period 2011-2018. In fact, body composition has

9 been inconsistently assessed across NHANES survey cycles and across age groups. In

10 addition, no study has compared the trends of general obesity in the U.S. using RFM, a

11 surrogate for body fat percentage, and BMI. Furthermore, no study has examined current

12 obesity trends among U.S. adults over a period of nearly 22 years. The aim of this study was to

13 compare the temporal trends in general obesity by sex, ethnicity, and age group among adults

14 in the U.S. from 1999 to 2020 using RFM and BMI.

#### 1 MATERIAL AND METHODS

#### 2 <u>Study design, data source, and participants</u>

In this population-based study, we performed an analysis of cross-sectional individual-level data collected by the National Health and Nutrition Examination Survey (NHANES) through interviews and physical examination in a subset of a representative sample of the U.S. population from 1999-2000 through 2017-March 2020. Initial complete dataset included 107,622 participants of all ages. NHANES suspended data collection in March 2020 as a consequence of the COVID-19 pandemic. Thus, the most current cycle data available are "combined data collected from 2019 to March 2020 with data from the NHANES 2017-2018 cycle to form a nationally representative sample of NHANES 2017-March 2020 pre-pandemic data" <sup>30</sup>. Analysis was restricted to adults 20-79 years of age (n=54.232 potentially eligible) because of three reasons: 1) the diagnosis of obesity in younger adults is based on BMI-for-age percentiles as recommended by the Centers for Disease Control and Prevention (CDC)<sup>7</sup>; 2) in NHANES 2007-2008 and subsequent cycles, the upper age limit was 80 years, whereas in earlier cycles the age limit was 85 years; and 3) to obtain age-adjusted prevalence estimates using 5-year intervals according to the strata for age and sex available from the 2000 US Census Bureau (20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75-79) <sup>31</sup>. Another criterion for inclusion was that individuals had been interviewed and evaluated by physical examination. Women who reported to be pregnant or had a positive urine pregnancy test were excluded from analysis. Observations with missing data on body weight, height, or waist circumference were also excluded.

According to the NHANES physical examination protocol, waist circumference was measured just above the uppermost lateral border of the right ilium (hip bone). Weight and height were measured using standard methods <sup>32</sup>. Information on ethnicity was collected through a questionnaire. The mean unweighted response rate for examined sample across survey cycles 

**BMJ** Open

| 2        |
|----------|
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| ,<br>8   |
| 9        |
|          |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
| 16       |
| 17       |
| 18       |
| 19       |
| 20       |
| 20<br>21 |
| 21<br>22 |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32       |
| 33       |
| 33<br>34 |
|          |
| 35       |
| 36       |
| 37       |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46       |
| 40<br>47 |
|          |
| 48       |
| 49       |
| 50       |
| 51       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 58<br>59 |
| 22       |

60

between 1999-2000 and 2017-March 2020 for individuals 20-79 years was 67.5% (range 50.8 74.5%) <sup>33</sup>.

Since this study used publicly available de-identified data, approval from an Institutional Review
Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects
(detailed in 45 CFR part 46) <sup>34</sup>.

6 <u>Obesity diagnosis</u>

General obesity was diagnosed using RFM, a validated surrogate for whole-body fat percentage
<sup>23</sup>, and validated cutoffs to predict all-cause mortality: RFM ≥40% for women and ≥30% for men
<sup>27</sup>. RFM was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex);
sex equals 0 for men and 1 for women <sup>23</sup>. BMI-defined obesity was diagnosed if BMI was 30
kg/m<sup>2</sup> or higher <sup>7</sup>.

12 <u>Statistical Analysis</u>

Data collected during the survey cycles from 1999-2000 through 2017-2020 were analyzed 13 14 using sampling weights following the recommended analytic guidelines, to account for 15 oversampling, nonresponse rates, and subsampling for physical examination <sup>35</sup>. The proportion 16 of missing data was 5.2% of all eligible participants. Given this low percentage of missing data, we performed a complete case analysis <sup>36</sup>. Since age distribution of study samples may vary 17 18 across survey cycles, all prevalence estimates were adjusted for age to make the estimates 19 more comparable throughout the study period <sup>31</sup>. Estimates across the age categories 20-39, 40-59, and 60-79 years were also adjusted for age using 5-year intervals according to 20 corresponding 2000 US Census Bureau age categories by sex <sup>31</sup>. The changes in obesity 21 22 prevalence from 1999-2000 to 2017-March 2020 were assessed using the Wald test. For 23 multiple comparisons of prevalence across ethnic groups and age groups, we applied the

Page 10 of 41

#### **BMJ** Open

> Bonferroni correction. Because Asian Americans were not oversampled before NHANES 2011, our analyses by ethnicity were restricted to Mexican, European, and African Americans. To determine the possible role of menopause in the high prevalence of RFM-defined obesity in women, we performed a post hoc analysis. Data related to menopause were self-reported. We defined postmenopausal women as those with natural menopause and no missing information on age at menopause. For this analysis, women were excluded if menopause occurred before age 40 or after age 62<sup>37</sup>, or if they reported oophorectomy (surgical removal of one or two ovaries), treatment with estrogen/progesterone for hysterectomy/oophorectomy, breastfeeding, pregnancy in past year of the interview, or irregular period due to medical conditions or treatment. Temporal trends in prevalence of obesity were tested for the assumption of linearity using logistic regression models, comparing linear and non-linear regression models using the likelihood-ratio test <sup>38</sup>. For the non-linear models, restricted cubic splines with 3 knots were used at years 2001-2002, 2009-2010, and 2017-2020, based on the quantiles recommended by Harrel <sup>39</sup>. Survey cycles were analyzed as a continuous variable. For visualization purposes, trend lines were smoothed using the Lowes method <sup>40</sup>. Statistical significance was set to an alpha level of 0.05. All statistical analyses were performed using Stata 14 for Windows (StataCorp LP, College Station, TX). Prevalence estimates and standard errors were obtained using the survey 'svy' command with Taylor linearization. Patient and public involvement Patients and the public were not involved in this study. This study will be available to the public

22 once it is published in the scientific literature.

#### 

## **RESULTS**

## 2 <u>Clinical characteristics</u>

3 After applying the inclusion and exclusion criteria, the final sample for analysis comprised

4 47,667 adults (online supplemental figure 1). The median age of the study population was 45

5 years (interquartile range: 33 to 58); 50.6% were women; 67.2% were European Americans,

6 11.2% were African Americans, and 8.3% were Mexican Americans (Table 1).

|   | All  | Women   | Men  |
|---|--|---|--|
|   | 47,667   | 23,931 (50.6%)  | 23,736 (49.4%)   |
| Median age (IQR), years   | 45 (33-58)   | 46 (33-59)  | 44 (32-57)   |
| Ethnicity, n (%)  |  |   |  |
| Mexican American  | 8,416 (8.3)  | 4,204 (7.7)   | 4,212 (9.0)  |
| European American   | 19,691 (67.2)  | 9,710 (67.0)  | 9,981 (67.5)   |
| African American  | 10,673 (11.2)  | 5,417 (12.0)  | 5,256 (10.4)   |
| Other/multi-racial  | 8,887 (13.3)   | 4,600 (13.4)  | 3,928 (13.1)   |
| Body weight (SD), kg  | 82.6 (21.3)  | 76.3 (20.5)   | 89.0 (20.1)  |
| Mean height (SD), cm  | 168.9 (10.0)   | 162.1 (6.9)   | 175.9 (7.5)  |
| Mean waist circumference (SD), cm   | 98.5 (16.5)  | 95.9 (16.9)   | 101.2 (15.6)   |
| Mean BMI (SD), kg/m <sup>2</sup>  | 28.9 (6.8)   | 29.0 (7.5)  | 28.7 (5.9)   |
| Mean RFM (SD), %  | 34.9 (8.5)   | 41.2 (6.0)  | 28.4 (5.3)   |
| RFM-defined obesity, % (95% CI) †   | 50.1 (48.9-50.8)   | 59.4 (58.4-60.5)  | 40.6 (39.4-41.8)   |
| BMI-defined obesity, % (95% CI) ‡   | 36.2 (35.4-37.1)   | 37.8 (36.8-38.7)  | 34.6 (33.5-35.8)   |
| Abdominal obesity, % (95% CI) §   | 54.0 (53.0-55.0)   | 63.8 (62.8-64.9)  | 43.9 (42.7-45.1)   |
| standard deviation.<br>* Sample size represents unweighted  | data. Estimates repr   | esent weighted data.  |  |
| BMI, body mass index; CI, confidence<br>standard deviation.<br>* Sample size represents unweighted<br>† Defined as having an RFM of 40% of<br>was calculated as follows: 64 – (20 × I<br>and 1 for women; height and waist circ<br>not adjusted for age.<br>‡ Defined as a having a BMI of 30 kg/<br>kilograms divided by the square of the<br>§ Defined as having a waist circumfere<br>men, according to the recommendatio<br>Expert Panel on Detection, Evaluation | data. Estimates repr<br>r higher for women a<br>neight/waist circumfe<br>cumference were me<br>m <sup>2</sup> or higher. BMI wa<br>height in meters. Es<br>ence of more than 88<br>ns of the National Cl | esent weighted data.<br>and an RFM of 30% or<br>erence) + (12 × sex); s<br>easured in the same un<br>as calculated as the boo<br>stimates were not adju<br>3 cm for women and m<br>holesterol Education P | r higher for men. RFM<br>ex equals 0 for men<br>hits. Estimates were<br>ody weight in<br>sted for age.<br>hore than 102 cm for<br>Program (NCEP) |

| 2  |
|----|
| 3  |
| 4  |
| 4  |
| 5  |
| 6  |
| 7  |
| 8  |
| -  |
| 9  |
| 10 |
| 11 |
| 12 |
| 13 |
|    |
| 14 |
| 15 |
| 16 |
| 17 |
|    |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
|    |
| 23 |
| 24 |
| 25 |
| 26 |
| 20 |
| 27 |
| 28 |
| 29 |
| 30 |
|    |
| 31 |
| 32 |
| 33 |
| 34 |
| 35 |
|    |
| 36 |
| 37 |
| 38 |
| 39 |
| 40 |
|    |
| 41 |
| 42 |
| 43 |
| 44 |
|    |
| 45 |
| 46 |
| 47 |
| 48 |
| 49 |
|    |
| 50 |
| 51 |
| 52 |
| 53 |
|    |
| 54 |
| 55 |
| 56 |
| 57 |
| 58 |
|    |
| 59 |
| 60 |

1

1

#### Obesity prevalence and temporal trends

Our findings indicate a higher proportion of individuals with obesity when RFM was used instead 2 of BMI. The overall age-adjusted prevalence of RFM-defined obesity increased from 42.4% 3 4 (95% confidence interval, 38.3% to 46.4%) in 1999-2000 to 55.4% (53.0% to 57.9%) in 2017-5 March 2020. The corresponding BMI-defined obesity prevalence increased from 30.4% (26.7% 6 to 34.0%) to 42.1% (39.4% to 44.8%). We found a linear increase in the overall prevalence of obesity during the study period using either RFM (P<0.001; P=0.38 for non-linearity) or BMI 7 8 (P<0.001; P=0.55 for non-linearity). Obesity prevalence and temporal trends by sex 9 10 We observed a consistently higher prevalence of RFM-defined obesity in women compared with 11 men across years. In contrast, this difference was not consistent for BMI-defined obesity (Figure 1). In 2017-March 2020, the prevalence of RFM-defined obesity was significantly higher in 12 women than in men (P<0.001). In contrast, the prevalence of BMI-defined obesity was similar in 13 women and men (P=0.97). Among women, the prevalence of RFM-defined obesity increased 14 from 50.8% (46.2% to 55.3%) in 1999-2000 to 64.7% (62.1% to 67.3%) in 2017-March 2020, a 15 linear increase of 13.9 percentage points (9.0% to18.9%; P<0.001). For comparison, the 16

prevalence of BMI-defined obesity in women was 42.2% (39.4% to 45.0%) in 2017-March 2020,

a linear increase of 8.3 percentage points (3.5-13.2%; P<0.001) (Table 2).

20

19

**Table 2.** Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by sex: 1999-2000 through 2017-Mach 2020.\*

|                             | RFM-defined obesity | BMI-defined obesity |
|-----------------------------|---------------------|---------------------|
| All participants (n=47,667) |                     |                     |
| Prevalence, % (95% CI)      |                     |                     |
| 1999-2000                   | 42.4 (38.3-46.4)    | 30.4 (26.7-34)      |

| 1        |
|----------|
| 2        |
| 3        |
| 4        |
| 5        |
| 6        |
| 0        |
| 7        |
| 8        |
| 9        |
| 10       |
|          |
|          |
| 12       |
| 13       |
| 14       |
| 15       |
| 15<br>16 |
| 16       |
| 17<br>18 |
| 18       |
| 19       |
| 20       |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 25       |
| 26       |
| 27       |
| 28       |
| 20       |
| 29<br>30 |
| 30       |
| 31       |
| 32       |
| 33       |
| 34       |
| 54       |
| 35<br>36 |
| 36       |
| 37       |
| 37<br>38 |
|          |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
|          |
| 44       |
| 45       |
| 46       |
| 47       |
| 48       |
|          |
| 49       |
| 50       |
| 51       |
| 52       |
| 53       |
|          |
| 54       |
| 55       |
| 56       |
| 50       |

| 2001-2002              | 42.5 (41.1-43.9)                      | 30.0 (27.6-32.4) |
|------------------------|---------------------------------------|------------------|
| 2003-2004              | 46.9 (44.7-49.2)                      | 32.1 (29.3-34.9) |
| 2005-2006              | 47.1 (43.7-50.5)                      | 34.3 (31.1-37.4) |
| 2007-2008              | 47.7 (45.0-50.5)                      | 33.7 (31.5-36.0) |
| 2009-2010              | 48.5 (46.1-50.8)                      | 35.7 (33.6-37.8) |
| 2011-2012              | 49.8 (46.6-53.0)                      | 35.4 (32.5-38.3) |
| 2013-2014              | 51.3 (48.7-53.8)                      | 37.8 (35.6-40)   |
| 2015-2016              | 53.7 (49.3-58.0)                      | 40.0 (36.4-43.6) |
| 2017-2020              | 55.4 (53.0-57.9)                      | 42.1 (39.4-44.8) |
| Prevalence change†     | 13.0 (8.5-17.5)                       | 11.8 (7.4-16.1)  |
| P for non-linearity‡   | 0.38                                  | 0.55             |
| P value for trend‡     | <0.001                                | <0.001           |
| Women (n=23,931)       |                                       |                  |
| Prevalence, % (95% CI) |                                       |                  |
| 1999-2000              | 50.8 (46.2-55.3)                      | 33.9 (29.6-38.1) |
| 2001-2002              | 51.6 (49.2-53.9)                      | 32.9 (29.7-36.0) |
| 2003-2004              | 55.3 (51.2-59.3)                      | 33.5 (29.7-37.2) |
| 2005-2006              | 53.9 (50.4-57.4)                      | 34.8 (31.5-38.1) |
| 2007-2008              | 56.4 (53.5-59.3)                      | 35.4 (32.7-38.0) |
| 2009-2010              | 58.1 (55.3-60.8)                      | 36.0 (34.0-37.9) |
| 2011-2012              | 60.8 (56.8-63.6)                      | 36.9 (33.4-40.5) |
| 2013-2014              | 61.3 (57.9-64.7)                      | 40.0 (36.8-43.2) |
| 2015-2016              | · · · · · · · · · · · · · · · · · · · | 41.7 (38.1-45.3) |
| 2017-2020              | 64.7 (62.1-67.3)                      | 42.2 (39.4-45.0) |
| Prevalence changet     | 13.9 (9.0-18.9)                       | 8.3 (3.5-13.2)   |
| P for non-linearity§   | 0.10                                  | 0.39             |
| P value for trend§     | <0.001                                | <0.001           |
| Men (n=23,736)         |                                       |                  |
| Prevalence, % (95% CI) |                                       |                  |
| 1999-2000              | 33.9 (29.9-37.8)                      | 27.0 (23.5-30.4) |
| 2001-2002              | 33.1 (30.6-35.5)                      | 27.0 (24.8-29.2) |
| 2003-2004              | 38.4 (35.9-40.8)                      | 30.7 (27.6-33.9) |
| 2005-2006              | 40.2 (35.9-44.4)                      | 33.5 (29.3-37.8) |
| 2007-2008              | 38.8 (35.6-42.0)                      | 32.1 (29.3-34.8) |
| 2009-2010              | 38.7 (35.2-42.2)                      | 35.3 (31.4-39.2) |
| 2011-2012              | 39.2 (35.9-42.5)                      | 33.8 (30.7-36.9) |
| 2013-2014              | 41.2 (38.7-43.7)                      | 35.6 (33.2-38.1) |
| 2015-2016              | 42.7 (37.7-47.7)                      | 38.2 (33.3-43.2) |
| 2017-2020              | 45.8 (42.0-49.7)                      | 42.0 (37.8-46.3) |
| Prevalence changet     | 12.0 (6.6-17.3)                       | 15.1 (9.8-20.4)  |
| P for non-linearity§   | 0.82                                  | 0.84             |
| P value for trend§     | < 0.001                               | <0.001           |

BMI, body mass index; CI, confidence interval; RFM, relative fat mass.

\* Prevalence estimates represent weighted data. RFM-defined obesity was diagnosed as having an RFM of 40% or higher for women and having an RFM of 30% or higher for men. RFM was calculated as follows: 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Height and waist circumference were measured in the same units. BMI-defined obesity was diagnosed as having a BMI of 30 kg/m<sup>2</sup> or higher. BMI was calculated as the body weight in kilograms divided by the square of the height in meters. Estimates were not adjusted for age.

† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for age, sex, and ethinicity.

§ Adjusted for age and ethnicity.

57 58

59

60

1 2

Among men, the prevalence of RFM-defined obesity increased from 33.9% (29.9% to 37.8%) in

1999-2000 to 45.8% (42.0% to 49.7%) in 2017-March 2020, a linear increase of 12.0 3

Page 14 of 41

| 3        |
|----------|
| 4        |
| 5        |
| 6        |
| _        |
| 7        |
| 8        |
| 9        |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
| 16       |
| 17       |
| 18       |
| 19       |
| 20       |
| 20       |
| 21<br>22 |
|          |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32       |
| 33       |
| 34       |
| 35       |
| 36       |
| 37       |
| 38       |
| 30<br>39 |
|          |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46       |
| 47       |
| 48       |
| 49       |
| 50       |
| 51       |
| 52       |
| 53       |
| 55<br>54 |
| 54<br>55 |
| 55<br>56 |
|          |
| 57       |
| 58       |
| 59       |
| 60       |

1 2

percentage points (6.6% to 17.3%; P<0.001). The prevalence of BMI-defined obesity in men</li>
 was 42.0% (37.8% to 46.3%) in 2017-March 2020, a linear increase of 15.1 percentage points
 (9.8% to 20.4%).

4 Obesity prevalence and temporal trends by ethnicity

5 The highest prevalence of RFM-defined obesity across years was observed among Mexican 6 Americans. In contrast, the highest prevalence of BMI-defined obesity was observed among 7 African American women but not men (Figure 2). In 2017-March 2020, the prevalence of RFM-8 defined obesity was significantly higher in Mexican Americans compared with African Americans 9 (Bonferroni corrected P<0.001) or European Americans (P<0.001). BMI-defined obesity 10 prevalence was similar in Mexican and African Americans (P=0.99) and both groups had a higher prevalence than European Americans (P=0.003 and P=0.001, respectively). 11 The largest increase in the prevalence of RFM-defined obesity from 1999-2000 to 2017-March 12 13 2020 occurred in Mexican American men, with a linear increase of 18.3 percentage points (12.0% to 24.5%; P<0.001) (online supplemental table 3 and Figure 2). The highest increase in 14 15 the prevalence of BMI-defined obesity also occurred in Mexican American men, with a linear

increase of 21.2 percentage points (15.3% to 27.1%; P<0.001) (online supplemental table 3 and

17 Figure 2).

18 Obesity prevalence and temporal trends by age group

In women and men, the highest prevalence of RFM-defined obesity across years was observed
in older adults (60-79 years) (Figure 3 and online supplemental table 4).

21

In contrast, no differences were observed in the prevalence of obesity between individuals 60-

23 79 years and 40-59 years when using BMI for the diagnosis of obesity (Figure 3). In 2017-March

#### **BMJ** Open

| 2  |    |
|--|----|
| 3  | 1  |
| 5<br>6   | 2  |
| 4<br>5<br>6<br>7<br>8                                    | 3  |
| 9  | 4  |
| 10<br>11<br>12   |    |
| 12<br>13   | 5  |
| 14<br>15   | 6  |
| 16<br>17   | 7  |
| 18<br>19   | 8  |
| 20<br>21   | 9  |
| 20<br>21<br>22<br>23<br>24<br>25<br>26<br>27<br>28<br>29 | 10 |
| 24<br>25   | 11 |
| 26<br>27   | 12 |
| 28<br>29   | 12 |
| 30<br>31   |    |
| 32<br>33   |    |
| 34   |    |
| 35<br>36   |    |
| 37<br>38   |    |
| 39<br>40   |    |
| 41<br>42   |    |
| 43<br>44   |    |
| 45   |    |
| 46<br>47   |    |
| 48<br>49   |    |
| 50<br>51   |    |
| 52<br>53   |    |
| 54<br>55   |    |
| 56   |    |
| 57<br>58   |    |

59

60

2020, the prevalence of RFM-defined obesity was significantly higher in individuals 60-79 years compared with those 40-59 years (Bonferroni corrected P<0.001) or 20-39 years (P<0.001). We found no statistically significant differences in the prevalence of BMI-defined obesity across age groups (P>0.17 for all comparisons).

Although our analysis by age showed an increased prevalence of obesity in older women and men (Figure 3), we performed a sensitivity analysis to specifically explore the possible role of menopause. Our findings from this post hoc analysis revealed that the crude prevalence of RFM-defined obesity in 2017-2020 was 56.4% (95% CI, 53.5-59.3%) among premenopausal women (n=1,935) and 76.4% (71.0-81.8%) among postmenopausal women (n=1,406). The mean age at last menstrual period was 49 years in this population. For comparison, among men, the corresponding prevalence of obesity was 39.7% (34.9-44.6%) in those younger than 50 years (n=1,790) and 56.2% (52.9-59.5%) in men 50 years of age and older (n=1,886). 

### 1 DISCUSSION

 Our study shows that, compared with BMI, the use of a surrogate for whole-body fat percentage revealed a much higher prevalence of general obesity among adults in the U.S., particularly among women, affecting nearly two-thirds of all women and nearly half of all men in 2017-2020, with an overall prevalence of 55.4%. This is an additional 22.5% of women and 3.8% of men 20-79 years being defined as obese compared with a BMI-based definition with the current criteria.

The use of RFM also revealed that the highest prevalence of general obesity over the study period from 1999 to 2020 occurred among Mexican Americans and not among African Americans, as was observed when BMI was used to diagnose obesity. Likewise, the use of RFM showed that the highest prevalence of general obesity over this study period occurred among older adults (60-79 years) and not among adults 40-59 years, as was observed when BMI was used. The higher prevalence of obesity in older individuals does not appear to be fully explained by a loss of skeletal muscle with age, since absolute fat mass also increases with age, although mainly visceral fat <sup>41 42</sup>. However, it is difficult to draw a firm conclusion from cross-sectional data. Our findings are consistent with those from other studies also showing a higher body fat percentage in older individuals <sup>12 23 41 43-46</sup>. 

Overall, women had a markedly higher prevalence of RFM-defined obesity across years than
 men, a difference that was less evident when using BMI. Previous studies have shown no
 differences in the prevalence of BMI-defined obesity between women and men <sup>3447</sup>. In the
 present study, the difference in the prevalence of RFM-defined obesity for 2017-2020 between
 women and men was nearly 20 percentage points.

The highest prevalence of RFM-defined obesity was observed in Mexican Americans, and the increase was linear over the study period, albeit this linear increase was largely driven by a steady increase among men. Among Mexican American women, a decrease was observed

Page 17 of 41

#### **BMJ** Open

| 1        |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 20<br>21 |  |
| 22       |  |
| 22       |  |
| 23<br>24 |  |
| 24<br>25 |  |
| 25<br>26 |  |
|          |  |
| 27<br>28 |  |
|          |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |

60

since 2015. A previous study reported that, between 2003 and 2006, the prevalence of BMIdefined obesity was higher among African Americans compared with Mexican Americans, but
between 2015 and 2018, Mexican American men had a higher prevalence than African
American men <sup>29</sup>. In contrast, RFM revealed a consistently higher prevalence of general obesity
among Mexican Americans over the observed time, in both women and men. Socio-economic
characteristics are probably the main determinants of differences in the prevalence of general
obesity between ethnic groups <sup>48</sup>.

8 It has been argued that the fat mass index (FMI, body fat mass adjusted for the square of the 9 height, expressed in kg/m<sup>2</sup>) should be used as a reference of fat mass instead of body fat percentage (body fat mass adjusted for body weight) to avoid including fat mass both in the 10 11 numerator and the denominator, as this is not mathematically advisable <sup>49</sup>. However, the concept of obesity (excess body fat) and all different forms to express it, for example BMI 6 50 51, 12 13 FMI <sup>52 53</sup>, fat mass/fat-free-mass <sup>54 55</sup>, body fat percentage <sup>12 56</sup>, to cite a few, should not be seen only as mathematical constructs but also as biological variables with important implications as 14 risk factors for disease and mortality. In the present study, we chose body fat percentage as the 15 reference because numerous studies have shown that body fat percentage is associated with 16 17 mortality <sup>13-20 57</sup>. What is also important to note is that FMI does not appear to be superior to body fat percentage or BMI as a predictor of cardiovascular mortality <sup>14</sup>, all-cause mortality <sup>58 59</sup> 18 or cardiovascular risk factors <sup>60</sup>. Because of its association with mortality, body fat percentage is 19 of great clinical relevance. Recent studies support the utility of RFM to predict type 2 diabetes <sup>61</sup> 20 21 and heart failure <sup>62</sup>.

Further research is needed to better understand the clinical implications of our study findings: 1)
the much higher prevalence of general obesity among women when RFM is used as opposed to
BMI; 2) the higher burden of general obesity on Mexican Americans compared with African and
European Americans; and 3) the higher prevalence of general obesity in older individuals.

Page 18 of 41

It is difficult to establish whether the higher prevalence of general obesity estimated using RFM would translate into a higher risk of cardiovascular disease (CVD). The association between obesity and CVD is very complex and several factors may mediate this association <sup>63</sup>. Although subcutaneous fat appears to have a relative protective effect against CVD <sup>64</sup>, others have shown that subcutaneous fat is also associated with cardiovascular risk factors, although less strongly than visceral fat <sup>65</sup>. A major limitation of these studies, however, is that the analyses involved a small region of the abdominal trunk.

In women, who biologically have a higher body adiposity than men, the possible protective
effect of estrogens on metabolism could be attenuated by the high prevalence of RFM-defined
obesity. This could help explain, for example, the similar relative increase in the U.S. prevalence
of diabetes in women and men from 1999 to 2019 (by ~74%) (www.healthdata.org) or the
similar prevalence of diabetes in women (14.1% [11.8-16.7%]) and men (15.4% [13.5-17.5%]) in
2017-2020 <sup>66</sup>. Our findings, although cross-sectional, do not appear to support a protective role
of estrogens against obesity *per se*.

The temporal trends in RFM- and BMI-defined obesity in both women and men follow a parallel pattern. However, stratified analysis by ethnicity showed some differences. RFM revealed that Mexican Americans have a higher prevalence of obesity than European or African Americans. Although we cannot establish causality, this finding coincides with the higher absolute increase in the prevalence of diabetes and liver disease observed in Mexican Americans from 1999 to 2018 compared with European and African Americans <sup>67</sup>.

Whether the increased whole-body fat percentage in older individuals confers a higher risk on
mortality also requires further investigation as age *per se* is a strong risk factor for mortality <sup>68</sup>,
and the relationship between obesity and mortality could be mediated by age <sup>69</sup>. In addition, this
can be confounded by concomitant severe disease. For instance, several studies have shown
an inverse association between body fat percentage (but also BMI and FMI) and mortality in

Page 19 of 41

#### **BMJ** Open

| 2   |  |
|---|--|
| 2<br>3  |  |
|   |  |
| 4<br>5  |  |
| 5   |  |
| 6   |  |
| 7   |  |
| 8   |  |
| 9   |  |
| 10  |  |
| 11  |  |
| 11  |  |
| 12  |  |
| 13  |  |
| 14  |  |
| 15  |  |
| 16  |  |
| 17  |  |
| 18  |  |
| 19  |  |
| 20  |  |
| ∠∪<br>כ1  |  |
| 5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>20<br>21<br>22<br>23<br>24 |  |
| 22  |  |
| 23  |  |
| 23<br>24<br>25<br>26<br>27  |  |
| 25  |  |
| 26  |  |
| 27<br>28<br>29<br>30  |  |
| 28  |  |
| 20  |  |
| 29  |  |
| 30  |  |
| 31  |  |
| 32<br>33  |  |
| 33  |  |
| 34  |  |
| 35  |  |
| 33<br>34<br>35<br>36<br>37<br>38  |  |
| 37  |  |
| 38  |  |
|   |  |
| 39  |  |
| 40  |  |
| 41  |  |
| 42  |  |
| 43  |  |
| 44  |  |
| 45  |  |
| 46  |  |
| 40<br>47  |  |
|   |  |
| 48  |  |
| 49  |  |
| 50  |  |
| 51  |  |
| 52  |  |
| 53  |  |
| 54  |  |
| 55  |  |
| 55<br>56  |  |
| 56<br>57  |  |
| 5/  |  |
| 58  |  |
| 59  |  |
| 60  |  |

1 older patients <sup>59 70 71</sup>. Conversely, the high body fat percentage in older individuals could explain 2 the association of BMI-defined obesity with diabetes and cardiovascular disease in older 3 individuals <sup>72-75</sup>. The increase in body adiposity with aging coincides with the high prevalence of many cardiometabolic alterations occurring more often in older individuals, such as glucose 4 5 intolerance, insulin resistance, dyslipidemia, and hypertension <sup>69</sup>. BMI did not detect a higher 6 prevalence of general obesity in individuals aged 60 years and older compared with younger 7 adults, unlike when RFM was used. These findings further support that notion that BMI is a poor predictor of morbidity and mortality in older individuals <sup>46 76</sup>. 8 9 Abdominal obesity and general obesity are overall underestimated when using BMI (Table 1 and online supplemental table 1). It is also important to mention that the prevalence of 10 11 abdominal obesity is overall higher compared with the prevalence of RFM-defined obesity, 12 except among Mexican Americans (online supplementary table 1). However, the closer 13 proportions of abdominal obesity and RFM-defined general obesity is expected. Since RFM is based on waist circumference, and waist circumference is a surrogate for intra-abdominal fat 77 14 15 <sup>78</sup>, RFM could be a surrogate for both general obesity and abdominal obesity. Although RFM has been shown to predict trunk fat percentage, the prediction error is greater for trunk fat 16 17 percentage than for whole-body fat percentage <sup>23</sup>. 18 It is plausible that the association of fat mass with mortality is, at least partly, reflecting the effect of fat-free mass on mortality. Although body fat percentage is associated with mortality, the 19 20 implications of fat-free mass percentage, as opposed to body fat percentage, as a predictor of 21 mortality require careful examination. Although the proportion of body FFM is the numeric 22 complement of the proportion of body fat mass (%FM=100%-%FFM), this does not take into 23 account the fact that FFM is not exclusively muscle mass. Unless muscle mass and fat mass are measured accurately, it will be difficult to distinguish the overall contribution of fat mass from 24

the largest metabolically tissue in the body, the skeletal muscle, to predict mortality. The

Page 20 of 41

problem is that accurate estimates of skeletal muscle mass remain a challenge <sup>79</sup>. The current
 evidence suggests that increased fat mass is associated with higher mortality whereas
 increased fat-free mass is associated with lower mortality <sup>13 80 81</sup>.

The opposite relationship of fat mass and fat-free mass with mortality could be altered due to weight loss interventions (which induce more fat mass loss than muscle mass loss) or because of loss of muscle mass due to age <sup>82</sup>. In older individuals, increased fat-free mass has been associated with lower mortality, whereas lower fat mass has also been associated with increased risk of mortality <sup>83</sup>, suggesting frailty could be a more important factor for mortality risk than body composition. Future studies should focus on comparing the association of fat mass and the metabolic components of fat-free mass with mortality. The muscle-mass centric view of health or disease <sup>84 85</sup>, rather than focusing on BMI or body fat percentage, is interesting but requires further research due to the complex interrelationship between fat mass and fat-free mass (and muscle mass).

Our study has strengths. First, we used a previously validated surrogate for whole-body fat percentage in adults in the U.S.<sup>23</sup>, which has a high diagnostic accuracy (91%) for DXA-defined obesity <sup>27</sup> and has been shown to result in lower total misclassification of DXA-defined high body adiposity compared with BMI among women (RFM: 12.7%; BMI: 56.5%) and men (RFM: 9.4% BMI: 13.0%)<sup>23</sup>. Second, to define general obesity, we used previously validated RFM cutoffs to predict all-cause mortality in a large U.S. adult population <sup>27</sup>. Previously proposed cutoffs for fat-defined obesity have been based on arbitrary values <sup>86 87</sup> or on corresponding BMI cutoffs <sup>12</sup>. Third, we used measured anthropometrics. RFM requires only waist circumference and height for its calculation, which allowed us to estimate the prevalence of general obesity in a large adult population of the U.S. (n=44,754) with a wide age range, over a period of nearly 22 years. Fourth, NHANES have used a consistent methodology across survey cycles to measure anthropometrics, reducing the risk of measurement error that could affect our results.

Page 21 of 41

1

#### BMJ Open

| 2        |
|----------|
| 3        |
| 4        |
| 5        |
| 6        |
| 7        |
| 8        |
| 9        |
| 10       |
| 11       |
| 12       |
| 13       |
| 14       |
| 15       |
| 16       |
| 17       |
| 18       |
| 19       |
| 20       |
| 21       |
| 22       |
| 23       |
| 24       |
| 25       |
| 26       |
| 27       |
| 28       |
| 29       |
| 30       |
| 31       |
| 32       |
| 33       |
| 34       |
| 35       |
| 36       |
| 36<br>37 |
| 38       |
| 39       |
| 40       |
| 41       |
| 42       |
| 43       |
| 44       |
| 45       |
| 46       |
| 47       |
| 48       |
| 49       |
| 50       |
| 51       |
| 52       |
| 53       |
| 54       |
| 55       |
| 56       |
| 57       |
| 58       |
| 59       |

60

1 Our study also has limitations. First, RFM was developed and validated using DXA as the 2 reference method. However, DXA is an indirect method to assess body fatness and is 3 susceptible to bias introduced mainly by age, degree of fatness, and disease <sup>88 89</sup>. Thus, there are limitations to the level of accuracy and precision that RFM can perform. Nevertheless, RFM 4 5 is an attempt to provide a relatively easy and affordable alternative method to BMI to better 6 assess body fatness. Second, although the overall obesity misclassification has been reported to be lower with RFM than with BMI in American (21) and Korean individuals (20), another 7 8 limitation is that the proportion of obesity misclassification is not trivial when using RFM. Third, 9 our analysis was performed using data from a representative sample of the non-institutionalized 10 U.S. population only. Fourth, our estimates of prevalence trends could have been affected by some variability in sampling across NHANES survey cycles <sup>35</sup>. Finally, we did not analyze the 11 prevalence trends for Asian Americans during the period studied because NHANES began 12 13 oversampling Asian Americans only from 2011-2012 onwards and RFM cutoffs used to diagnose general obesity have not been validated among Asian populations. 14 15 From a public health perspective, we argue that due to the underdiagnosis of obesity when 16 using BMI, the most affected populations are not receiving adequate medical care that they 17 require. Aspects that will need further research are the implications of some possible overdiagnosis of obesity <sup>90</sup> and the stigma that would be associated with it <sup>91</sup>. 18 In conclusion, the use of RFM, a surrogate for whole-body fat percentage, revealed a much 19 20 higher prevalence of general obesity in the U.S. from 1999 to 2020, particularly among women, 21 than that estimated by BMI. RFM, but not BMI, also revealed a disproportionate higher 22 prevalence of general obesity in adults aged 60 years and older and Mexican Americans. Using 23 BMI as the lone measure to define obesity may lead to significant misclassification of large obese subpopulations as non-obese, particularly among women. Our findings may have 24

- 1 implications for the use of resources in public health to tackle obesity-related health problems in
  - 2 the most affected populations.

to pretterien ont

| 1              |    |  |
|----------------|----|--|
| 2<br>3<br>4    | 1  | ETHICS APPROVAL  |
| 5<br>6<br>7    | 2  | Since this study used publicly available de-identified data, approval from an Institutional Review |
| 7<br>8<br>9    | 3  | Board was not required, as indicated in the Federal Policy for the Protection of Human Subjects    |
| 10<br>11       | 4  | (detailed in 45 CFR part 46) 35.   |
| 12<br>13<br>14 | 5  |  |
| 15<br>16       | 6  | DATA AVAILABILITY STATEMENT  |
| 17<br>18<br>19 | 7  | All data utilized are publicly and freely available from the NHANES website at                     |
| 20<br>21       | 8  | https://wwwn.cdc.gov/nchs/nhanes/  |
| 22<br>23<br>24 | 9  |  |
| 25<br>26<br>27 | 10 | ACKNOWLEDGMENTS  |
| 28<br>29       | 11 | We thank the Centers for Disease Control and Prevention (CDC) and the National Center for          |
| 30<br>31<br>32 | 12 | Health Statistics (NCHS) for providing access to the NHANES datasets. We also thank all            |
| 33<br>34       | 13 | subjects who participated in the surveys from 1999 through 2020.                                   |
| 35<br>36       | 14 |  |
| 37<br>38<br>39 |    |  |
| 40<br>41       |    |  |
| 42<br>43       |    |  |
| 44<br>45       |    |  |
| 46<br>47<br>48 |    |  |
| 48<br>49<br>50 |    |  |
| 51<br>52       |    |  |
| 53<br>54       |    |  |
| 55<br>56<br>57 |    |  |
| 57<br>58<br>59 |    | 22   |
| 60             |    | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml                          |

| 3        |  |
|----------|--|
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 20<br>21 |  |
| 21<br>22 |  |
|          |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 40<br>41 |  |
| 41       |  |
| 42<br>43 |  |
| 43<br>44 |  |
| 44<br>45 |  |
|          |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 53       |  |
| 54       |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |

60

1 2

1

## **AUTHOR CONTRIBUTIONS**

2 OOW was responsible for the conception and design of the study. OOW contributed to the 3 statistical analysis. OOW and TS contributed to the interpretation of data and critical revision of 4 the manuscript. OOW and TS drafted the final version of the manuscript and agreed to the 5 submitted version of the manuscript. OOW is the manuscript's guarantor. OOW accepts full 6 responsibility for the work and the conduct of the study, had access to the data, and controlled 7 the decision to submit for publication.

## 8 FUNDING

9 This research received no specific grant from any funding agency in the public, commercial or 10 not-for-profit sectors.

## 11 COMPETING INTERESTS

12 OOW is the lead author of the original article describing the development and validation of RFM.

13 OOW currently works as an editor for The Lancet group. TS declares no conflict of interest.

## 14 TRANSPARENCY STATEMENT

OW (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and
 transparent account of the study being reported; that no important aspects of the study have
 been omitted; and that any discrepancies from the study as originally planned have been

18 explained.

## 19 PATIENT AND PUBLIC INVOLVEMENT

20 Patients and the public were not involved in this study. This study will be available to the public

21 once it is published in the scientific literature.

REFERENCES

- 1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288(14):1723-7. doi: 10.1001/jama.288.14.1723
- 2. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA 2016;315(21):2284-91. doi: 10.1001/jama.2016.6458
- 3. Hales CM. Carroll MD. Frvar CD. et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief 2020(360):1-8.
- 4. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files - Development of files and prevalence estimates for selected health outcomes. National Health Statistics Reports 2021(158):1-20.
- 5. Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond) 2008;32 Suppl 3:S56-9. doi: 10.1038/ijo.2008.87
- 6. WHO. Physical status: the use and interpretation of anthropometry. WHO Technical Report Series. Geneva, 1995.
- 7. CDC. Defining adult overweight & obesity. Available at: https://www.cdc.gov/obesity/basics/adult-defining.html. Accessed April 18, 2022.
- 8. Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. Am J Clin Nutr 1986;44(6):996-7. doi: 10.1093/ajcn/44.6.996
- 9. Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996;143(3):228-39.
- 10. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368(9536):666-78. doi: 10.1016/S0140-6736(06)69251-9
- 11. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010;34(5):791-9. doi: 10.1038/ijo.2010.5
- 12. Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing quidelines based on body mass index. Am J Clin Nutr 2000;72(3):694-701.
- 13. Heitmann BL, Erikson H, Ellsinger BM, et al. Mortality associated with body fat, fat-free mass and body mass index among 60-year-old swedish men-a 22-year follow-up. The study of men born in 1913. Int J Obes Relat Metab Disord 2000;24(1):33-7.
- 14. Ortega FB, Sui X, Lavie CJ, et al. Body Mass Index, the most widely used but also widely criticized index: Would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality? Mayo Clin Proc 2016;91(4):443-55.
- 15. Padwal R, Leslie WD, Lix LM, et al. Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med 2016;164(8):532-41.
- 16. Zong G, Zhang Z, Yang Q, et al. Total and regional adiposity measured by dual-energy X-ray absorptiometry and mortality in NHANES 1999-2006. Obesity (Silver Spring)
- 2016;24(11):2414-21. doi: 10.1002/oby.21659

17. Dong B, Peng Y, Wang Z, et al. Joint association between body fat and its distribution with all-cause mortality: A data linkage cohort study based on NHANES (1988-2011). PLoS One 2018;13(2):e0193368. doi: 10.1371/journal.pone.0193368 18. Lahmann PH, Lissner L, Gullberg B, et al. A prospective study of adiposity and all-cause mortality: the Malmo Diet and Cancer Study. Obes Res 2002;10(5):361-9. doi: 10.1038/oby.2002.50 19. Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and cancer subgroups in the UK Biobank, and their modification by smoking. Diabetes Care 2018;41(9):1878-86. doi: 10.2337/dc17-2508 20. Jayedi A, Khan TA, Aune D, et al. Body fat and risk of all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. Int J Obes (Lond) 2022;46(9):1573-81. doi: 10.1038/s41366-022-01165-5 21. Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today 2015;50(3):117-28. doi: 10.1097/NT.000000000000092 22. CDC. Body mass index : considerations for practitioners. https://stacks.cdc.gov/view/cdc/25368 [Accessed December 8, 2021]. 23. Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage - A cross-sectional study in American adult individuals. Sci Rep 2018;8(1):10980. doi: doi.org/10.1038/s41598-018-29362-1 24. Paek JK, Kim J, Kim K, et al. Usefulness of relative fat mass in estimating body adiposity in Korean adult population. Endocr J 2019:66(8):723-29. doi: 10.1507/endocrj.EJ19-0064 25. Guzman-Leon AE, Velarde AG, Vidal-Salas M, et al. External validation of the relative fat mass (RFM) index in adults from north-west Mexico using different reference methods. PLoS One 2019;14(12):e0226767. doi: 10.1371/journal.pone.0226767 26. Correa CR, Formolo NPS, Dezanetti T, et al. Relative fat mass is a better tool to diagnose high adiposity when compared to body mass index in young male adults: A cross-section study. Clin Nutr ESPEN 2021;41:225-33. doi: 10.1016/j.clnesp.2020.12.009 27. Woolcott OO, Bergman RN. Defining cutoffs to diagnose obesity using the relative fat mass (RFM): Association with mortality in NHANES 1999-2014. Int J Obes (Lond) 2020;44:1301-10. doi: 10.1038/s41366-019-0516-8 28. Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ 2021;372:n365. doi: 10.1136/bmj.n365 29. Gupta RD, Chakraborty PA, Al Kibria GM. Racial/Ethnic disparities in prevalence and trends of obesity, grade 3 obesity, and abdominal obesity among US adults, 2003-18. Obesity Medicine 2021;28 (no pagination)(100372) doi: https://dx.doi.org/10.1016/j.obmed.2021.100372 30. CDC. NHANES 2017-March 2020 pre-pandemic data release notes. https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/releasenotes.aspx?Cycle=2017-2020 [Accessed October 10, 2022]. 31. Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050, U.S. Bureau of the Census, Current Population Reports. Reports, P25-1130, U.S. Washington, DC, 1996. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

| 1<br>2<br>3    | 32. National Health and Nutrition Examination Survey (NHANES). Anthropometry procedures manual. <u>http://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/manual_an.pdf</u> [Accessed May 16, 2016].                                       |
|----------------|--|
| 4<br>5         | 33. CDC. NHANES response rates and population totals. Available at:<br><u>https://wwwn.cdc.gov/nchs/nhanes/responserates.aspx</u> . Accessed July 19, 2022.  |
| 6<br>7<br>8    | 34. HHS. U.S. Department of Health & Human Services. Federal policy for the protection of human subjects. <u>https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html</u> . Accessed April 2, 2022., 2020. |
| 9<br>10        | 35. Johnson CL, Paulose-Ram R, Ogden CL, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. <i>Vital Health Stat 2</i> 2013(161):1-24.   |
| 11<br>12<br>13 | 36. CDC. National Health and Nutrition Examination Survey. Module 1: Datasets and Documentation. <u>https://wwwn.cdc.gov/nchs/nhanes/tutorials/module1.aspx</u> [accessed July 18, 2022].  |
| 14<br>15<br>16 | 37. Appiah D, Nwabuo CC, Ebong IA, et al. Trends in age at natural menopause and reproductive life span among US women, 1959-2018. <i>JAMA</i> 2021;325(13):1328-30. doi: 10.1001/jama.2021.0278                                     |
| 17<br>18       | 38. Durrleman S, Simon R. Flexible regression models with cubic splines. <i>Stat Med</i> 1989;8(5):551-61. doi: 10.1002/sim.4780080504   |
| 19<br>20       | 39. Harrell FE. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York: Springer 2001.   |
| 21             | 40. Cox NJ. Speaking Stata: Smoothing in various directions. Stata Journal 2005;5(4):574-93.   |
| 22<br>23       | 41. Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. <i>J Gerontol</i> 1972;27(4):438-43. doi: 10.1093/geronj/27.4.438   |
| 24<br>25       | 42. Song M-Y, Ruts E, Kim J, et al. Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. <i>Am J Clin Nutr</i> 2004;79(5):874-80.   |
| 26<br>27       | 43. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. <i>Br J Nutr</i> 1991;65(2):105-14.  |
| 28<br>29<br>30 | 44. Noppa H, Andersson M, Bengtsson C, et al. Body composition in middle-aged women with special reference to the correlation between body fat mass and anthropometric data. <i>Am J Clin Nutr</i> 1979;32(7):1388-95.               |
| 31<br>32<br>33 | 45. Jensky-Squires NE, Dieli-Conwright CM, Rossuello A, et al. Validity and reliability of body composition analysers in children and adults. <i>Br J Nutr</i> 2008;100(4):859-65. doi: 10.1017/S0007114508925460                    |
| 34<br>35       | 46. Kuk JL, Saunders TJ, Davidson LE, et al. Age-related changes in total and regional fat distribution. <i>Ageing Res Rev</i> 2009;8(4):339-48. doi: 10.1016/j.arr.2009.06.001  |
| 36<br>37       | 47. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. <i>JAMA</i> 2012;307(5):491-7.   |
| 38<br>39       | 48. Lakerveld J, Mackenbach J. The upstream determinants of adult obesity. <i>Obes Facts</i> 2017;10(3):216-22. doi: 10.1159/000471489   |
| 40<br>41       | 49. Wells JC. Toward body composition reference data for infants, children, and adolescents. <i>Adv Nutr</i> 2014;5(3):320S-9S. doi: 10.3945/an.113.005371   |
|                | 26   |
|                | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml  |
|                | 2 3<br>4 5<br>6 7<br>8 9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20<br>21<br>22<br>23<br>24<br>25<br>26<br>27<br>28<br>29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>39<br>40                   |

**BMJ** Open

50. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2021;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973 51. Quetelet L. A Treatise on Man and the Development of his Faculties. Cambridge: Cambridge University Press 2013. 52. VanItallie TB, Yang MU, Heymsfield SB, et al. Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr 1990;52(6):953-9. doi: 10.1093/ajcn/52.6.953 53. Kyle UG, Schutz Y, Dupertuis YM, et al. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition 2003;19(7-8):597-604. doi: 10.1016/s0899-9007(03)00061-3 54. Goran MI, Allison DB, Poehlman ET. Issues relating to normalization of body fat content in men and women. Int J Obes Relat Metab Disord 1995;19(9):638-43. 55. Prado CM, Wells JC, Smith SR, et al. Sarcopenic obesity: A Critical appraisal of the current evidence. Clin Nutr 2012;31(5):583-601. doi: 10.1016/j.clnu.2012.06.010 56. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998;22(12):1164-71. 57. Parra-Soto S, Cowley ES, Rezende LFM, et al. Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study. BMC Med 2021;19(1):7. doi: 10.1186/s12916-020-01848-8 58. Auyeung TW, Lee JS, Leung J, et al. Survival in older men may benefit from being slightly overweight and centrally obese--a 5-year follow-up study in 4,000 older adults using DXA. J Gerontol A Biol Sci Med Sci 2010;65(1):99-104. doi: 10.1093/gerona/glp099 59. Rolland Y, Gallini A, Cristini C, et al. Body-composition predictors of mortality in women aged >/= 75 y: data from a large population-based cohort study with a 17-y follow-up. Am J Clin Nutr 2014;100(5):1352-60. doi: 10.3945/ajcn.114.086728 60. Jeong SM, Lee DH, Rezende LFM, et al. Different correlation of body mass index with body fatness and obesity-related biomarker according to age, sex and race-ethnicity. Sci Rep 2023;13(1):3472. doi: 10.1038/s41598-023-30527-w 61. Suthahar N, Wang K, Zwartkruis VW, et al. Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. Eur J Intern Med 2023;109:73-78. doi: 10.1016/j.ejim.2022.12.024 62. Suthahar N, Meems LMG, Withaar C, et al. Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND. Scientific Reports 2022;12(1):147. doi: 10.1038/s41598-021-02409-6 63. Tutor AW, Lavie CJ, Kachur S, et al. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis 2022 doi: 10.1016/j.pcad.2022.11.013 64. Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care 2009;32(6):1068-75. doi: 10.2337/dc08-2280 65. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116(1):39-48. doi: 10.1161/CIRCULATIONAHA.106.675355 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

Page 29 of 41

66. CDC. National Diabetes Statistics Report. Estimates of diabetes and its burden in the United States. https://www.cdc.gov/diabetes/data/statistics-report/index.html [Accessed April 2, 2023]. 67. Caraballo C, Herrin J, Mahajan S, et al. Temporal trends in racial and ethnic disparities in multimorbidity prevalence in the United States, 1999-2018. Am J Med 2022;135(9):1083-92 e14. doi: 10.1016/j.amjmed.2022.04.010 68. Tian YE, Cropley V, Maier AB, et al. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat Med 2023 doi: 10.1038/s41591-023-02296-69. Schwartz RS. Obesity in the elderly: Prevalence, consequences, and treatment. In: Bray GA, Bouchard C, eds. Handbook of obesity Etiology and pathophysiology. Second edition ed. New York: Marcel Dekker, Inc. 2004:135-48. 70. de Santana FM, Domiciano DS, Goncalves MA, et al. Association of appendicular lean mass, and subcutaneous and visceral adipose tissue with mortality in older Brazilians: The Sao Paulo Ageing & Health Study. J Bone Miner Res 2019;34(7):1264-74. doi: 10.1002/jbmr.3710 71. Lee JS, Auyeung TW, Kwok T, et al. Survival benefit of abdominal adiposity: a 6-year follow-up study with Dual X-ray absorptiometry in 3,978 older adults. Age (Dordr) 2012;34(3):597-608. doi: 10.1007/s11357-011-9272-y 72. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident diabetes in Chinese adults: a population-based cohort study. BMJ Open 2018;8(9):e021768. doi: 10.1136/bmjopen-2018-021768 73. Lind L. Sundstrom J. Arnlov J. et al. Impact of aging on the strength of cardiovascular risk factors: A longitudinal study over 40 years. J Am Heart Assoc 2018;7(1) doi: 10.1161/JAHA.117.007061 74. Masaki KH, Curb JD, Chiu D, et al. Association of body mass index with blood pressure in elderly Japanese American men. The Honolulu Heart Program. Hypertension 1997;29(2):673-7. doi: 10.1161/01.hyp.29.2.673 75. Tromp J, Paniagua SMA, Lau ES, et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ 2021;372:n461. doi: 10.1136/bmj.n461 76. Chang SH, Beason TS, Hunleth JM, et al. A systematic review of body fat distribution and mortality in older people. Maturitas 2012;72(3):175-91. doi: 10.1016/j.maturitas.2012.04.004 [published Online First: 2012/05/19] 77. Edston E. A correlation between the weight of visceral adipose tissue and selected anthropometric indices: an autopsy study. Clin Obes 2013;3(3-4):84-9. doi: 10.1111/cob.12021 78. Conway JM, Chanetsa FF, Wang P. Intraabdominal adipose tissue and anthropometric surrogates in African American women with upper- and lower-body obesity. Am J Clin Nutr 1997;66(6):1345-51. doi: 10.1093/ajcn/66.6.1345 79. Bosy-Westphal A, Muller MJ. Identification of skeletal muscle mass depletion across age and BMI groups in health and disease--there is need for a unified definition. Int J Obes (Lond) 2015;39(3):379-86. doi: 10.1038/ijo.2014.161 80. Allison DB. Zhu SK. Plankev M. et al. Differential associations of body mass index and adiposity with all-cause mortality among men in the first and second National Health and Nutrition Examination Surveys (NHANES I and NHANES II) follow-up studies. Int J Obes Relat Metab Disord 2002;26(3):410-6. doi: 10.1038/sj.ijo.0801925 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

81. Zhu S. Heo M. Plankev M. et al. Associations of body mass index and anthropometric

indicators of fat mass and fat free mass with all-cause mortality among women in the first and

second National Health and Nutrition Examination Surveys follow-up studies. Ann Epidemiol 2003;13(4):286-93. doi: 10.1016/s1047-2797(02)00417-9 82. Heymsfield SB, Gonzalez MC, Shen W, et al. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 2014;15(4):310-21. doi: 10.1111/obr.12143 83. Spahillari A, Mukamal KJ, DeFilippi C, et al. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. Nutr Metab Cardiovasc Dis 2016;26(11):1039-47. doi: 10.1016/j.numecd.2016.06.011 84. Bosy-Westphal A, Muller MJ. Diagnosis of obesity based on body composition-associated health risks-Time for a change in paradigm. Obes Rev 2021;22 Suppl 2:e13190. doi: 10.1111/obr.13190 85. Flegal KM. Use and misuse of BMI categories. AMA J Ethics 2023;25(7):E550-58. 86. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999;69(3):373-80. doi: 10.1093/ajcn/69.3.373 87. Lobman TG, Houtkooper L, Going SB. Body Fat Measurement Goes High-Tech: Not All Are Created Equal. ACSM's Health & Fitness Journal 1997;1(1):30-35. 88. Wells JC, Fewtrell MS. Measuring body composition. Arch Dis Child 2006;91(7):612-7. doi: 10.1136/adc.2005.085522 89. Clasey JL, Kanaley JA, Wideman L, et al. Validity of methods of body composition assessment in young and older men and women. J Appl Physiol (1985) 1999;86(5):1728-38. 90. Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what it is and what it isn't. BMJ Evid Based Med 2018;23(1):1-3. doi: 10.1136/ebmed-2017-110886 91. Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health 2010;100(6):1019-28. doi: 10.2105/AJPH.2009.159491 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 

BMJ Open

| ן<br>ר   |  |
|----------|--|
| 2        |  |
| 3        |  |
| 4        |  |
| 5        |  |
| 6        |  |
| 7        |  |
| 8        |  |
| 9        |  |
| 10       |  |
| 11       |  |
| 12       |  |
| 13       |  |
| 14       |  |
| 15       |  |
|          |  |
| 16       |  |
| 17       |  |
| 18       |  |
| 19       |  |
| 20       |  |
| 21       |  |
| 22       |  |
| 23       |  |
| 24       |  |
| 25       |  |
| 26       |  |
| 27       |  |
| 28       |  |
| 29       |  |
| 30       |  |
| 31       |  |
| 32       |  |
| 33       |  |
|          |  |
| 34       |  |
| 35       |  |
| 36       |  |
| 37       |  |
| 38       |  |
| 39       |  |
| 40       |  |
| 41       |  |
| 42       |  |
| 43       |  |
| 44       |  |
| 45       |  |
| 46       |  |
| 47       |  |
| 48       |  |
| 49       |  |
| 50       |  |
| 51       |  |
| 52       |  |
| 52<br>53 |  |
| 53<br>54 |  |
|          |  |
| 55       |  |
| 56       |  |
| 57       |  |
| 58       |  |
| 59       |  |
|          |  |

60

8

## 1 FIGURE LEGENDS


Figure 1. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by
sex: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes
method on weighted prevalence estimates. Body fat-defined obesity was determined using the
relative fat mass (RFM). RFM was calculated as follows: RFM = 64 - (20 × height/waist
circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if
RFM was 40% or higher for women and RFM was 30% or higher for men.


9 ethnicity: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes
10 method on weighted prevalence estimates. The relative fat mass (RFM) was calculated as
11 follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1
12 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or


Figure 2. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by

13 higher for men.

Figure 3. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by age group: 1999-2000 through 2017-March 2020. Trend lines were smoothed using the Lowes method on weighted prevalence estimates. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men.







| 1        |   |
|----------|---|
| 2        |   |
| 3        | Supplemental material   |
| 4        | ••  |
| 5<br>6   |   |
| 7        | Temporal trends in obesity defined by the relative fat mass (RFM) index among                                       |
| 8        |   |
| 9        | adults in the United States from 1999 to 2020: population-based study   |
| 10       | ······  |
| 11       |   |
| 12       |   |
| 13       | Orison O. Woolcott <sup>1,2,*</sup> , Till Seuring <sup>3</sup>   |
| 14       | ,   |
| 15       |   |
| 16       |   |
| 17       | <sup>1</sup> Ronin Institute, Montclair, NJ, USA; <sup>2</sup> Institute for Globally Distributed Open Research and |
| 18<br>19 |   |
| 20       | Education (IGDORE), Los Angeles, CA, USA; <sup>3</sup> Luxembourg Institute of Socio-Economic                       |
| 21       |   |
| 22       | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 23       |   |
| 24       |   |
| 25       |   |
| 26       |   |
| 27       |   |
| 28       |   |
| 29<br>20 |   |
| 30<br>31 |   |
| 32       | Research (LISER), Esch-sur-Alzette, Luxembourg  |
| 33       |   |
| 34       |   |
| 35       |   |
| 36       |   |
| 37       |   |
| 38       |   |
| 39       |   |
| 40<br>41 |   |
| 41       |   |
| 43       |   |
| 44       |   |
| 45       |   |
| 46       |   |
| 47       |   |
| 48       |   |
| 49       |   |
| 50       |   |
| 51<br>52 |   |
| 52<br>53 |   |
| 55       |   |
| 55       |   |
| 56       |   |
| 57       |   |
| 58       | 1   |
| 59       |   |
| 60       | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml   |

Supplemental Table 1. Prevalence of general and abdominal obesity among study participants by sex and ethnicity.\*

|                                   | Mexican American | European American | African American |
|-----------------------------------|------------------|-------------------|------------------|
| Women                             | n=4,204          | n=9,710           | n=5,417          |
| RFM-defined obesity, % (95% CI) † | 72.7 (70.3-75.1) | 56.6 (55.2-58.0)  | 69.9 (68.3-71.4) |
| BMI-defined obesity, % (95% CI) ‡ | 45.5 (43.2-47.9) | 35.4 (34.0-36.7)  | 54.5 (52.9-56.1) |
| Abdominal obesity, % (95% CI) §   | 71.5 (69.2-73.8) | 62.8 (61.4-64.1)  | 75.0 (73.6-76.3) |
| Men                               | n=4,212          | n=9,981           | n=5,256          |
| RFM-defined obesity, % (95% CI) † | 47.0 (44.9-49.1) | 41.7 (40.3-43.2)  | 33.7 (32.1-35.3) |
| BMI-defined obesity, % (95% CI) ‡ | 38.4 (36.3-40.4) | 35.0 (33.6-36.5)  | 35.9 (34.2-37.6) |
| Abdominal obesity, % (95% CI) §   | 41.2 (39.1-43.2) | 47.6 (46.2-49.1)  | 37.5 (35.9-39.0) |

\* Sample size represents unweighted data. Estimates represent weighted data.

BMI, body mass index; CI, confidence interval; IQR, interquartile range; RFM, relative fat mass; SD, standard deviation.

† Defined as an RFM ≥40% for women and ≥30% for men. Estimates are not adjusted for age.

‡ Defined as a BMI ≥30 kg/m<sup>2</sup>. Estimates are not adjusted for age.

§ Defined as a waist circumference >88 cm for women and >102 cm for men, according to the recommendations of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Estimates are not adjusted for age.

| Characteristic          | All†          | With complete data | With missing data |  |
|-------------------------|---------------|--------------------|-------------------|--|
| Sample size, n (%)      | 50,283 (100)  | 47,667 (95.6)      | 2,616 (4.4)       |  |
| Median age (IQR), years | 45 (33-58)    | 45 (33-58)         | 47 (34-63)        |  |
| Male sex, n (%)         | 24,954 (49.2) | 23,736 (49.4)      | 1,218 (45.4)      |  |
| Ethnicity, n (%)        |               |                    |                   |  |
| Mexican American        | 8,827 (8.3)   | 8,416 (8.3)        | 411 (8.6)         |  |
| European American       | 20,618 (66.9) | 19,691(67.2)       | 927 (58.6)        |  |
| African American        | 11,433 (11.4) | 10,673(11.2)       | 760 (16.7)        |  |
| Other/multi-racial      | 9,405 (13.4)  | 8,887 (13.2)       | 518 (16.1)        |  |

\* Sample size represents unweighted data. Estimates represent weighted data.

† This group includes participants with complete data and participants with missing data on body weight (n=666), height (n=596), and waist circumference (n=2,340).

to beet to lie wont

|                               |                                      | RFM-defined obesity                  | /                                    |   | BMI-defined obesity                  |                                      |                                |  |
|-------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|---|--------------------------------------|--------------------------------------|--------------------------------|--|
|                               | Mexican                              | European                             | African                              |   | Mexican                              | European                             | African                        |  |
|                               | American                             | American                             | American                             |   | American                             | American                             | American                       |  |
| All participants              | n=8,416                              | n=19,691                             | n=10,673                             |   | n=8,416                              | n=19,691                             | n=10,673                       |  |
| Prevalence, % (95%            |                                      |                                      |                                      |   |                                      |                                      |                                |  |
| CI)                           |                                      |                                      |                                      |   |                                      |                                      |                                |  |
| 1999-2000                     | 53.1 (48.5-57.7)                     | 39.4 (34.2-44.6)                     | 48.3 (45.0-51.7)                     |   | 34.7 (28.9-40.6)                     | 28.3 (23.9-32.7)                     | 39.8 (35.7-43.                 |  |
| 2001-2002                     | 52.1 (47.1-57.1)                     | 41.0 (38.9-43.1)                     | 46.0 (42.9-49.0)                     |   | 30.7 (26.7-34.7)                     | 29.8 (27.0-32.6)                     | 38.3 (34.4-42                  |  |
| 2003-2004                     | 60.1 (55.2-65.0)                     | 44.8 (41.0-48.6)                     | 52.7 (49.4-56.0)                     |   | 36.9 (32.2-41.6)                     | 30.6 (27.7-33.4)                     | 45.1 (39.7-50                  |  |
| 2005-2006                     | 55.4 (51.8-58.9)                     | 44.9 (40.7-49.2)                     | 51.5 (47.9-55.1)                     |   | 33.8 (31.2-36.4)                     | 33.1 (29.2-36.9)                     | 45.9 (42.3-49                  |  |
| 2007-2008                     | 62.2 (56.2-68.2)                     | 45.7 (41.5-49.9)                     | 52.5 (49.1-56.0)                     |   | 39.9 (33.8-46.1)                     | 32.4 (28.7-36.0)                     | 43.7 (39.2-48                  |  |
| 2009-2010                     | 61.5 (59.4-63.6)                     | 46.4 (43.0-49.8)                     | 56.8 (51.8-61.8)                     |   | 40.5 (36.7-44.4)                     | 34.2 (31.1-37.2)                     | 49.4 (44.2-54                  |  |
| 2011-2012                     | 63.6 (58.6-68.6)                     | 46.8 (42.8-50.9)                     | 57.4 (54.8-60.0)                     |   | 46.1 (41.3-50.8)                     | 33.0 (29.4-36.5)                     | 48.4 (44.6-52                  |  |
| 2013-2014                     | 65.0 (61.2-68.9)                     | 49.4 (46.6-52.3)                     | 55.0 (50.0-59.9)                     |   | 46.1 (41.0-51.2)                     | 36.6 (33.6-39.5)                     | 47.9 (43.7-52                  |  |
| 2015-2016                     | 70.3 (67.0-73.5)                     | 51.2 (46.9-55.4)                     | 56.6 (52.0-61.2)                     |   | 48.7 (44.3-53.1)                     | 38.5 (34.5-42.5)                     | 48.7 (43.8-53                  |  |
| 2017-2020                     | 68.8 (64.5-73.1)                     | 54.1 (50.8-57.4)                     | 57.1 (54.4-59.8)                     |   | 50.2 (46.8-53.5)                     | 41.7 (37.7-45.6)                     | 49.9 (47.2-52                  |  |
| Prevalence change†            | 15.7 (9.6-21.7)                      | 14.7 (8.8-20.5)                      | 8.7 (4.6-12.9)                       |   | 15.4 (9.0-21.9)                      | 13.4 (7.7-19)                        | 10.2 (5.5-14.8                 |  |
| P for non-linearity‡          | 0.58                                 | 0.97                                 | 0.25                                 |   | 0.52                                 | 0.10                                 | 0.35                           |  |
| P value for trend‡            | <0.001                               | <0.001                               | <0.001                               |   | <0.001                               | <0.001                               | <0.001                         |  |
| Women                         | n=4,204                              | n=9,710                              | n=5,417                              |   | n=4,204                              | n=9,710                              | n=5,417                        |  |
| Prevalence, % (95%            | ·                                    |                                      |                                      |   |                                      |                                      |                                |  |
| CI)                           |                                      |                                      |                                      |   |                                      |                                      | 10.0 (10.5.50                  |  |
| 1999-2000                     | 62.8 (55.1-70.5)                     | 46.2 (40.2-52.1)                     | 64.2 (59.6-68.8)                     |   | 39.8 (31.1-48.5)                     | 30.3 (25.2-35.3)                     | 49.2 (42.5-56                  |  |
| 2001-2002                     | 66.4 (58.6-74.3)                     | 47.8 (44.2-51.4)                     | 64.2 (59.0-69.4)                     |   | 37.0 (30.2-43.8)                     | 31.1 (27.6-34.7)                     | 48.7 (42.8-54                  |  |
| 2003-2004                     | 75.0 (68.3-81.6)                     | 50.6 (43.9-57.2)                     | 70.7 (65.5-75.8)                     |   | 42.7 (36.0-49.3)                     | 30.3 (25.7-34.8)                     | 53.9 (46.3-61                  |  |
| 2005-2006                     | 72.0 (66.4-77.5)                     | 49.9 (45.6-54.2)                     | 66.2 (60.9-71.5)                     |   | 41.3 (34.8-47.7)                     | 32.8 (28.3-37.3)                     | 52.7 (48.5-56                  |  |
| 2007-2008                     | 74.8 (71.2-78.4)                     | 52.3 (47.5-57.2)                     | 67.9 (63.2-72.6)                     |   | 44.7 (38.8-50.6)                     | 32.8 (28.7-36.9)                     | 49.2 (45.2-53                  |  |
| 2009-2010                     | 77.8 (74.8-80.9)                     | 53.4 (49.5-57.2)                     | 74.6 (68.6-80.7)                     |   | 45.7 (42.0-49.3)                     | 32.1 (29.0-35.3)                     | 58.5 (52.0-64                  |  |
| <u>2011-2012</u><br>2013-2014 | 74.6 (66.2-83.0)<br>81.2 (74.7-87.6) | 56.3 (51.4-61.3)                     | 74.9 (72.1-77.8)                     |   | 49.0 (40.4-57.5)                     | 33.3 (28.0-38.7)                     | 57.9 (53.5-62                  |  |
| 2015-2014                     | 84.6 (79.7-89.5)                     | 57.3 (53.4-61.2)<br>60.0 (56.2-63.8) | 72.5 (68.8-76.2)<br>72.3 (68.3-76.4) |   | 51.7 (45.2-58.3)<br>52.2 (48.4-56.1) | 37.6 (33.7-41.6)<br>38.5 (34.0-43.0) | 56.7 (53.1-60<br>57.1 (52.6-61 |  |
| 2013-2018                     | 76.9 (70.8-83.1)                     | 62.3 (59.0-65.7)                     | 72.4 (68.6-76.2)                     |   | 49.6 (43.1-56.0)                     | 40.3 (36.4-44.2)                     | 57.3 (53.7-60                  |  |
| Prevalence change†            | 14.1 (4.7-23.6)                      | 16.2 (9.7-22.7)                      | 8.3 (2.5-14.0)                       |   | 9.8 (-0.6-20.1)                      | 10.0 (3.9-16.1)                      | 8.1 (0.8-15.4)                 |  |
| P for non-linearity§          | 0.026                                | 0.77                                 | 0.34                                 |   | 0.76                                 | 0.12                                 | 0.71                           |  |
| P value for trend§            | 0.020                                | <0.001                               | <0.001                               |   | <0.001                               | <0.001                               | <0.001                         |  |
| Men                           | n=4,212                              | n=9,981                              | n=5,256                              |   | n=4,212                              | n=9,981                              | n=5,256                        |  |
| Prevalence, % (95%            | 11-4,212                             | 11=3,301                             | 11=3,230                             | _ | 11-4,212                             | 11=3,301                             | 11=0,200                       |  |
| CI)                           |                                      |                                      |                                      |   |                                      |                                      |                                |  |
| 1999-2000                     | 42.9 (39.4-46.5)                     | 33.2 (28.6-37.7)                     | 27.5 (23.1-31.9)                     |   | 29.1 (24.6-33.6)                     | 26.8 (22.9-30.6)                     | 26.8 (23.0-30                  |  |
| 2001-2002                     | 40.6 (34.7-46.4)                     | 34.1 (30.9-37.4)                     | 25.8 (21.4-30.1)                     |   | 25.9 (21.9-29.9)                     | 28.3 (25.3-31.4)                     | 26.5 (22.8-30                  |  |
| 2003-2004                     | 47.1 (39.3-54.8)                     | 38.9 (35.5-42.4)                     | 31.2 (27.2-35.2)                     |   | 31.7 (25.0-38.3)                     | 30.9 (27.0-34.7)                     | 34.2 (27.7-40                  |  |
| 2005-2006                     | 40.8 (34.1-47.4)                     | 40.0 (35.1-44.9)                     | 34.1 (28.3-39.9)                     |   | 27.4 (22.7-32.1)                     | 33.3 (28.7-37.9)                     | 37.2 (31.2-43                  |  |
| 2007-2008                     | 50.9 (43.3-58.4)                     | 38.8 (34.7-42.9)                     | 33.8 (28.8-38.9)                     |   | 35.1 (28.0-42.1)                     | 32.0 (27.9-36.0)                     | 36.9 (31.0-42                  |  |
| 2009-2010                     | 47.8 (44.6-51.0)                     | 39.4 (34.6-44.3)                     | 35.4 (31.4-39.5)                     |   | 36.3 (30.9-41.6)                     | 36.1 (30.8-41.3)                     | 38.6 (33.1-44                  |  |
| 2011-2012                     | 52.5 (45.6-59.4)                     | 37.6 (34.3-40.9)                     | 36.4 (32.3-40.5)                     |   | 42.7 (36.0-49.5)                     | 32.5 (29.7-35.3)                     | 37.5 (32.8-42                  |  |
| 2013-2014                     | 52.4 (48.6-56.3)                     | 41.7 (38.1-45.3)                     | 35.2 (28.6-41.8)                     |   | 43.6 (38.2-49.1)                     | 35.6 (31.6-39.5)                     | 37.9 (32.5-43                  |  |
| 2015-2016                     | 55.9 (50.9-60.8)                     | 42.3 (36.5-48.1)                     | 38.1 (31.9-44.2)                     |   | 45.3 (38.5-52.1)                     | 38.4 (32.5-44.3)                     | 38.9 (33.5-44                  |  |
| 2017-2020                     | 61.2 (55.8-66.6)                     | 45.8 (40.3-51.2)                     | 39.1 (35.4-42.8)                     |   | 50.3 (46.1-54.5)                     | 43.1 (36.9-49.2)                     | 41.2 (36.7-45                  |  |
| Prevalence change†            | 18.3 (12.0-24.5)                     | 12.6 (5.7-19.5)                      | 11.6 (6.1-17.1)                      |   | 21.2 (15.3-27.1)                     | 16.3 (9.3-23.3)                      | 14.4 (8.7-20.1                 |  |
| P for non-linearity§          | 0.21                                 | 0.80                                 | 0.50                                 |   | 0.24                                 | 0.45                                 | 0.08                           |  |
| P value for trend§            | <0.001                               | <0.001                               | <0.001                               |   | <0.001                               | <0.001                               | <0.001                         |  |

. tal Tabla 2 A ide in REM defined abasity by attribute 1000 2000 th ... . . . . . . . . . . .

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference) + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval.

† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

Adjusted for age and sex.
 § Adjusted for age.

2020 \*

## **BMJ** Open

Supplemental Table 4. Age-adjusted U.S. adult prevalence temporal trends in RFM-defined obesity by age group: 1999-2000 through 2017-March

| 1      |        |
|--------|--------|
| 2      |        |
| 3      |        |
| _      |        |
| 4      |        |
| 5      |        |
| ~      |        |
| 6      |        |
| 7      |        |
| 8      |        |
|        |        |
| 9      |        |
| 1      | 0      |
| 1      | 1      |
|        | 1      |
| 1      |        |
| 1      | 3      |
| 1      | 4      |
|        |        |
| 1      |        |
| 1      | 6      |
| 1      | 7      |
|        |        |
| 1      | 8      |
|        | 9      |
| 1      | 2      |
| 2      | 0      |
| 2      | 1<br>2 |
| 2      | י<br>ר |
| 2      | 2      |
| 2      |        |
| 2      | 4      |
| 2      |        |
|        |        |
| 2      |        |
| 2      | 7      |
| 2      | '      |
| 2      |        |
| 2      | 9      |
|        | 0      |
|        |        |
| 3      |        |
| 3      | 2      |
| 3      |        |
|        |        |
| 3      |        |
| 3      | 5      |
| ר<br>ר | 6      |
| 3      | 0      |
| 3      | 7      |
| ຊ      | 8      |
|        |        |
|        | 9      |
|        | 0      |
| 4      | 1      |
|        |        |
| 4      |        |
| 4      | 3      |
| Л      | 4      |
|        |        |
| 4      | -      |
| 4      | 6      |
| 4      |        |
|        |        |
| 4      |        |
| 4      | 9      |
|        | 0      |
|        |        |
| 5      | 1      |
| 5      |        |
|        |        |
| 5      | _      |
|        | 4      |
| 5      | 5      |
| 5      |        |
|        | 6      |

| 55 |
|----|
| 56 |
| 57 |
|    |

| 58 |  |
|----|--|
| 59 |  |

60

RFM-defined obesity BMI-defined obesity 20-39 years old 20-39 years old 40-59 years old 60-79 years old 40-59 years old 60-79 years old All participants n=16,747 n=16,912 n=14,008 n=16,747 n=16,912 n=14,008 Prevalence, 95% CI 1999-2000 29.0 (24.5-33.6) 46.9 (40.5-53.4) 61.8 (58.1-65.6) 25.4 (21.5-29.3) 33.2 (26.9-39.4) 35.4 (31.3-39.5) 2001-2002 30.2 (27.2-33.1) 45.0 (42.2-47.8) 63.8 (61.3-66.3) 25.3 (22.4-28.1) 33.2 (29.9-36.4) 33.7 (30.7-36.8) 51.2 (47.8-54.6) 2003-2004 34.2 (31.2-37.1) 65.8 (62.5-69.0) 28.1 (24.6-31.7) 35.9 (32.1-39.7) 33.0 (29.4-36.5) 53.2 (47.9-58.5) 28.5 (24.1-32.9) 40.1 (35.6-44.6) 34.9 (31.5-38.3) 2005-2006 32.6 (28.7-36.5) 66.0 (62.2-69.8 66.1 (62.4-69.8) 35.7 (32.4-39.1) 2007-2008 35.5 (31.1-39.9) 51.6 (48.5-54.7) 30.2 (26.2-34.3) 37.4 (33.8-40.9) 2009-2010 37.2 (32.8-41.6) 50.5 (47.7-53.4) 68.5 (65.2-71.8) 32.5 (28.7-36.3) 36.0 (33.9-38.2) 41.8 (38.0-45.7) 2011-2012 53.6 (49.9-57.3) 38.3 (33.8-42.9) 37.7 (33.1-42.3) 68.0 (62.9-73.1 30.4 (26.2-34.5) 39.3 (36.1-42.5) 2013-2014 40.0 (36.2-43.9) 54.5 (50.3-58.7) 68.8 (64.6-73.0) 34.4 (31.3-37.5) 40.6 (36.2-45.1) 39.3 (35.2-43.5) 2015-2016 43.0 (39.0-47.0) 57.1 (50.6-63.6) 69.8 (64.7-74.9) 36.0 (32.2-39.8) 42.8 (37.5-48.2) 42.8 (37.5-48.2) 2017-2020 44.6 (40.5-48.6) 59.4 (56.2-62.7) 70.6 (67.2-74.0) 39.8 (35.6-44.0) 44.3 (41.2-47.4) 42.7 (39.1-46.3) Prevalence change† 15.5 (9.7-21.3) 12.5 (5.6-19.4) 8.8 (3.9-13.6) 14.5 (8.9-20.0) 11.2 (4.5-17.8) 7.3 (2.0-12.5) 0.46 P for non-linearity‡ 0.48 0.21 0.65 0.94 0.25 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 P value for trend‡ < 0.001 Women n=8,295 n=8,684 n=6,952 n=8,295 n=8,684 n=6,952 Prevalence, 95% CI 1999-2000 36.9 (30.9-42.9) 56.2 (48.9-63.5) 67.7 (63.3-72.2) 28.7 (23.6-33.7) 37.4 (30.2-44.5) 37.4 (31.6-43.2) 2001-2002 39.9 (35.3-44.5) 52.9 (48.1-57.6) 72.0 (69.3-74.7) 28.9 (24.1-33.6) 35.0 (30.2-39.8) 36.6 (32.0-41.2) 42.0 (35.8-48.2) 59.7 (54.9-64.5) 38.1 (32.3-43.9) 2003-2004 73.0 (68.3-77.7) 29.0 (23.8-34.1) 33.6 (28.5-38.7) 71.3 (66.4-76.2) 40.7 (35.9-45.6) 2005-2006 40.3 (35.3-45.4) 58.7 (53.5-63.8) 29.2 (24.1-34.3) 34.8 (28.4-41.2) 2007-2008 46.1 (40.4-51.7) 60.0 (56.2-63.8) 69.8 (64.5-75.1) 33.0 (27.3-38.6) 37.6 (32.6-42.5) 36.0 (30.0-41.9) 2009-2010 46.4 (40.6-52.2) 78.5 (75.8-81.3) 31.8 (28.2-35.4) 35.5 (31.7-39.3) 45.1 (40.7-49.5) 59.3 (55.5-63.1) 2011-2012 47.6 (42.1-53.1) 64.6 (60.1-69.0) 76.7 (69.8-83.5) 31.9 (28.0-35.9) 39.4 (35.1-43.6) 42.1 (34.4-49.7) 2013-2014 50.8 (46.6-55.1) 63.3 (58.1-68.5) 78.0 (74.6-81.4) 36.6 (33.9-39.3) 43.6 (38.2-48.9) 40.2 (34.1-46.2) 45.0 (37.3-52.8) 2015-2016 53.3 (48.9-57.8) 69.1 (62.7-75.5) 77.1 (70.6-83.6) 37.1 (33.5-40.7) 44.8 (38.4-51.1) 53.3 (48.5-58.0) 67.9 (63.6-72.3) 81.0 (76.4-85.6) 39.9 (35.3-44.4) 45.4 (40.9-49.8) 2017-2020 42.8 (38.9-46.7) 16.4 (9.1-23.7) 5.5 (-2.3-13.2) Prevalence change† 11.7 (3.6-19.9) 13.3 (7.1-19.5) 11.2 (4.7-17.7) 8.0 (1.0-15.0) P for non-linearity§ 0.16 0.39 0.99 0.44 0.42 0.97 < 0.001 < 0.001 < 0.001 P value for trends < 0.001 < 0.001 < 0.001 n=8,452 Men n=8,228 n=7,056 n=8,452 n=8,228 n=7,056 Prevalence, 95% CI 1999-2000 22.4 (18.0-26.8) 36.8 (30.4-43.2) 54.7 (49.9-59.5) 22.7 (18.3-27.0) 28.8 (22.8-34.8) 33.2 (28.2-38.1) 2001-2002 20.8 (17.4-24.1) 37.1 (33.5-40.7) 53.5 (49.8-57.1) 21.7 (18.5-24.9) 31.2 (28.0-34.5) 30.4 (26.0-34.8) 2003-2004 26.9 (23.3-30.4) 42.3 (36.7-47.9) 57.2 (52.5-62.0) 27.4 (22.5-32.3) 33.6 (28.4-38.9) 32.3 (27.4-37.2) 34.7 (29.9-39.5) 2005-2006 25.4 (20.1-30.7) 47.4 (40.5-54.2) 59.8 (54.8-64.7) 27.6 (22.0-33.1) 39.5 (33.1-45.9) 2007-2008 25.4 (21.2-29.5) 42.8 (37.8-47.8) 61.8 (57.7-65.9) 27.6 (23.8-31.4) 33.7 (28.8-38.5) 39.2 (34.8-43.5) 2009-2010 28.5 (23.6-33.3) 41.6 (37.7-45.5) 56.9 (51.1-62.7) 33.2 (27.2-39.2) 36.6 (33.0-40.2) 37.5 (32.3-42.8) 2011-2012 28.4 (23.9-33.0) 42.3 (38.0-46.6) 58.1 (52.1-64.2) 28.9 (23.5-34.2) 39.1 (35.6-42.5) 34.2 (29.2-39.2) 2013-2014 30.0 (25.5-34.5) 45.5 (40.3-50.7) 58.6 (51.6-65.5) 32.5 (28.1-36.8) 37.7 (32.2-43.3) 38.6 (30.7-46.4) 2015-2016 33.1 (28.3-38.0) 44.5 (36.5-52.6) 61.4 (55.4-67.5) 35.0 (29.0-41.0) 40.8 (34.6-47.1) 40.2 (34.9-45.5) 2017-2020 35.9 (30.2-41.5) 50.8 (46.2-55.4) 58.8 (54.3-63.3) 39.5 (33.1-46.0) 45.8 (41.1-50.6) 39.7 (34.0-45.4) Prevalence change† 13.4 (6.5-20.4) 14.0 (6.4-21.6) 4.1 (-2.3-10.5) 16.8 (9.3-24.4) 17.0 (9.7-24.4) 6.5 (-0.7-13.8) P for non-linearity§ 0.47 0.42 0.16 0.97 0.41 0.24 < 0.001 < 0.001 <0.001 < 0.001 P value for trend§ <0.001 < 0.001

\* Prevalence estimates represent weighted data. The relative fat mass (RFM) was calculated as follows: RFM = 64 - (20 × height/waist circumference)
 + (12 × sex); sex equals 0 for men and 1 for women. Obesity was diagnosed if RFM was 40% or higher for women and RFM was 30% or higher for men. CI denotes confidence interval.


† Absolute difference (prevalence in 2017-2020 minus the prevalence in 1999-2000).

‡ Adjusted for sex and ethnicity.

§ Adjusted for ethnicity.

**BMJ** Open

NHANES 1999-March 2020



Supplemental Figure 1. Selection of study participants.

STROBE Statement—checklist of items that should be included in reports of observational studies

|                        | Item<br>No | Recommendation   | Pag<br>No |
|------------------------|------------|--|-----------|
| Title and abstract     | 1          | ( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract              | 1         |
|                        |            | the abstract   | 2.4       |
|                        |            | ( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found | 3-4       |
| <b>.</b>               |            | was done and what was found  |           |
| Introduction           | 2          | Explain the scientific background and rationals for the investigation being                                  | 6-7       |
| Background/rationale   | 2          | Explain the scientific background and rationale for the investigation being reported                         | 0-/       |
| Objectives             | 3          | State specific objectives, including any prespecified hypotheses   | 7         |
| Methods                |            |  |           |
| Study design           | 4          | Present key elements of study design early in the paper  | 8         |
| Setting                | 5          | Describe the setting, locations, and relevant dates, including periods of                                    | 8         |
| -                      |            | recruitment, exposure, follow-up, and data collection  |           |
| Participants           | 6          | (a) Cohort study—Give the eligibility criteria, and the sources and  | 8, 1      |
| -                      |            | methods of selection of participants. Describe methods of follow-up  |           |
|                        |            | Case-control study—Give the eligibility criteria, and the sources and  |           |
|                        |            | methods of case ascertainment and control selection. Give the rationale                                      |           |
|                        |            | for the choice of cases and controls   |           |
|                        |            | Cross-sectional study—Give the eligibility criteria, and the sources and                                     |           |
|                        |            | methods of selection of participants   |           |
|                        |            | (b) Cohort study—For matched studies, give matching criteria and   | NA        |
|                        |            | number of exposed and unexposed  |           |
|                        |            | Case-control study—For matched studies, give matching criteria and the                                       |           |
|                        |            | number of controls per case  |           |
| Variables              | 7          | Clearly define all outcomes, exposures, predictors, potential confounders,                                   | 9-1       |
|                        |            | and effect modifiers. Give diagnostic criteria, if applicable  |           |
| Data sources/          | 8*         | For each variable of interest, give sources of data and details of methods                                   | 8-1       |
| measurement            |            | of assessment (measurement). Describe comparability of assessment  |           |
|                        |            | methods if there is more than one group  |           |
| Bias                   | 9          | Describe any efforts to address potential sources of bias  | 9-1       |
| Study size             | 10         | Explain how the study size was arrived at  | 8         |
| Quantitative variables | 11         | Explain how quantitative variables were handled in the analyses. If  | 9-1       |
|                        |            | applicable, describe which groupings were chosen and why   |           |
| Statistical methods    | 12         | ( <i>a</i> ) Describe all statistical methods, including those used to control for                           | 9-1       |
|                        |            | confounding  |           |
|                        |            | (b) Describe any methods used to examine subgroups and interactions  | 9-1       |
|                        |            | (c) Explain how missing data were addressed  | 8         |
|                        |            | (d) Cohort study—If applicable, explain how loss to follow-up was  | 9-1       |
|                        |            | addressed  |           |
|                        |            | Case-control study—If applicable, explain how matching of cases and  |           |
|                        |            | controls was addressed   |           |
|                        |            | Construction for the IC and institution and the last the destation   |           |
|                        |            | Cross-sectional study—If applicable, describe analytical methods taking                                      |           |
|                        |            | account of sampling strategy   |           |

Continued on next page

| Participants     | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially           | 11    |
|------------------|-----|---|-------|
|                  |     | eligible, examined for eligibility, confirmed eligible, included in the study,            |       |
|                  |     | completing follow-up, and analysed  |       |
|                  |     | (b) Give reasons for non-participation at each stage                                      | 11    |
|                  |     | (c) Consider use of a flow diagram  | Supp  |
|                  |     |   | Fig 1 |
| Descriptive      | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and     | 11    |
| data             |     | information on exposures and potential confounders  |       |
|                  |     | (b) Indicate number of participants with missing data for each variable of interest       | Supp  |
|                  |     |   | Table |
|                  |     |   | 1     |
|                  |     | (c) Cohort study—Summarise follow-up time (eg, average and total amount)                  | NA    |
| Outcome data     | 15* | Cohort study—Report numbers of outcome events or summary measures over time               | NA    |
|                  |     | Case-control study—Report numbers in each exposure category, or summary                   | NA    |
|                  |     | measures of exposure  |       |
|                  |     | Cross-sectional study—Report numbers of outcome events or summary measures                | 11-18 |
| Main results     | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and       | NA    |
|                  |     | their precision (eg, 95% confidence interval). Make clear which confounders were          |       |
|                  |     | adjusted for and why they were included   |       |
|                  |     | (b) Report category boundaries when continuous variables were categorized                 | 12-18 |
|                  |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a | NA    |
|                  |     | meaningful time period  |       |
| Other analyses 1 |     | Report other analyses done—eg analyses of subgroups and interactions, and                 | 11-18 |
|                  |     | sensitivity analyses  |       |
| Discussion       |     |   |       |
| Key results      | 18  | Summarise key results with reference to study objectives                                  | 19    |
| Limitations      | 19  | Discuss limitations of the study, taking into account sources of potential bias or        | 23-24 |
|                  |     | imprecision. Discuss both direction and magnitude of any potential bias                   |       |
| Interpretation   | 20  | Give a cautious overall interpretation of results considering objectives, limitations,    | 24    |
|                  |     | multiplicity of analyses, results from similar studies, and other relevant evidence       |       |
| Generalisability | 21  | Discuss the generalisability (external validity) of the study results                     | 24    |
| Other informati  | on  |   |       |
| Funding          | 22  | Give the source of funding and the role of the funders for the present study and, if      | 26    |
| C                |     | applicable, for the original study on which the present article is based                  |       |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.